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Prostate cancer is diagnosed in almost 200,000 men in the U.S. annually. With 
approximately 30,000 deaths, the mortality to incidence ratio is relatively low in 
comparison to other common cancers. Moreover, the primary treatment modalities, 
radical prostatectomy and radiation therapy, are associated with a substantial reduction 
in quality of life. Consequently, there is a growing interest in focal therapy which aims 
to treat the target tumor while minimizing damage to surrounding tissue.  
Focal laser ablation (FLA) is a form of focal therapy in which a laser fiber is 
inserted into a target tumor and oncologic control is achieved through thermally induced 
coagulative necrosis. Many groups have performed FLA using magnetic resonance 
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imaging (MRI) for laser fiber targeting and real-time feedback. While this approach has 
shown promise, we contend that the resource intensive nature of MRI will forever 
preclude widespread adoption of FLA.  
This thesis presents a concerted effort to translate FLA from the MRI suite to the 
urology clinic. To this end we performed a clinical trial using magnetic resonance – 
ultrasound fusion guidance and interstitial thermal probes for treatment targeting and 
monitoring respectively. This approach proved to be safe and potentially effective; 
however, the utility of thermal probes was found to be inherently limited due to the need 
for empirically derived thermal damage models. 
In an effort to provide an improved monitoring modality we developed an 
interstitial optical monitoring system that directly assesses the state of tissue based on 
laser-tissue interaction.  To correlate the optical signal and the growth of the coagulation 
zone we created a tissue mimicking phantom which simulates the thermal and optical 
response of prostatic tissue and facilitates visualization of the coagulation zone on MRI. 
FLA was performed in the phantom under MRI surveillance with simultaneous interstitial 
optical monitoring resulting in the development of a real-time feedback algorithm. The 
algorithm was subsequently tested in ex vivo bovine tissue and was capable of 
identifying the coagulation border with a mean absolute error of 0.3±0.1mm. Further 
work is necessary to demonstrate the utility of interstitial optical monitoring in vivo. 
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CHAPTER 1 
Introduction 
 
1. Introduction 
Prostate cancer (CaP) is the second most common cancer and the most common in males 
with an estimated 175,000 new cases and 32,000 deaths in 2019 [1]. The unusual 
disparity between diagnosis and mortality is clear when compared with the 116,000 new 
cases and 77,000 deaths associated with the second most common cancer in men, lung 
and bronchus. This situation has arisen largely due to the widespread adoption of 
prostate specific antigen (PSA) screening which has resulted in detection of many 
smaller, lower stage and clinically insignificant cancers. As diagnosis and treatment are 
tightly coupled, there has been a corresponding trend of overtreatment [2]. 
Overtreatment of prostate cancer is of particular concern as traditional 
interventions such as radical prostatectomy and radiation therapy are associated with 
decreased quality of life due to high rates of incontinence and impotence [3]. Many 
patients are faced with the decision to elect for either radical intervention or active 
surveillance and choose the former due to the fear of living with cancer. While radical 
intervention significantly reduces mortality rates, many patients who choose active 
surveillance never require intervention [4]. Indeed, much of what is diagnosed as ‘cancer’ 
is essentially benign as it is insufficiently aggressive to threaten the patient’s life. For 
example, it has been found that men over 70 years old with favorable risk CaP are 18.6 
times more likely to die from a non-CaP related condition [5]. Consequently, there is a 
need to develop a treatment modality capable of oncologic control without negatively 
impacting quality of life. 
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Focal therapy represents a promising minimally invasive treatment for CaP that 
may prove to be both effective and free from long-term complications such as 
incontinence and impotence. The goal of focal therapy is to treat only the cancerous 
tissue while sparing surrounding healthy tissue. It has been demonstrated clinically with 
technologies such as focal laser ablation (FLA) [6], high intensity focused ultrasound [7] 
and irreversible electroporation [8].  This thesis focuses on FLA which consists of 
inserting a laser fiber into the target tumor and inducing hyperthermic conditions 
sufficient to cause cell death through a process known as coagulative necrosis. FLA has 
been performed by many groups using magnetic resonance imaging to both guide the 
laser fiber to the target and monitor the treatment progress via magnetic resonance 
thermometry (MRT) [6], [9]–[11]. While these studies have shown promising results, we 
contend that the critical barrier to the adoption of FLA will be the requirement for real-
time MRI.  
At UCLA we have substantial experience performing targeted biopsies with 
magnetic resonance – ultrasound (MR-US) fusion guidance. This technique fuses existing 
MRI data with real-time ultrasound (US) imaging facilitating targeted biopsies in a clinic 
setting rather than an MRI suite. Given that a biopsy needle can be directed to a target 
tumor using MR-US fusion guidance, there is little reason to believe that a laser fiber 
cannot be targeted in the same manner. A greater challenge lies in ensuring both safety 
and efficacy without using MRT. In this thesis, we describe our efforts to translate FLA 
from the MRI suite to the clinic with the central hypothesis that interstitial probes can 
be used to monitor treatment progress in real-time. 
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1.1. Overview of Chapters 
Chapter 2 outlines potential focal therapy modalities and provides an extensive review 
of methods of monitoring focal therapy. Chapter 3 presents a clinical trial in which FLA 
was performed using MR-US fusion guidance and interstitial thermal probes for 
targeting and monitoring respectively. Chapter 4 introduces an alternative method of 
monitoring FLA based on the underlying principles of laser-tissue interaction. To 
demonstrate the feasibility of this method a tissue mimicking phantom was developed 
as outlined in Chapter 5. Finally, the development and evaluation of an interstitial optical 
monitoring system is described in Chapter 6. A brief summary of each chapter can be 
found below.  
 
1.1.1. Chapter 2 
This chapter begins with a brief introduction to CaP diagnostic methods and outlines 
the rationale for focal therapy. The second section summarizes the origins, mechanism 
of action and clinical application of hyperthermia based focal therapy modalities 
including FLA, microwave ablation MWA, radiofrequency ablation RFA and high intensity 
focused ultrasound HIFU. The various methods of monitoring these procedures are 
outlined in the remaining sections. As coagulative necrosis is induced via hyperthermia, 
the most common feedback modalities rely on thermal dosimetry. Interstitial probes 
(thermocouples, thermistors, fluoroptic probes, fiber Bragg grating) and radiologic 
imaging (acoustic thermometry, MRT, and computed tomography (CT) thermometry) 
represent the most promising approaches to thermal dosimetry. While focal therapy 
safety may be assured based on raw thermal data, efficacy requires the use of thermal 
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models to predict the extent of coagulative necrosis. The most commonly used model is 
the Arrhenius thermal damage model, the application and limitations of which are 
discussed at length. Finally, alternative techniques that do not rely on thermal dosimetry 
are discussed. These include advanced ultrasound techniques (contrast enhanced 
ultrasound and Nakagami imaging), elastography (vibroacoustography, acoustic 
radiation force impulse imaging, supersonic shear wave imaging, harmonic motion 
imaging, magnetic resonance elastography) and optical monitoring (diffuse optical 
spectroscopy, interstitial point optical measurements).  
 
1.1.2. Chapter 3 
FLA is performed by many groups using MRI for both targeting and monitoring; however, 
the direct costs involved will likely limit widespread adoption of this emerging 
technology. In this chapter we outline a clinic trial undertaken to demonstrate that FLA 
can be performed safely and effectively using MR-US fusion guidance and interstitial 
thermal probes for targeting and monitoring respectively.  The key aspect of interest in 
this thesis was the utility of the interstitial thermal probes. 10 men with intermediate 
risk CaP were recruited and treated with MR-US fusion guided FLA. During the procedure, 
temperature was monitored with interstitial thermal probes placed at key locations 
including the laser tip and the rectal wall. The probe at the laser tip was positioned at a 
radial distance of 8mm with goal of inducing coagulative necrosis throughout the 
volume between the laser fiber and thermal probe. In all patients the temperature 
recorded by this probe exceeded 55°C while the rectal wall remained at approximately 
body temperature.  As no long-term serious adverse events were reported, the trial 
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provides substantial evidence suggesting that MR-US fusion guided FLA with interstitial 
thermal can be performed safely. 
Oncologic control was assessed over a 9-month period. In the first four patients, 
minimal PSA decline was observed and residual clinically significant cancer was detected 
via biopsy. The final 6 patients were treated using a refined protocol in which an 
echogenic biopsy needle was used to improve laser fiber placement. This cohort of 
patients exhibited PSA decline similar to a previous MR-guided FLA trial. Moreover, on 
follow-up biopsy no evidence of CaP was seen in 3 patients while only small volumes of 
clinically insignificant cancer were seen in the other 3 patients. Finally, the thermal data 
collected in the trial was used to perform retrospective analysis of the utility of 
interstitial optical probes. The optimal exposure duration was quantified using the 
Arrhenius damage model calibrated with kinetic parameters determined in various 
studies. Due to wildly conflicting estimates of these parameters, significantly different 
estimates of the optimal exposure duration were calculated. Consequently, we conclude 
that the utility of interstitial thermal probes is inherently limited due to inaccurate 
thermal damage models. 
 
1.1.3. Chapter 4 
Chapter 4 introduces the concept of interstitial optical monitoring, reviews the 
fundamentals of laser-tissue interaction and presents a preliminary proof of concept 
study. The propagation of light in tissue is governed by the absorption coefficient and 
reduced scattering coefficient. The inverse of each coefficient is the mean free path 
between absorption and scattering events respectively. The effective penetration depth 
is a function of both coefficients and is defined as the mean free path between 
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attenuation events. In tissues with long penetration depth, light is distributed over a 
large volume while the opposite occurs if the penetration depth is short.  
During focal laser ablation photons travel through the tissue until they are absorbed by 
a chromophore. The deposited energy causes an increase in temperature which 
eventually leads to tissue coagulation which is characterized by an increase in the 
reduced scattering coefficient and a corresponding decrease in the optical penetration 
depth. We therefore hypothesize that the signal recorded by an interstitial optical probe 
at fixed location is a function of both the optical penetration depth and the size of the 
coagulation zone. 
A preliminary proof of concept study is described in which FLA is performed on 
ex vivo bovine muscle while being monitored by thermal and optical probes. The optical 
signal decreases as the coagulation boundary grows and reaches a steady state which 
may correlate to the moment in which the coagulation boundary reaches the probe. In 
contrast, the thermal probe exhibits an almost constant increase that is not correlated 
to the propagation of the coagulation boundary. 
The key limitation of this study is the inability to visualize the growth of the 
coagulation zone and hence correlate it with the optical signal. A material must be 
developed that possesses similar optical and thermal properties to prostatic tissue while 
also facilitating quantification of the coagulation zone as a function of time. 
 
1.1.4. Chapter 5 
In this chapter we present the development of a tissue-mimicking phantom with optical 
and thermal properties matched to human prostate. This phantom provides a platform 
for the development and characterization of the optical monitoring system outlined in 
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chapter 6. The phantom should also find utility in the testing of FLA instrumentation, 
validation of FLA simulations and the development of MRT sequences. 
The phantom consists of a polyacrylamide gel doped with Naphthol Green B, 
Intralipid, and Bovine Serum Albumin (BSA). The necessary concentration of each 
ingredient was determined by measuring the optical properties via fluence 
measurements and light diffusion theory. FLA was then performed under the same 
conditions as a previous clinical trial in which temperature was monitored via a thermal 
probe. The thermal data and induced coagulation zone were compared to clinical data 
to illustrate the similarity between the phantom and patient. FLA was also performed 
under magnetic resonance thermometry (MRT). 
The requisite concentrations of Naphthol Green B, Intralipid and BSA were found 
to be 0.144% (w/v), 8.06% (v/v) and 31.4% (v/v) respectively. In the native state, the 
absorption coefficient and reduced scattering coefficient (𝜇𝑠
′  ) were 0.66 ± 0.06 cm-1 and 
8.27 ± 0.50 cm-1 respectively, with 𝜇𝑠
′  increasing to 17.63 ± 1.41 cm-1 after coagulation. 
The thermal response of the phantom was similar to that observed clinically with 
maximum thermal probe measurements of 64.2°C and 66.9°C respectively. The shape of 
the induced coagulation zone was qualitatively and quantitatively similar to the MRT 
zone of elevated temperature and the coagulation zone observed clinically.  
In conclusion, in this chapter a phantom which simulates optical and thermal 
response to 980nm FLA was constructed and demonstrated to be similar to human 
prostate. 
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1.1.5. Chapter 6 
In this chapter an optical monitoring system is developed and evaluated in both the 
tissue mimicking phantom and ex vivo bovine muscle. The primary components of the 
system are an interstitial optical probe, a photodiode, a microcontroller and a PC running 
custom developed software capable of real-time analysis and feedback. 
The system is based on the hypothesis that the optical intensity at a fixed point 
can be correlated to the growth of the coagulation boundary. To demonstrate this, four 
optical probe prototypes were tested in the tissue mimicking phantom using MRI to 
track the coagulation boundary over time. The tissue mimicking phantom was designed 
specifically to facilitate contrast between the coagulated and native states and thus 
facilitate this novel experiment. A correlation between the recorded optical signal and 
the growth of the coagulation zone was clearly demonstrated. As hypothesized, the 
optical signal decreases as the coagulation boundary propagates towards the optical 
probe and reaches an inflection point at the moment of contact. Despite different 
designs, the 4 interstitial optical probes exhibited similar performance with mean 
absolute error ranging from 0.25mm to 0.39mm.  
The chosen optical probe, termed ‘Ballistic’, is designed to preferentially detect 
ballistic and snake photons i.e. photons that travel directly from the laser fiber to the 
optical probe. This probe was tested in ex vivo bovine muscle with the goal of achieving 
predefined coagulation zones based on feedback from the custom developed software 
platform. A total of 20 samples were tested with target coagulation radii ranging from 
4-7mm. The mean absolute error between the target coagulation radius and the 
measured radius was 0.3±0.1mm. These promising results suggest that interstitial 
optical monitoring can be used as a feedback modality for FLA. The primary advantage 
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of this approach over interstitial thermal probes is that inaccurate thermal damage 
models are not required. 
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CHAPTER 2 
Background 
 
2. Background 
2.1. Prostate Cancer Management 
2.1.1. Imaging 
In contrast to breast cancer, conventional imaging techniques such as US, x-ray, 
computed tomography (CT) and positron emission tomography (PET) have limited utility 
in CaP diagnosis. The diagnostic accuracy of transrectal ultrasound is similar to a digital 
rectal exam as some cancers are visible while some are not; therefore, it has minimal 
value in cancer detection [12]–[14]. Similarly CT scans fail to differentiate intraprostatic 
anatomy and play no role in CaP detection or staging [15]. PET is useful for localization 
of biochemically recurrent CaP but suffers from low specificity resulting in difficulty 
differentiating between benign and malignant prostatic tissue [16].  
Unlike conventional imaging modalities, multiparametric magnetic resonance 
imaging (mpMRI) has high sensitivity for detecting clinically significant CaP [17]. The 
region of interest (ROI) identified by mpMRI is quantified based on T2-weighted, diffusion 
weighted and dynamic contrast-enhanced images. While mpMRI has demonstrated high 
sensitivity for CaP, the T2-weighted image used to define the ROI volume has been found 
to underestimate the extent of the cancerous lesion [18].  
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2.1.2. Biopsy 
Transrectal ultrasound (TRUS) guided biopsy is a diagnostic standard for men with 
suspected cancer on the basis of elevated PSA or abnormal digital rectal exam. A 
systematic biopsy usually involves the acquisition of 10-12 cores via a template to 
ensure sampling throughout the gland. Minor bleeding and urinary symptoms are 
frequently observed after biopsy but usually do not require intervention [19]. There is 
also an increasing risk of infection which must be promptly treated with antibiotics. The 
advent of mpMRI lead to the adoption of MRI guided biopsies in which the suspicious 
ROI is directly sampled. The value of this approach is illustrated in a study where CaP 
was found in >50% of men with a previous negative TRUS biopsy and elevated PSA [20]. 
Widespread adoption of MRI guided biopsy is hindered due to the associated high costs 
and long procedure times. Consequently, magnetic resonance – ultrasound fusion (MR-
US) biopsy was developed. This technique combines the previously acquired mpMRI 
derived ROI with real-time ultrasound via a fusion biopsy platform (Figure 1). The ROI 
from the MRI scan is imported by the fusion platform and registered with the real-time 
ultrasound image allowing the ROI to be displayed and targeted.  
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Figure 1: The Artemis MRI-US fusion biopsy platform (Eigen, Grass Valley, CA) 
 
In comparison to standard TRUS biopsy, MR-US fusion biopsy provides increased 
detection of high-risk prostate cancer and also decreased detection of low-risk CaP.  In 
one study MR-US fusion biopsy detected 30% more high high-risk CaP and 17% fewer 
low-risk CaP than standard biopsy [21]. As the procedure can be performed in a clinic, 
the cost and procedure time is dramatically lower than MRI guided biopsy while still 
offering the ability to sample tissue from suspicious regions. In addition, a systematic 
biopsy can also be taken in the same session without a substantial increase in procedure 
time. 
 
2.1.3. Rational for Focal Therapy 
Men diagnosed with CaP are usually offered three options: 1) radical prostatectomy, 2) 
radiation therapy and 3) active surveillance. Radical prostatectomy is a surgical 
procedure in which the prostate and surrounding tissue is excised. The procedure is 
commonly undertaken using a minimally invasive approach with the Da Vinci Surgical 
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System (Intuitive Surgical Inc., Sunnyvale, CA). In contrast, radiation therapy achieves 
oncologic control without removing tissue. This is undertaken either with external beam 
radiation or brachytherapy. The final option, active surveillance, is not a treatment but 
rather a strategy to assess the progression of CaP and only intervene when deemed 
appropriate. Active surveillance consists of PSA blood tests, digital rectal exams and 
repeat biopsies at regular intervals. Men with life expectancy >10yr and low-risk CaP are 
ideal candidates for AS; however, 30% of these men will eventually need radical 
intervention [5]. 
There is a low incidence of disease progression for both radical prostatectomy 
and radiation therapy [22]; however, these procedures are associated with high rates of 
side-effects such as erectile dysfunction and urinary incontinence [3]. It is therefore 
desirable to either delay RP as long as possible or to forego the procedure entirely when 
it is not necessary. The patient is often faced with a difficult decision whether to opt for 
intervention and live with the ensuing reduction in quality of life or choose active 
surveillance. The conundrum in choosing treatment is illustrated in a study in which 347 
men received RP and 348 underwent active surveillance. At 23.2 years follow-up it was 
noted that RP significantly reduced mortality; however, a large proportion of the active 
surveillance  group did not require any palliative treatment [4]. Many patients elect for 
intervention due to the fear of living with cancer; therefore, overtreatment has become 
a concern. This trend for overtreatment is exacerbated by the widespread adoption of 
PSA and biopsy which has resulted in detection of many smaller, lower stage and 
clinically insignificant cancers.  
Active surveillance and intervention are the obvious choice for low-risk and high-
risk CaP respectively. However, the choice of treatment is particularly difficult for men 
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diagnosed with intermediate risk CaP. For this reason, there is a growing interest in focal 
therapy, the goal of which is to treat the cancerous tissue while minimizing damage to 
surrounding structures. There are a number of competing approaches under 
investigation including cryotherapy, irreversible electroporation and hyperthermia, the 
latter of which is the focus of this thesis. All of these procedures offer a minimally 
invasive method of treating tissue and can be targeted to the correct location due to 
improved diagnostic techniques. In particular, mpMRI and targeted biopsy have 
facilitated localization of the cancerous lesion within the prostate. 
 
2.2. Hyperthermia 
Hyperthermia as a form of treatment consists of raising tissue temperature to elicit a 
cellular response, which may include death. It dates back to 2600BC when the Egyptian 
polymath Imhotep reportedly used ‘fire drills’ to treat breast cancer [23]. Despite this 
ancient origin, widespread adoption of hyperthermia in cancer treatment has always 
been hampered due to difficulty administering thermal energy in the desired location 
with the appropriate magnitude and exposure duration. While ‘fire drills’ have been 
consigned to history, treatment planning and control techniques remain rather 
primitive. 
Today, hyperthermia is employed both as an adjuvant treatment modality to 
chemotherapy and radiotherapy as well as in isolation via thermal ablation. This chapter 
focuses on the latter in which high temperatures are used to induce cellular damage via 
conformational changes of molecules, bond destruction and membrane alterations. At 
50°C, enzyme activity is inhibited leading to reduced energy transfer within the cell and 
the disruption of repair mechanisms. Coagulation cellular necrosis occurs at 
15 
 
approximately 60°C due to denaturation of proteins and collagen. At temperatures above 
80°C, membranes become increasingly permeable and thus fail to maintain equilibrium 
chemical concentrations. Vaporization of water molecules arises at 100°C. The resulting 
gas bubbles can cause mechanical ruptures and thermal decomposition of tissue 
fragments. Tissue carbonization occurs after vaporization and at extreme temperature, 
above 300°C, tissue can even melt [24]. In general, tumor cells are more sensitive to 
hyperthermia than normal cells [25]–[28]. With appropriate dosimetry, cancer control 
can therefore be achieved while minimizing damage to surrounding healthy tissue. This 
has been demonstrated clinically in many organs, including the prostate [29], breast [30], 
pancreas [31], kidney [32] and liver [33]. 
This thesis focuses on thermal ablation which has many advantages over 
traditional cancer control techniques including a lower cost [34], minimal morbidity [35], 
less invasive [34] and in many cases can be undertaken as an outpatient procedure [36]. 
Energy delivery to the target has evolved considerably since the pioneering work 
undertaken by Westermark [37] and Coley [38] who induced hyperthermic conditions via 
circulating hot water and toxin induced fever respectively. Today the primary modalities 
are high intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), microwave 
ablation (MWA) and focal laser ablation (FLA). These technologies have largely solved the 
historic technical difficulties associated with delivering energy to targets deep within 
the body. In contrast, feedback mechanisms have progressed at a slower rate.  
The remainder of this chapter presents the state of the art in methods of 
monitoring thermal ablation and is divided into sections. The first section outlines the 
origin, mechanism of action, advantages and disadvantages of HIFU, RFA, MWA and FLA. 
The current approaches to monitoring the induced temperature change are outlined in 
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the second section. Examples of clinical application are provided where possible. 
Methods of modelling tissue damage based on thermal data are discussed in third 
section. Due to the limitations of these models, there is a growing interest in developing 
alternative techniques to assess thermal damage. Progress in this area is discussed in 
the fourth section. In the final section we discuss the need for real-time feedback and 
the barriers to clinical deployment of the most promising feedback technologies. 
 
2.3. Modern Thermal Ablation Modalities 
2.3.1. High Intensity Focused Ultrasound 
HIFU was initially used by Fry et al. [39] in 1954 to produce destructive lesions in the 
brain for neurological studies. It did not become popular until the 1980s when Coleman 
et al. [40] utilized the technology to treat glaucoma. This work led to the development 
of the first FDA approved HIFU device, the Sonocare CST-100 Therapeutic Ultrasound 
System (Sonocare Inc., NJ, USA) [41]. In 1989 Harr et al. [42] explored the possibility of 
using HIFU to treat liver tumors. Over 100,000 cases have since been treated including 
solid malignant tumors in the pancreas, liver, prostate and breast [34].  
HIFU relies on two mechanisms to cause tissue destruction: (1) conversion of 
mechanical energy into heat, and (2) acoustic cavitation. Mechanical energy propagates 
harmlessly through the tissue as a sound wave. Upon reaching a focal point its intensity 
is of sufficient magnitude to cause tissue necrosis. The first method, conversion of 
mechanical energy to heat, occurs because ultrasonic waves cause vibration and rotation 
of molecules resulting in the production of frictional heat. The second method of tissue 
destruction, acoustic cavitation, arises due to compression and rarefaction caused by 
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ultrasonic waves. If of sufficient magnitude the negative pressure created by rarefaction 
draws gas out of the tissues to form bubbles. These bubbles collapse violently resulting 
in mechanical damage to the surrounding tissue [43]. 
The primary advantage of HIFU is that it is non-invasive and utilizes non-ionizing 
radiation. From a clinical perspective this reduces cost, recovery time and risk of 
infection while the absence of scarring is cosmetically preferable. HIFU does have some 
drawbacks including longer treatment times, limited depth of penetration and the need 
for an excellent acoustic window [34]. It also struggles to target moving tissue and is 
therefore more suitable in stationary organs such as the kidney and prostate [44]. The 
liver for example is not an ideal organ given that it is subject to both respiratory motion 
and sonic shadowing caused by the ribs [43]. Skin-burn can result in the event of poor 
acoustic coupling between the therapeutic window and the skin. Damage can also be 
caused by US reflecting off hard surfaces such as bone or from gas-containing regions 
such as the bowel [43]. Reliable thermometry and feedback of lesion growth remain 
significant problems with HIFU. Although no technique has been perfected, sonographic 
thermometry [45] and elastography [34] may prove useful.  
 
2.3.2. Radiofrequency Ablation 
RFA was pioneered by French physicist Jacques-Arsene d’Arsonval in the late 19th 
century. He treated 75 patients for various conditions by placing them in large induction 
solenoids. The technique became known as “Arsonvalisation” [23]. In the early 20th 
century, diathermy, the heating of tissue by high frequency electrical currents, was 
introduced by the German physician Karl Franz Nagelschmidt [23]. Modern 
percutaneous RF ablation was successfully demonstrated independently by McGahan et 
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al. [46] and Rossi et al. [47] in 1990. This technique involves inserting insulated 
electrodes through the skin with the distal end exposed. Three years later RF ablation 
was successfully demonstrated in human liver tumors [48]. Today RF ablation is 
commonly used for primary hepatocellular carcinoma, neuroendocrine hepatic 
metastases, esophageal dysplastic lesions, primary and secondary liver malignancies 
[28]. 
In RFA, heat is generated in the tissue via ionic agitation [49]. A complete electric 
circuit is required between the electrodes and the grounding pads or between two or 
more electrodes. Current passes through tissue due to the presence of ionic fluid. The 
alternating current causes ions to oscillate back and forth rapidly resulting in the 
production of frictional heat. Thermal conduction enables heat to transfer to areas of 
the tissue that are not along the electrical path. 
As with all the techniques discussed here RFA is less invasive than traditional 
surgical approaches which results in lower cost, less risk of infection and faster recovery 
times. Of all of these techniques RFA is the most widely used [50]. In particular it is now 
the standard of care for surgical management of primary and secondary liver 
malignancies [28]. Disadvantages of RFA include the need for grounding pads which can 
cause skin burns and the necessity for tissue with good thermal and electrical 
conductivity [51]. 
 
2.3.3. Microwave Ablation 
Development of MWA applicators for tumor treatment began in the 1970s [52]. 
Numerous studies have since demonstrated that MWA therapy is capable of providing 
sufficient energy to control tumors via hyperthermia alone [53], [54] and significantly 
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increase the effectiveness of chemotherapy and radiotherapy [55]–[59]. The initial 
designs consisted of a single antenna; however, arrays were subsequently developed to 
increase the ablation volume and enable conformity to irregular tumor volumes [52]. 
Clinical trials have demonstrated the use of MWA for tumor treatment in the liver [60], 
lung [61], kidney [62], bone [63], pancreas [64], adrenal glands [63], brain [53], [55] and 
prostate [54], [65].  
Electromagnetic radiation can be visualized as a wave oscillating from a positive 
to negative electric charge. Water molecules are polar with the hydrogen side of the atom 
having a positive charge, while the oxygen side has a negative charge. The interaction 
between electromagnetic radiation and water thus causes the water molecule to flip as 
the sign of the electromagnetic radiation oscillates from positive to negative. The 
interaction is maximized as microwaves are tuned to the natural frequency of water 
molecules. The net result is that the molecules flip back and forth 2-5 billion times per 
second. Heat is created through friction and if of sufficient magnitude and duration will 
cause cellular death via coagulation necrosis [66]. 
In contrast to RFA, MWA produces higher tissue temperatures, larger ablation 
volumes, shorter ablation times and an improved convective profile [66]. In addition, 
MWA does not require grounding pads, which have been known to cause burns. MWA is 
also more effective than RFA in tissue with large heat sinks (kidney and liver) and tissues 
with poor electrical and thermal conductivity (lung and bone) [51]. While MWA has been 
identified as a possible replacement for RFA, there are some limitations that have 
prevented this from becoming a reality. Microwave power is more difficult to generate 
and deliver than that used in RFA or FLA as coaxial cables must be used. These cables 
are much thicker than those used in RFA and FLA and the cable itself is susceptible to 
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heating which causes energy delivery to surrounding healthy tissue. In addition MWA 
probes tend to be large and the resulting ablation zone tends to be long thin and difficult 
to predict [67]. Cooled-shaft antennas have recently been developed which allow higher 
power outputs while minimizing skin burns and undesirable heating from the cable [68]. 
 
2.3.4. Focal Laser Ablation 
In the 1980s the neodymium-doped yttrium-aluminum garnet (Nd:YAG) laser was used 
as a precise method of surgical dissection to treat head and neck tumors [44]. FLA was 
soon utilized to treat liver tumors with significant work being undertaken in the late 
1980s and early 1990s by Hashimoto [69], Hahl et al. [70] and Dowlatshahi et al. [71]. 
The results of a clinical trial by Nolsoe et al. [72] in 1993 successfully demonstrated that 
the procedure was both efficacious and safe. Since then FLA has found utility in the 
treatment of tumors in many organs including prostate [11], [29], [73], breast [74], liver 
[75], lung [76] and brain [77]. 
FLA causes temperature elevation due to the transfer of photon energy to kinetic 
energy. This process consists of two steps; absorption and deactivation. In the 
absorption step the target molecule (A) absorbs a photon of light with energy ℎ𝜈 and is 
promoted to an excited state (A*): 𝐴 + ℎ𝜈 → 𝐴∗ . By colliding with a neighboring molecule 
(M) the target molecule becomes deactivated and the photon energy increases the kinetic 
energy of M:  𝐴∗ + 𝑀(𝐸𝑘𝑖𝑛) → 𝐴 + 𝑀(𝐸𝑘𝑖𝑛 + Δ𝐸𝑘𝑖𝑛). Ultimately this increase in kinetic energy 
results in tissue destruction [24].   
Due to its minimally invasive nature, FLA has the same advantages as the other 
techniques in terms of cost, length of hospital stay, and chance of infection. In addition, 
the optical fibers used in FLA are of smaller diameter than probes used by MW and RF. 
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This makes FLA ideal for small organs such as the prostate. However, in FLA, high 
temperatures immediately adjacent to the laser fiber can cause carbonization. The 
resulting charring severely limits optical penetration and thus prevents further lesion 
growth. In other modalities such as MWA, charring does not prevent energy transfer. 
Another limitation is the small ablation zone, typically 10-15mm in diameter. To create 
larger ablation zones multiple ablations can be undertaken by moving the fiber or by 
using a beam spitting multiple fiber system [78]. 
 
2.4. Thermal Dosimetry 
Achieving accurate thermal dosimetry is a necessary prerequisite to estimating damage 
using traditional approaches such as the Arrhenius model. There are many methods 
available to record temperature, most of which have been adapted from various 
industrial applications. Thermal dosimetry can be divided into four groups: 
thermography, electrical probes, optical fiber probes and radiologic imaging. 
 
2.4.1. Thermography 
Thermography enables the recording of temperature over a 2D area using noninvasive 
techniques. There are three common types: liquid crystal, infrared and microwave. 
 
Liquid crystal 
Liquid crystals are organic compounds such as cholesterol derivatives. They reflect light 
in a temperature dependent manner as the wavelength reflected decreases with rising 
temperature. The sensor must contact the material whose temperature is being 
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examined. Thermochromic liquid crystals are particularly useful for determining 
thermal profiles when developing complex ablative techniques [79], [80]. Clinically they 
were once considered to have some limited utility in breast cancer detection [81]. 
Thermochromic liquid crystals must be sprayed onto the location of interest and thus 
are not suitable for interstitial use; hence, the scarcity of reports on clinical utilization. 
 
Infrared  
This technique uses an infrared (IR) camera to record electromagnetic radiation emitted 
from the target surface. The sensor is either a crystal of mercury-cadmium-telluride or 
indium-antimonide, both of which change electrical conductivity depending on the 
radiant power received [82]. IR cameras have been used in the development of ablative 
techniques [83]–[86] but not in a clinical setting. This is likely due to the requirement for 
a direct line of sight which is difficult to achieve in minimally invasive treatment. 
 
Microwave 
Microwave signals are detected using a radiometer which consists of an antenna and 
receiver. The radiometer can either be in contact or at a distance from the target. In 
contrast to the aforementioned techniques, microwave thermography can detect signal 
from subsurface tissues. The depth of penetration decreases with increasing frequency 
while the opposite is true for spatial resolution, hence, a balance must be struck between 
these two desirable characteristics. It is possible to undertake interstitial monitoring of 
ablative therapies [87]; however, adoption of this technique has been limited due to poor 
spatial and temporal resolution. In addition, ablation tends to form air bubbles within 
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the target which scatters microwaves and thus interferes with temperature estimation 
[88]. 
 
2.4.2. Electrical Probes 
An alternative to 2D thermographic mapping is 1D point measurements via interstitial 
electrical probes. 
 
Thermistors 
Thermistors work on the semiconductor property that electrical resistance decreases as 
temperature increases [89]. They can be manufactured with very small dimensions; outer 
diameters of 1mm are attainable. In addition they possess fast response times on the 
order of one second [82]. Self-heating and conduction can cause significant errors. Self-
heating occurs when the probe absorbs energy at a faster rate than the surrounding 
tissue. Such a scenario would arise if a probe was placed within two optical penetration 
depths of a laser during FLA. Furthermore, the thermal conductivity of metals can be up 
to 1000 times greater than soft tissue. As a result conduction error can occur when the 
probe is placed in a high temperature gradient [82]. Metals also possess a density 3-10 
times greater than soft tissue. This becomes a problem in HIFU procedures. Due to the 
density mismatch the ultrasound wave induces relative motion between the tissue and 
wire. Friction leads to a heating affect called ‘viscous heating’ which artificially inflates 
the temperature measurement [90]. Nevertheless thermistors have been used to monitor 
temperature during MWA [68], RF ablation [91] and FLA [74]. 
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Thermocouples 
Thermocouple sensors are based on the Seebeck effect which states that an electrical 
potential difference occurs between two points in an electrically conducting material if 
they are simultaneously at different temperatures. Junctions are required to make an 
effective sensor as unlike thermistors, thermocouples are relative sensors. One 
conductor must be at a known temperature as the voltage produced depends on the 
temperature difference between the two conductors [92]. Advantages include low cost, 
versatility and ability to measure temperature over a wide range [82]. In contrast to 
thermistors, thermocouples come in a very small form factor with micro-thermocouples 
having outer diameters well below 1mm. 
Rapid response times of 0.1s are also advantageous [82]. Micro-thermocouples 
have been used to monitor temperature at the tumor boundary during laser induced 
hyperthermia [93]. Thermocouples are manufactured from metal and suffer from self-
heating and conduction errors as described for thermistors. Thermocouples are 
frequently incorporated into the design of RF electrodes to enable temperature 
monitoring at the tip of the electrode [94], [95]. Thermocouples have also been used to 
monitor MWA [96], [97] and FLA [98], [99].  
 
2.4.3. Fiber-optic Temperature Sensors 
The primary advantage of fiber-optic temperature sensors is that they contain no 
metallic components and as such are suitable for environments containing electrical and 
magnetic fields. This is a major advantage as many thermal ablation procedures are 
carried out under MR guidance. There are two types of fiber-optic temperature sensors 
suitable for monitoring ablation procedures: fluoroptic probes and fiber Bragg Grating 
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(FBG) sensors. Both of these sensors are invasive as they require thermal coupling with 
the tissue.  
 
Fluoroptic Probes 
Fluoroptic probes consist of a sensor composed of phosphor and a pulsed light source 
such as a xenon flash lamp. The phosphor sensor is placed at the end of an optical fiber. 
The light source causes the phosphor to fluoresce. Its decay is temperature dependent; 
therefore, temperature can be derived by recording the decay time [92].  Both excitation 
and emission occur along a single optical fiber which can be interstitially placed to 
provide a point measurement. This technology was pioneered by Lumasense 
Technologies (Santa Clara, Ca, USA) in the 1970s. These probes can achieve an accuracy 
of 0.5°C and a range of -100°C to +330°C with a measurement rate of up to 4Hz. Probe 
diameter can be as small as 0.25mm with a response time of 200ms.  
A disadvantage of this system is artifact induced during FLA. FLA is frequently 
performed using light at a wavelength of 980nm. This lies within the spectrum used by 
the fluoroptic temperature measurement system. As a result, considerable measurement 
error can occur if probes are placed too close to the laser fiber. This artifact can be 
mitigated by coating the probe with an optically opaque material or blocking the 
offending wavelength with a filter. Self-heating can also occur due to absorption of light 
by the probe coating [100]. Fluoroptic probes have been used in clinical trials for the 
treatment of prostate cancer using FLA [29], [73] and MWA[65] as well as RFA for breast 
cancer [101]. 
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Fiber Bragg Grating Sensors 
In contrast to fluoroptic probes, FBG sensors are capable of measuring temperature at 
multiple positions in the same optical fiber. FBG sensors use an optical fiber with a 
periodic variation in refractive index. Light travelling down the fiber is then reflected in 
a wavelength specific manner. Most of the reflected light causes destructive interference 
but at a narrow range of wavelengths constructive interference allows light to travel back 
up the fiber. The maximum reflectivity occurs at the Bragg wavelength given by: 
𝜆𝑏 = 2𝜂𝑒𝑓𝑓𝛬 
where 𝜂𝑒𝑓𝑓 is the refractive index and 𝛬 is the FBG period. A shift in wavelength occurs 
when either a change in strain or temperature is applied. For this reason, if used as an 
interstitial temperature sensor the fiber must be protected by a rigid support. By 
removing the strain dependence, the shift in wavelength can be used to determine 
temperature [102]. 
Using multiple FBGs in the same fiber enables distributed temperature sensing 
(DTS) along the length of the fiber. The two most common approaches for DTS are 
Wavelength-Division Multiplexing (WDM) and Time-Division Multiplexing (TDM). In WDM 
many different FBGs with unique Bragg wavelengths are distributed along the fiber. A 
tunable swept-wavelength light source is used to emit light at wavelengths matching the 
Bragg wavelengths of the FBGs. In this way the location of the reflected wave is 
determined by its wavelength. The width of the FBG reflections and the light source 
limits the number of sensors in a given channel to approximately 100. The alternative 
approach, TDM, utilizes a pulsed broadband light source. Sensor location is determined 
by the time it takes to receive the reflected light. Sensor spacing must be sufficient to 
differentiate pulses from adjacent sensors. There is no tunable laser in this system, thus 
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it is considerably less expensive than the WDM approach [102]. A major advantage of 
FBG sensors is that multiple FBGs can be incorporated into a single fiber. Submillimeter 
resolution with an accuracy of ±0.5°C has been demonstrated during ex vivo monitoring 
of RF ablation [103].  Adoption of this technology for medical applications has been 
hindered by the relatively high equipment costs [104]. 
 
2.4.4. Radiologic Imaging 
Acoustic Temperature Sensors 
There are numerous ultrasound parameters that exhibit temperature dependence 
including frequency-dependent attenuation and back scattered power but the shift in 
ultrasound frequency signal appears the most promising. The shift in signal occurs due 
to thermal expansion and a change of the speed of sound in the medium with 
temperature elevation. Thermal expansion has only a minor effect in comparison to the 
temperature dependence of the speed of sound. The primary limitation is that the speed 
of sound increases only in non-fatty tissues and only up to 50°C [105], thus, this 
technique is inappropriate for hyperthermia at high temperatures.  
Acoustic temperature sensing is used commercially in the Sonablate®500 HIFU 
system which provides a package called ‘Tissue Change Monitoring’ (TCM). TCM uses 
spectral analysis of RF backscattered ultrasound signals to estimate tissue temperature. 
The reliability of this technique remains to be proven. Focus Surgery, the developer of 
the Sonablate system, performed an in vivo study to assess the accuracy of the TCM 
system [106]. 5 men with histologically confirmed prostate cancer received HIFU 
treatment. Temperature within the target zone was monitored via thermocouples and 
TCM. The average temperature found was 84°C and 91°C for the thermocouples and TCM 
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software respectively. While the study clearly demonstrates a correlation between TCM 
readings and temperature, the accuracy of the system deteriorates above 50°C. The 
authors speculate that this may be due to tissue expansion and cavitation/microbubbles.  
 
Magnetic Resonance Thermometry  
Magnetic resonance thermometry (MRT) provides a non-invasive method for monitoring 
thermotherapy. MR parameters such as T1 relaxation [107], T2 relaxation [108] and water 
diffusion [109] are temperature dependent; however, proton resonance frequency (PRF) 
shift is the dominant approach [110] for MRT. The PRF method takes advantage of the 
linear correlation between temperature and the frequency shift of protons. The 
frequency shift is determined by measuring the difference in phase acquired by two 
gradient echo scans. The change in temperature between the scans (Δ𝑇) is given by: 
Δ𝑇 =  
φ − φref
𝛾 ∙ 𝛼 ∙ 𝐵0 ∙ 𝑇𝐸
 
where 𝛼 is the PRF change coefficient, TE is the time to echo of a gradient echo pulse 
sequence, 𝜑 is the phase of the acquired signal, 𝜑𝑟𝑒𝑓 is the phase of the reference signal, 
𝛾  is the gyromagnetic ratio and 𝐵0 is the magnetic field strength of the MR scanner. 
The need for a baseline phase image renders this technique inherently vulnerable 
to motion artifact (Figure 2). Clinically, these artifacts can arise due to cardiac, 
respiratory, peristaltic or bulk motion. In an effort to mitigate this limitation a 
referenceless approach was developed in which the reference phase is acquired from a 
region outside the thermotherapy zone instead of the baseline scan [111]. This approach 
has been successfully demonstrated in vivo for monitoring ablation of the liver via FLA 
[112] and HIFU [113].  Regardless of the approach used the references signal must be 
acquired from a region of known temperature. This is generally assumed to be 37°C; 
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however, this assumption is not always valid. Bitton et al. found that residual heat from 
successive ablations during HIFU could result in a baseline temperature as high as 50°C 
resulting in a 91% underestimate of the induced damage zone [114]. The PRF approach 
suffers from many other sources of error including perfusion-based phase changes, 
ablation induced structural changes and magnetic susceptibility variations. These issues 
are covered in greater details in an excellent review article by Winter et al. [115]. 
A further limitation of MRT is the inability to use ferromagnetic materials, which 
necessitates the development of specialized tools. Poor temporal resolution and spatial 
averaging can also limit utility. The temperature measured by MRI is averaged for each 
voxel and has been shown to be up to 30% less than the peak value within the voxel 
[116]. Nevertheless, PRF shift thermometry is a promising non-invasive technique and 
has been used clinically to monitor FLA [29], RFA [117] and HIFU [118] and MWA [65]. 
 
 
Figure 2: Comparison of MR thermometry and interstitial thermal probe measurement during FLA for the treatment of 
prostate cancer. Motion artifact is responsible for the noise evident in the MR data [73]. 
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CT Thermometry 
X-ray attenuation depends on the interaction between the x-ray and the intervening 
tissue which is primarily Compton scattering. Compton scattering is influenced by 
temperature and although it is beyond the scope of this review paper to discuss the 
physics in further detail it can be shown that the relationship between temperature and 
received x-ray intensity is given by: 
Δ𝐶𝑇 ≈  −[1000 + 𝐶𝑇(𝑇0)] ∙ 𝛼 ∙ Δ𝑇 
where Δ𝐶𝑇 is the change in CT number due to a change in temperature, 𝐶𝑇(𝑇0) is the 
initial temperature, 𝛼 is the volumetric expansion coefficient and Δ𝑇 is the change in 
temperature [104]. This technique is rarely used as CT scans subject patients to 
excessive ionizing radiation. Nevertheless experimental work has demonstrated that it 
can be used to monitor both FLA [119] and RFA [120]. Further information on this topic 
can be found in a recent review article by Fani et al. [121]. 
 
2.5. Damage Estimation 
In oncology, the goal of thermal ablation is to destroy cancerous cells while minimizing 
damage to surrounding structures. This may be achieved using thermal data in 
conjunction with damage estimation models such as the Arrhenius model and the 
Thermal Isoeffect Dose model. 
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2.5.1. Arrhenius Model 
The Arrhenius model was developed by Swedish chemist Svante Arrhenius (1859-1927) 
to demonstrate the relationship between temperature and the rate constant of a 
chemical reaction: 
𝑘 = 𝐴𝑒−
𝐸𝑎
𝑅𝑇 
where k is the chemical reaction rate constant (s-1), A is the pre-exponential/frequency 
factor [s-1], 𝐸𝑎 is the activation energy barrier [J mole
-1], R is the universal gas constant 
(1.987 x 10-3 Kcal/mole∙ 𝐾, and T is the temperature (K). Arrhenius’ equation 
demonstrates that lower activation energies and higher temperatures increase the rate 
constant of a given reaction. The exponential part quantifies the fraction of reactant 
molecules with sufficient energy to react in accordance with the Maxwell-Boltzmann law. 
The pre-exponential factor is the product of the rate at which molecules come into 
contact, the frequency/collision factor (Z), and the relative orientation of those 
molecules called the steric factor (𝜌) i.e. 𝐴 = 𝑍𝜌. 
This first order rate process model was first applied to hyperthermia by Moritz 
and Henriques in 1947[122]–[125]. In their work, damage was quantified using a single 
parameter (Ω) as shown below: 
ln (
𝐶(0)
𝐶(𝑡)
) =  𝐴 ∫ 𝑒
−
𝐸𝑎
𝑅𝑇(𝑡)
𝜏
0
 𝑑𝑡 = Ω(𝑡) 
where C(0) is the concentration of viable cells before the procedure and C(𝝉) is the 
concentration at time=𝝉. The fraction of surviving cells is thus given by: 
𝐶(𝜏) = 100𝑒−Ω (%) 
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In practice the kinetic parameters (A and Ea) must be determined a priori. This can be 
done experimentally by assuming the tissue becomes non-viable at a certain fraction of 
remaining cells. This value is often assumed to be 36.8% which implies that Ω = 1.  
 
2.5.2. Thermal Isoeffect Dose Model 
Thermal damage is a function of the magnitude in the change of temperature (Δ𝑇) and 
the duration of said change; therefore, the °C∙min may seem an appropriate metric. 
However, this metric fails to account for variation in the rate of cell death. For example, 
if temperature was raised from 37°C to 42°C and held for 10 minutes one would get 
50°min. An elevation from 37°C to 62°C for 2 minutes also results in 50°min. The latter 
results in far greater cell death than the former; therefore, the °C∙min unit cannot be 
used as a measure of thermal damage [126]. Similarly, analysis based on energy input 
using a unit of Joules is also biologically meaningless as it fails to consider the duration 
of time at the elevated temperature. Moreover, in traditional hyperthermic treatment the 
tissue in question is gradually heated and thus time at desired elevated temperature is 
less than total exposure duration. To solve these issues the thermal isoeffect dose (TID) 
model was introduced by Sapareto and Dewey [127]. The TID model converts thermal 
history into cumulative equivalent minutes at 43°C (CEM43) and is calculated as follows 
[128]: 
𝐶𝐸𝑀43 =  ∑ 𝑡 𝑥 𝑅
43−𝑇𝑖  
𝑁
𝑖=1
 
Where CEM43 is the cumulative number of equivalent minutes at 43°C, t is the time 
interval (min), T is the average temperature during the time interval t and R is the 
number of minutes needed to compensate for a 1°C temperature change to an isoeffect 
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of thermal injury. The parameter R is dependent on temperature and the activation 
energy: 𝑅 = 𝑒−𝐸𝑎/(𝑅𝑔𝑇(𝑇+1) where Rg is the gas constant. Further details on both models 
can be found in an excellent review article by Dewhirst et al. [128]. 
 
2.5.3. Challenges with Traditional Models 
The TID model is derived from the Arrhenius model; however, due to some assumptions 
and simplifications the results are not necessarily identical. The TID and Arrhenius 
models provide similar results below 50°C ; however, the TID model tends to 
underpredict thermal injury for temperatures exceeding 50°C [129]. Many studies have 
set R to a constant value of 0.5 for traditional hyperthermia techniques which utilize 
temperatures below 50°C. While appropriate for such conditions this assumption 
provides erroneous results for hyperthermia techniques above 50°C which is commonly 
observed during ablation procedures. Instead R should be calculated as a function of 
temperature and activation energy [129]. 
A major limitation of both models is the requirement for a priori knowledge of 
the kinetic parameters. Bhowmick et al. conducted a study to determine these 
parameters for the prostate [130]. In that study, 1mm thick slices of prostatic tissue 
were placed on a temperature-controlled copper block. Tissue response for various 
temperature-time combinations was assessed via histology and die uptake assays. Table 
1 shows the empirically derived kinetic parameters found by Bhowmick et al. as well as 
many other authors. The difficulty obtaining reliable values is elucidated by the 
conflicting results of the dye uptake and histology study in the Bhowmick study alone 
[130].  Furthermore, throughout the literature many different values have been derived 
for the same tissue. Some of the difficulty is attributed to the fact that the kinetic 
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parameters depend on the cell or tissue type analyzed, the injury assay (clonogenics, 
dye uptake, histology) used and the time permitted post thermal therapy to allow for 
injury manifestation [129].  An inability to ensure isothermal heating is also an issue 
with errors occurring due to either temperature gradients existing in the tissue or 
damage incurred during the ramping up and down of temperature to the desired 
magnitude. The general trend is that dye uptake assays for cell injury provide a lower 
activation energy and higher thermal threshold than clonogenics assays and similar 
results to histology [129]. Recently, MacLellan et al. demonstrated a method of deriving 
the thermal dose parameters using a combination of thermal data gathered in real-time 
via MRT and post-treatment T1-weighted MRI [131]. The technique requires only 
retrospective analysis of clinically acquired data; thus, it greatly simplifies the 
acquisition of the model parameters in comparison to traditional laboratory 
experiments. Perhaps this technique will lead to improved quantification of the thermal 
dose parameters and facilitate widespread implementation of the Arrhenius model. 
There is considerable uncertainty involved in finding accurate kinetic parameters 
and relatively minor differences in these parameters can have a major impact on 
predicted damage volume. In Table 1 we have calculated the percentage of surviving 
cells for various kinetic parameters using the Arrhenius model with an exposure 
duration of 4 minutes and a temperature of 55°C. This is an idealized scenario but it 
demonstrates a number of important points that need to be considered when designing 
a treatment monitoring system. Firstly, kinetic parameters are organ-specific. In this 
case, if the parameters for skin were used for the kidney or prostate the treatment 
monitoring system would incorrectly indicate a survival of less than 3%. Secondly, even 
if organ specific kinetic parameters are used, the reliability of the Arrhenius model for 
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oncologic control remains unclear. For example, in prostate the parameters from the 
Rylander study indicate a cell survival under 5% in this scenario. In contrast the kinetic 
parameters found by Bhowmick et al. suggest approximately 60% of the cells will survive.  
The Arrhenius model is currently utilized clinically by the Visualase system (Medtronic, 
Dublin, Ireland) for monitoring FLA. A recent study found that the Visualase system 
overestimates the volume of tissue damage when compared to histopathology [132]. 
This may have occurred due to the utilization of inaccurate kinetic parameters. 
Alternatively, erroneous thermal data could have been responsible as the Visualase 
system relies on MRT which is susceptible to numerus sources of error including motion 
artifacts. Nevertheless, the Arrhenius and TID models represent promising solutions for 
damage estimation based on thermal data. In the next section, methods of monitoring 
ablation that do not rely on thermal data will be discussed. 
Table 1: Kinetic Parameters and Percentage Surviving Cells after 4 Minutes Exposure at 55°C 
 Ea (kJ mole
-1) A (s-1) Survival (%) 
Prostate 
Bhowmick (dye uptake) [130]  167.8 1.10 × 1024 59.78 
Bhowmick (histology) [130] 160.7 7.78 × 1022 61.20 
Rylander [133] 124 7.00 × 1017 4.64 
    
Kidney 
He (cell suspended) [134]  287.49 4.36 × 1043 16.39 
He (cell attached) [134] 314.89 3.15 × 1047 56.65 
Walsh [135] 202.6 1.29 × 1029 84.01 
    
Skin 
Henriques [122] 630 3.10 × 1098 2.07 
Weaver [136] 327 1.82 × 1051 ~0 
Takata [137] 669 9.39 × 10104 0.07 
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2.6. Non-Thermal Feedback Techniques 
Numerous methods of damage estimation exist which do not rely on thermal data and 
damage models. Techniques based on ultrasound, MRI and thermally induced changes 
in optical properties have been demonstrated; however, in many cases the clinical utility 
of the technology remains to be seen. This section is divided into the following 
categories: 1) Ultrasound Imaging, 2) Elastography and 3) Optical Monitoring. 
 
2.6.1. Ultrasound Imaging 
B-mode imaging  
In conventional B-mode images the induced lesion appears as a hyperechoic region. This 
is caused by the formation of acoustically or thermally generated bubbles which scatter 
more incident ultrasound than normal tissue [105]. While this method can identify the 
lesion, the margin remains poorly identified making it difficult to differentiate 
coagulated from healthy tissue.  Nevertheless, B-mode imaging has been used with HIFU 
[138] and MWA in China [139]. B-mode imaging has also been used clinically to monitor 
RFA of hepatic tumors but was found to result in significantly fewer complete ablations 
in comparison to contrast enhanced ultrasound (p=0.043) [140]. FLA for liver metastases 
has also been monitored via B-mode imaging; however, the authors noted that the 
margins were ‘irregular and poorly defined’ and insufficient for assessing the true extent 
of the ablation zone [141]. 
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Nakagami Imaging 
Nakagami imaging utilizes a statistical model to calculate the Nakagami parameter from 
the backscattered ultrasound signal [142]. Like B-mode imaging, contrast is generated 
due to the formation of bubbles in the ablation zone. In a recent study by Zhang et al. 
the Nakagami parameter was found to increase from 0.47 to 0.82 during MW ablation of 
ex vivo porcine liver [143]. In addition, Nakagami imaging exhibited a superior contrast-
to-noise than conventional B-mode imaging.  Similar results were found by the same 
group during HIFU in tissue-mimicking phantoms [142]. Experiments in porcine liver 
have also demonstrated the potential for RFA monitoring [144]. Interestingly, in the 
same study Nakagami imaging was found to be unsuitable for monitoring RFA in muscle 
tissue. It was hypothesized that muscle fibers act as strong scatterers thus limiting the 
effect of increased scatter from bubble formation. Additionally, there may be greater 
bubble formation in liver tissue as hepatic cells contain more intercellular fluids than 
muscle fibers. Motion and tissue inhomogeneity can also degrade parameter estimation. 
The use of Nakagami imaging in monitoring thermal ablation is a relatively recent 
development and further in vivo studies are required to fully demonstrate its potential. 
 
Contrast Enhanced Ultrasound  
Contrast enhanced ultrasound (CEUS) was developed to assess perfusion and has been 
used to detect tumors as tumors generally possess increased microvessel density. The 
technique involves injecting US contrast agents, which consist of small encapsulated gas 
bubbles into the vasculature. This increases the sensitivity of Doppler imaging thus 
enabling assessment of perfusion [145]. Thermal ablation results in a nonperfused 
lesion which appears as a hypoechoic region on CEUS images [29]. This has been 
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successfully demonstrated for lesions induced by FLA [146], HIFU [147], MWA [148] and 
RFA [149]. 
In 2015 Peng et al. [150] used intraprocedural CEUS to monitor HIFU treatment of 
uterine fibroids. Figure 3 clearly shows the development of an ablated zone as treatment 
progresses. In many studies the ablated volume is defined as the non-perfused region 
observed on post-treatment contrast enhanced MRI. In the study by Peng et al. there was 
no statistical difference between the non-perfused volume determined by CEUS 
immediately post-treatment and that found using MRI the following day. In an earlier 
study by Kennedy et al. [151] the ablated region identified by CEUS was confirmed via 
histologic analysis. CEUS has also been shown to perform at least as well as MRI and CT 
in the follow-up of patients treated for liver tumors by RFA [152]. Intraoperative CEUS 
offers a simple, effective, low cost method of monitoring thermal ablation. In 
comparison to temperature-based methods, it does not rely on the Arrhenius model. The 
advantage of CEUS was demonstrated by Solbiati et al. who noted that the introduction 
of CEUS resulted in a drop in the rate of partially ablated liver tumors from 16.1% to 
5.9% [149]. 
 
 
Figure 3: CEUS of uterine fibroid before(A), during (B) and after HIFU treatment (C) [150] 
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2.6.2. Elastography 
Elastographic techniques aim to map a tissues Young’s modulus (E), analogous to the 
palpation techniques long employed by clinicians when diagnosing tumors. Ablated 
tissue tends to be stiffer thus elastography can estimate the extent of ablation [105], 
[153], [154]. Ultrasound and MRI based elastography have been developed.  
Ultrasound elastography can be divided into two categories: static methods and 
dynamic methods. In static elastography a constant stress is applied to the tissue and 
resulting displacement is recorded. Strain can then be calculated; thus, providing a strain 
map called an elastogram. The Young’s modulus cannot be found as the applied stress 
is unknown.  
In dynamic methods either ultrasound radiation pressure or an eletro-mechanical 
actuator is used to induce shear waves in the tissue. By measuring the speed of 
propagation of these images one can calculate the shear modulus (𝜇) which is directly 
related to the Young’s modulus (𝐸 = 3𝜇) [155]. Dynamic methods suffer due to the 
presence of both compressive and shear waves within the imaged medium. To combat 
this transient elastography was developed which naturally separates these waves by 
tracking the shear waves induced by a short high intensity pulse [155]. 
 
Vibroacoustography 
Vibroacoustography (VA) is a dynamic elastography method which was introduced by 
Fatemi and Greenleaf in 1998 [156], [157]. It uses two confocal beams with slightly 
different center frequencies to cause a target to vibrate at a specified frequency. 
Mechanical properties of the target, including stiffness, can be determined by listening 
to the resulting sound. An image can be created by sweeping the focal spot across the 
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region of interest. Sweeping leads to an extended acquisition time which may prove 
problematic for in vivo applications, particularly where real-time imaging is required 
[155]. 
VA has been shown to be capable of quantifying lesion size post HIFU in an ex 
vivo animal study [158]. It has also been successful in identifying the frozen tissue 
induced during ex vivo prostate cryotherapy [159].  Although it has not been clinically 
demonstrated, evidence in the literature suggests that transrectal vibroacoustography is 
capable of delineating structures and anatomical zones within the prostate [160].  
 
Acoustic Radiation Force Impulse Imaging 
In contrast to vibroacoustography, acoustic radiation force impulse imaging (ARFI) is a 
transient elastographic technique. It was developed by Nightingale et al. in 2001 [161], 
[162]. ARFI uses a single focalized ultrasound beam to cause tissue displacement via a 
short duration (<1ms) high intensity acoustic pulse. The transducer then switches to 
imaging mode to detect displacements of the focal spot. Like VA, a 2D image can be 
acquired by sweeping the focal point across the ROI. Although this technique is safe, it 
has been shown to induce localized tissue heating [163]. Young’s modulus is not directly 
quantified, instead it is estimated by measuring parameters such as displacement and 
relaxation times [155]. 
Fahey et al. demonstrated that ARFI can be used to monitor ablation in real time 
[164]. In that study RFA was performed in vivo on ovine myocardial tissue under ARFI 
surveillance. It was found that ARFI is capable of determining lesion location, shape and 
size during the procedure. In a follow up study by Eyerly et al. it was found that ARFI 
can visualize RFA induced lesion dimensions with less than 2mm error [165].  Bing et al 
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demonstrated that HIFU and ARFI imaging can be accomplished with the same 
ultrasound transducer [166]. Custom beam sequences were used to identify the target, 
induce hyperthermia and monitor the formation of the resulting ablation lesion.  Fahey 
et al demonstrated ARFI during liver RF ablation in 5 patients [167]. Kwon et al. 
performed a similar study in 38 patients [168]. ARFI has been commercialized by 
Siemens Medical Solutions and is available on their ACUSON S2000™ in the Virtual 
Touch™ tissue Imaging tool. 
 
Supersonic Shear Imaging  
Supersonic shear imaging (SSI) was pioneered by Bercoff et al. in 2004 [169] The 
technique builds on pioneering work by Armen Sarvazyan who previously developed 
shear wave elasticity imaging (SWEI) [170]. SSI uses focused ultrasound beams to 
produce sources of mechanical vibration within tissue. These sources emit low 
frequency shear waves. By moving the source at speeds greater than the speed of sound, 
two intense plane shear waves are created via constructive interference. This is 
analogous to the “sonic boom” created by supersonic aircraft. The propagation of these 
waves is recorded using an ultrafast scanner which can acquire images at 5000 frames/s. 
Inversion algorithms are then used to create a shear wave elasticity (SWE) map of the 
analyzed medium [169], [171]. 
Mariani et al. demonstrated the use of SSI for monitoring RFA [172]. 29 in vivo 
thermal lesions were induced in porcine liver. The liver mean elasticity increased from 
6.4±0.3 kPA before RFA to 38.1±2.5 kPA post-ablation. Using a threshold of 20 kPa this 
technique correctly identified necrosis with a positive predictive value of 0.83 and a 
sensitivity of 0.8. In contrast, an expert radiologist failed to clearly delineate the induced 
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thermal lesion in 70% of cases using B-mode guidance. The contrast between the two 
methods is clearly elucidated in Figure 4 below. SSI is now available on the Aixplorer® 
system by SuperSonic Imagine but does not appear to have been used clinically for 
monitoring ablative therapy. 
 
 
Figure 4: Shear wave elasticity map (Top) and B-mode image (bottom)  obtained after creation of a thermal lesion in 
porcine liver [172]. SWE identifies the lesion as a region of increased stiffness. 
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Harmonic Motion Imaging 
In contrast to other elasticity imaging techniques Harmonic Motion Imaging (HMI) 
induces a spatially invariant internal vibration within the target via an amplitude-
modulated waveform. Tissue mechanical properties can then be derived by analyzing 
the dynamic tissue response [173]. Harmonic Motion Imaging for Focused Ultrasound 
(HMIFU) combines this technique with HIFU providing real-time synchronous monitoring 
of temperature-induced alteration of tissue mechanical properties [174]. This technique 
was successfully demonstrated in ex vivo porcine liver where the onset of coagulation 
was found to coincide with irreversible change in tissue mechanical properties [175]. A 
post-ablation increase in tissue stiffness was observed as has been described in previous 
works [153]. 
Similar results were found in an in vivo study using rabbit muscle [176]. In this 
study the ability to linearly scan a target region to identify the extent of coagulation was 
demonstrated. This technique has also been successfully demonstrated in vivo in 
transgenic breast cancer mouse [177]. Moreover, a recent in vitro study by Han et al. 
found good agreement between the depth (r2 = 0.81), width (r2 = 0.85) and area (r2 = 0.75), 
quantified via HMI and gross pathology [178]. The study was performed using HIFU on 
a canine liver. While existing literature focuses on the combination of HMI with HIFU, 
the technique could potentially be used with any ablation modality. 
 
Magnetic Resonance Elastography (MRE) 
MRE has been shown to provide accurate measurements of lesion size when compared 
to pathology. MRE involves applying a known force to the tissue and imaging the 
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resulting shear waves as they propagate through the tissue [179]. Moreover, It is feasible 
to measure temperature and stiffness simultaneously using MRE techniques [180]. 
Chen et al. demonstrated that MRE is capable of measuring stiffness changes 
induced by FLA [181]. In that study FLA was performed in vivo on porcine liver. A novel 
inertial acoustic driver was used to induce mechanical waves enabling tissue stiffness to 
be determined before, during and after FLA. Figure 5 shows elastograms obtained before 
(a) and after (b) FLA was performed for 2min at 15 W. The increase in tissue stiffness is 
clearly depicted in Figure 5 (C) along a profile through the ablation zone. As yet MRE has 
not been used clinically to monitor ablation. 
 
 
Figure 5: MR elastograms obtained before (A) and after (B) a 15 W laser application for 2min in porcine liver. The 
change in stiffness along a profile through the ablation zone (C) [181]. 
 
2.6.3. Optical Monitoring  
The techniques outlined in this section take advantage of thermally induced changes in 
tissue optical properties. While these techniques may appear complex in nature, the 
underlying principle is akin to visualizing the difference between raw and cooked meat. 
In contrast to the previous techniques in this section, optical monitoring requires line-
of-sight access and therefore interstitial probes must be used. 
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Diffuse Optical Spectroscopy 
Diffuse Optical Spectroscopy requires an interstitial fiber optic needle which is used to 
emit a spectral band of light and record the diffuse reflectance or fluorescence. Thermal 
ablation has been shown to increase reflectance intensity and decrease fluorescence 
intensity. Anderson et al. monitored both fluorescence and diffuse reflectance during 
canine hepatic RFA and demonstrated a correlation between thermal damage and the 
absolute magnitude of spectral change [182]. Similar results were reported by Buttemere 
et al. [183] and Hsu et al. [184]. In contrast to thermal monitoring, spectral changes 
persist after cooling thus margins can be interrogated both during treatment and 
immediately afterwards. 
Spliethhoff et al. argued that the absolute spectral intensities are sensitive to 
needle positioning, pooling of coagulated blood and instrument calibration [185]. In an 
effort to create a more robust method they proposed the use of an optical ablation ratio 
(OAR). The OAR is based on a first-order derivative analysis of the diffuse reflectance 
signal. In a follow-up study by the same group, 8 patients received RF ablation for the 
treatment of unresectable liver metastases [186]. Spectra were acquired using two 
different source-detector separation distances denoted long distance (LD) and short 
distance (SD). As shown in Figure 6, there was a significant increase in the OAR value 
between native and ablated tissue for both configurations (p < 0.01). 
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Figure 6: Optical ablation ratio in liver parenchyma (a) and liver metastases (b) before and after RF ablation. Data 
acquired from 8 patients. Figure adapted from Tanis et al. [187]. 
 
Interstitial Point Optical Measurements 
Whelan et al. demonstrated a method of monitoring FLA by placing an interstitial fiber 
optic sensor at a distance from a source fiber and recording the optical intensity during 
laser activation [188]. A 49% decrease in optical intensity was observed by an optical 
detection fiber placed 5mm from the source during FLA of in vivo porcine kidney. Similar 
results were observed for ex vivo bovine tissue where the optical intensity decreased by 
up to 83%. The decrease in optical intensity is attributed to an increase in the reduced 
scattering coefficient as a result of tissue coagulation. Further work by the same group 
supports this approach [189]–[191]; however, as yet the correlation between the optical 
signal and thermal damage has not been verified using histologic analysis of the induced 
thermal damage.  While this technique is being investigated for use with FLA, it may be 
possible to monitor RFA and MWA by incorporating a low power light source into the 
ablation probe. 
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Assessment of the interaction between light and tissue requires an unimpeded 
line-of-sight; therefore, interstitial probes are a necessity. As with interstitial thermal 
probes, multiple probes are required to monitor ablation throughout a volume. Both of 
these requirements leave optical monitoring at an inherent disadvantage to techniques 
previously outlined in this section which rely on ultrasound and MRI. Further research 
is necessary to demonstrate the clinical utility of optical methods of monitoring ablation. 
If successful, this approach is likely to offer a lower cost solution than both ultrasound 
and MR elastography. Moreover, optical techniques can be implemented in a similar 
manner to interstitial thermal probes and have two potential advantages. Firstly, the 
change in optical signal persists after cooling thus allowing for confirmation of the 
coagulation zone immediately after ablation. Secondly, optical techniques do not require 
damage estimation models such as the Arrhenius and TID model.  
 
2.7. Discussion & Conclusions 
HIFU, RFA, MWA and FLA have all been demonstrated as effective methods of inducing 
coagulative necrosis within target tumors. While the technology for energy delivery has 
advanced in recent years, there is a growing need for improved thermal ablation. This is 
illustrated in a clinical trial in which 27 men received FLA for the treatment of prostate 
cancer [192]. A 12-month follow-up biopsy found cancer in 10 patients, 3 of which had 
cancer within the ablation zone. Similar results were found by our group, where a 6-
month biopsy identified cancer within the ablation zone of 3 of the 8 treated patients 
[73]. Cancer was also found immediately outside the treated zone in 6 patients. These 
results demonstrate that FLA can successfully induce coagulative necrosis within the 
target. However, in the absence of accurate real time monitoring it is difficult to ensure 
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that thermal necrosis has been induced throughout the entire target while minimizing 
damage to surrounding structures.  
In this review paper we have outlined possible methods of controlling treatment 
to ensure efficacy. These methods can be divided into 2 categories: (1) thermal dosimetry 
and damage estimation, (2) non-thermal feedback techniques. Table 2 summarizes the 
available approaches to thermal dosimetry. Interstitial electric probes (thermistors and 
thermocouples) and optical probes (fluoroptic probes and fiber Bragg grating) appear to 
be the most promising invasive temperature-based feedback systems due to their small 
size, high accuracy and fast response. While thermocouples are widely used, particularly 
in RFA, these sensors suffer from self-heating and conduction errors. Furthermore 
‘viscous heating’ artificially inflates temperature measurement when used with HIFU. 
They are also not MR-safe which can be a major disadvantage given that many ablation 
procedures are performed under MR surveillance. Thermocouples are often integrated 
into RFA and MWA applicators and can also be placed interstitially via catheters to 
provide efficacy feedback and to monitor critical structures. Thermistors suffer from 
similar issues but are not available in such a small form factor and thus are less popular 
than thermocouples. Interstitial electric probes have found clinical utility in MWA, RFA 
and FLA. Unsurprisingly, these probes have not been utilized clinically with HIFU as they 
negate one of the key advantages of HIFU i.e. its non-invasive nature.  
Fiber-optic probes are similar to electric probes with the advantage that they are 
inherently MR safe. MR safety is an important characteristic as many ablation procedures 
rely on MRI for probe guidance. Unfortunately, fiber optic probes are expensive which 
compounds the already high cost associated with MRI. Fluoroptic probes have been used 
in many studies; however, like electrical probes they only provide a ‘point’ measurement. 
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When used to monitor FLA, self-heating and artifacts from laser light entering the fiber 
can degrade temperature recording. FBG sensors have the potential to solve all three of 
these issues. FBGs are capable of distributed sensing in a single fiber and are not 
susceptible to artifacts as they do not use the same wavelength as lasers used in FLA. 
High equipment cost and to a lesser extent the need to prevent strain have thus far 
limited the use of FBGs in a clinical setting. 
Table 2: Methods for monitoring ablation based on temperature measurement including current clinical application 
and limitations of each method 
Method HIFU MWA RFA FLA Primary Limitations 
Thermography 
Liquid Crystals     Surface measurement only 
Infrared Imaging     Surface measurement only 
Microwave     Poor spatial & temporal resolution 
 
Electrical Probes 
Thermistors  ✓ ✓ ✓ 
Interstitial point measurement, 
large size 
Thermocouples  ✓ ✓ ✓ Interstitial point measurement 
 
Fiber-optic Temperature Sensors 
Fluoroptic Probes  ✓ ✓ ✓ Interstitial point measurement 
Fiber Bragg 
Grating 
    
Interstitial point measurements, 
strain corrupts measurement, high 
cost 
 
Radiologic Imaging 
Acoustic 
Thermometry 
✓    Inaccurate above 50°C 
Magnetic 
Resonance 
Thermometry 
✓ ✓ ✓ ✓ High cost, motion artifact 
CT Thermometry     Ionizing Radiation 
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PRF shift based MR thermometry represents the most promising non-invasive 
method of recording temperature. It has been successfully utilized in numerous studies; 
however, it presents several weaknesses. The most important of which are the need for 
MR-safe equipment and a motionless target. It also suffers from poor temporal 
resolution as well greatly increasing the cost of ablative therapy. 
Given that ablation induces cellular destruction via temperature elevation, it is 
unsurprising that traditional monitoring systems are based on temperature 
measurement. This approach appears sufficient when the goal is to ensure safety by 
ceasing therapy if the temperature of sensitive structures outside the target approaches 
lethal levels. When optimizing efficacy, such methods may be insufficient as the 
relationship between thermal history and cellular destruction remains somewhat ill-
defined. The Arrhenius model has been widely used for this purpose. It relies upon 
knowledge of two elusive parameters: the pre-exponential factor and the activation 
energy. Parameters from the literature provide wildly different estimates of cellular 
destruction for the same thermal history. For this reason, non-thermal feedback 
techniques may have greater utility. Moreover, it should be noted that HIFU induces 
cellular damage through both heat and cavitation, the latter of which is not accounted 
for in the Arrhenius model.  
Table 3 summarizes the current methods of monitoring ablation without 
recording temperature. The three approaches in this category are: ultrasound imaging, 
elastography and optical monitoring. In conventional B-mode ultrasound imaging the 
ablation zone appears as a hyperechoic region. This has been observed clinically for all 
forms of ablative therapy; however, due to poor margin identification, B-mode imaging 
is insufficient as a monitoring method. Nakagami imaging has been shown to improve 
51 
 
margin estimation using the same conventional ultrasound systems as B-mode imaging. 
Nakagami imaging is a very recent development and its clinical utility has not yet been 
demonstrated.  CEUS is another effort to improve visualization of the ablation zone 
without changing the ultrasound system. It involves the injection of microbubbles into 
the vasculature to enable assessment of perfusion via Doppler ultrasonography. CEUS is 
capable of identifying lesions that are characterized by increased perfusion. In addition, 
it can be used to monitor the growth of the ablation zone as the ablation process involves 
the destruction of vasculature within the target, thus decreasing perfusion. CEUS is 
simple, low cost and results show that the estimated damage zone corresponds to 
estimates acquired via histology and MRI; however, it cannot be used for continuous 
real-time monitoring. 
Elastography offers an alternative approach to conventional ultrasound. 
Physicians have long identified tumors via manual palpation as tumors are often 
associated with unusual mechanical properties, in particular increased stiffness. In 
addition, ablation induced coagulative necrosis results in an increase in stiffness. 
Elastography aims to quantify a tissue’s Young’s modulus and can thus be used to both 
identify the tumor and monitor the ablation process. This change in mechanical 
properties can be quantified using US elastography or magnetic resonance elastography.  
To date, clinical application of elastography is very limited. ARFI and SSI have been 
commercialized by Siemens Medical solutions and SuperSonic Imagine respectively; 
however, only the former has been clinically demonstrated as a method for monitoring 
ablation. A general disadvantage of all elastographic techniques is the requirement for 
the development of specialized equipment. Consequently, the barrier to clinical entry is 
higher for these techniques in comparison to Nakagami Imaging and CEUS. Widespread 
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clinical application of these techniques will not occur until the clinical benefits are 
proven to outweigh the additional cost. Magnetic resonance elastography is at a 
particular disadvantage due to the high costs associated with MRI. 
Table 3: Methods for monitoring ablation that do not require temperature measurement including current clinical 
application and primary limitations of each method 
Method HIFU MWA RFA FLA Primary Limitations 
Ultrasound Imaging 
B-mode imaging ✓ ✓ ✓ ✓ Poor margin identification 
Nakagami Imaging     Unproven 
Contrast Enhanced 
Ultrasound 
✓ ✓ ✓ ✓ Not real time 
      
Elastography 
Vibroacoustography     
Requires specialized 
equipment, long acquisition 
time 
Acoustic Radiation 
Force Impulse Imaging 
  ✓  
Requires specialized 
equipment 
Supersonic Shear 
Imaging 
    
Requires specialized 
equipment 
Harmonic Motion 
Imaging 
    
Requires specialized 
equipment 
Magnetic Resonance 
Elastography 
    High cost 
      
Optical Monitoring 
Diffuse Optical 
Spectroscopy 
  ✓  
Interstitial point 
measurement  
Interstitial Point 
Optical Measurements 
    
Interstitial point 
measurement 
 
Optical monitoring aims to differentiate coagulated tissue from native tissue 
based on thermally induced changes in tissue optical properties. The technique requires 
the insertion of fiber optic probes into an area of interest such as the intended ablation 
margin. The contrast mechanisms for Diffuse Optical Spectroscopy are an increase in 
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reflectance intensity and a decrease in fluorescence intensity, both of which occur as a 
result of thermal coagulation. This approach has been demonstrated clinically for 
monitoring RFA of liver metastases. In contrast Interstitial Point Optical Measurements 
identify thermal coagulation due to an increase in scatter which results in a decrease in 
optical intensity measured by a probe placed at distance from the light source. This 
technique is particularly useful for monitoring FLA but could be used for RFA or MWA 
by integrating a light source into the respective probes. Development of optical 
monitoring techniques is very much in its infancy; hence, the dearth of clinical 
utilization. 
In conclusion, accurately controlling ablation procedures remains challenging. 
Temperature measurement is the most widespread approach for real-time monitoring 
of ablative therapy; however alternative approaches are under development. The 
increasing popularity of HIFU is likely to lead to increased efforts to develop US 
elastography. Likewise, the desire for minimally invasive interventions to replace 
traditionally invasive procedures, such as radical prostatectomy, may provide the 
impetus for further development of interstitial probes. Finally, while MRI is capable of 
both guiding interstitial probes and monitoring thermal damage (MRT and MRE), the 
high associated cost is likely to prohibit large scale adoption. Regardless of ablative 
modality, it is clear that future ablation techniques must include a method of feedback 
and confirmation to ensure reproducible clinical success. 
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CHAPTER 3 
Focal Laser Ablation with Interstitial Thermal 
Probe Monitoring 
 
3. Focal Laser Ablation with Interstitial Thermal Probe Monitoring 
3.1. Introduction 
Focal laser ablation is a promising minimally invasive approach for the treatment of 
prostate cancer. Many groups have successfully performed FLA under MRI surveillance 
[6], [9]–[11]. For example, Walser et al reported a significant decrease in PSA score 
(P<0.01) in 120 patients that received FLA for low- to intermediate-risk prostate cancer 
[6]. The total procedure time ranged from 60-250 minutes with a median of 122 minutes 
while laser ablation time ranged from 2.5-40 minutes with a median of 12.6 minutes. 
Over 24 months follow-up, clinically significant disease was found via biopsy in 15% of 
patients. The most common adverse events were hematuria (7.4%), erectile dysfunction 
(5.0%) and urinary retention (4.1%) with one patient experiencing a grade three adverse 
event (urinary tract infection). Similar results were found in our own in-bore clinical trial: 
PSA decrease (P<0.01), no grade three adverse events, clinically significant cancer in the 
treated area in 3 of 8 men, mean procedure time 4.9 hours  [73]. This experience led us 
to identify the need for MRI surveillance as a critical barrier to the widespread adoption 
of FLA.  MRI is inherently expensive and the reduced access to the patients exacerbates 
the already cumbersome nature of FLA leading to lengthy procedure times. 
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MRI performs two key functions: 1) to guide the laser fiber to the target, and 2) 
to monitor treatment progress via MR thermometry. We hypothesized that MR-US fusion 
guidance and interstitial thermal probes could be used for guidance and treatment 
monitoring respectively. MR-US fusion guidance facilitates targeting by co-registering 
regions of interest acquired via MRI with real-time ultrasound imaging. Consequently, 
the both the procedure cost and complexity are substantially decreased as it can be 
performed in a urology clinic rather than an MRI suite. In addition, the number of 
personnel is reduced as the procedure does not require an MR technologist or a 
radiologist. MR-US fusion biopsies are routinely performed at UCLA with procedure 
times less than 30 minutes. Given the ease with which a biopsy needle can be guided to 
ROIs defined by MRI, it is reasonable to assume that a laser fiber could be guided to an 
ROI defined by both MRI and biopsy data. By using a needle guide, interstitial thermal 
probes could be placed at known location to both monitor treatment progress and 
ensure safety. In contrast, to MR thermometry, thermal probes are not adversely affected 
by patient motion which was found to substantially impact thermal dosimetry in our in-
bore trial. 
MR-US fusion guidance and interstitial thermal probes were previously used for 
monitoring FLA by Lindner et al. [193]. In that study, 12 patients received FLA for low-
grade CaP. The laser fiber and thermal probes were inserted transperineally and 
treatment was verified with microbubble contrast. At 6-month follow-up biopsy, 67% of 
patients were cancer free in the treated zone. In this chapter, we will outline our clinical 
trial which represents the first clinical experience of MR-US fusion guided transrectal 
FLA monitored solely via interstitial thermal probes. Given the novel nature of this trial, 
we applied for and received an Investigational Device Exception from the FDA. The 
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primary goal of the trial was to demonstrate the feasibility and safety of MR-US fusion 
guided FLA monitored via interstitial thermal probes. In this chapter, we will summarize 
the clinical trial, compare results against our in-bore clinical trial and critically analyze 
the utility of interstitial thermal probes as a modality for monitoring FLA.  
 
3.2. Materials and Methods 
The clinical trial required the use of a diverse range of hardware: 
Laser Ablation system (Visualase, Medtronic) – The Visualase system (Figure 7A) is an 
FDA approved laser ablation system consisting of a peristaltic pump (K-pump, Kolster 
Methods), a 980nm laser (PhoTex15, Biotex) and dual lumen catheter (Medtronic). This 
is the same system that was used by many groups including ours for MR-guided FLA. 
Ultrasound System (Nobulus, Hitachi) – The Nobulus ultrasound system (Figure 7) with 
the C41V transrectal ultrasound probe provide real-time prostate and applicator 
visualization.  
MR-US Fusion Device (Artemis, Eigen, CA) – The Artemis system (Figure 7C) performs 
non-rigid registration of MRI data with real-time ultrasound. 
Fiber Optic Thermometry System (Luxtron, Lumasense) – The Luxtron system (Figure 
7D) is an FDA approved temperature measurement system capable of measuring 
temperature using Fluoroptic technology (Figure 8). The temperature measurement is 
based on the decay rate of a phosphor element embedded at the tip of an optical fiber. 
Custom Needle Guide: The needle guide (Figure 7D) contains a central 13GA channel 
and 15Ga channel for the dual lumen catheter and a single interstitial thermal probe 
respectively. The two channels are parallel and 8mm apart. 
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Figure 7: Key hardware used in MR-US fusion guided FLA: A) Visualase system, B) Nobulus ultrasound system C) 
Artemis MRI-US fusion system, D) Luxtron Fiber Optic Thermometry system, E) Needle guide 
 
 
Figure 8: A) Luxtron system with one of four fluoroptic probes attached. B) Fluoroptic technology – thermal 
measurement is based on the decay rate of a phosphor element embedded at tip of the probe 
 
3.2.1. Treatment Planning 
The size of the ablation is dependent on multiple factors such as the laser wavelength, 
exposure duration, power and diffuser size. The wavelength and diffuser size are fixed 
at 980nm and 15mm respectively due to the equipment provided with the Visualase 
system. The power and exposure duration were set to 13.75W and 3 minutes based on 
prior clinical experience. Finally, the location of the diffuser within the dual lumen 
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catheter can also alter the ablation zone; therefore, this was fixed as shown in Figure 9. 
Note that the laser fiber cannot be inserted to the end of the dual lumen catheter as to 
do so would impede the flow of saline necessary to cool the fiber. Based on preclinical 
testing in ex vivo bovine muscle, it was assumed that each laser activation would result 
in an elliptical ablation zone with major and minor axes of 24mm and 17mm respectively 
(Figure 9). The major axis is greater than the length of the diffuser as light is emitted 
both radially and longitudinally.  
 
 
Figure 9: Ablation zone used for treatment planning. Red arrows indicate light emission from the diffuser 
 
Patient specific treatment plans were created based on diagnostic MRI and biopsy. 
During biopsy procedures performed at UCLA, the location of each ROI and biopsy core 
are stored in 3D on the fusion device. This data was then combined with the MRI derived 
ROI to ascertain the size and location of the requite ablation zone (Figure 10A). To ensure 
treatment throughout the entire zone, ablation zones from individual laser activations 
were superimposed onto this prostate model. The final plan contains the number and 
location of each laser activation including the fiber trajectory and orientation. The laser 
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fiber is inserted through a needle guide which contains a parallel channel for a thermal 
probe. As a result, the orientation of the fiber must be set to optimize the position of 
the thermal probe. During consecutive overlapping laser activations, it is preferable to 
position the thermal probe in previously untreated tissue. This is necessary as laser-
tissue interaction changes considerably between native and coagulated tissue; therefore, 
the thermal response in a previously treated zone does not reflect that in the untreated 
zone. 
 
 
Figure 10: A) MRI derived ROI fused with biopsy data to create patient specific treatment plan. B) Treatment plan 
showing the requisite laser fiber trajectory 
 
The final setup is shown in Figure 11A which also includes three transperineally 
inserted interstitial thermal probes (ii-iv). These probes consist of a 15Ga flexi-needle 
containing a single fluoroptic probe. One of these probes, designated ‘rectal monitor’, 
was always located between the laser fiber and the rectal wall to preserve this sensitive 
structure and prevent a rectal fistula which is classified as a serious adverse event. The 
other two probes were inserted at the physician’s discretion and were typically placed 
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next to the lateral capsule and the urethra. The interstitial thermal probe, designated 
‘efficacy probe’, was inserted through the needle guide and positioned level with the 
laser fiber tip and at a radial distance of 8mm (Figure 11B). The orientation of the 
ultrasound probe was defined in the treatment plan to ensure that this probe always lies 
within the prostate and where possible in untreated tissue when performing overlapping 
ablations.  
 
 
Figure 11:A) Setup for MR-US fusion guided focal laser ablation. Treatment is monitored with one transrectal thermal 
probe (i) and up to three transperineally inserted thermal probes (ii-iv). B) Detailed view of transrectal ultrasound probe 
with needle guide, laser fiber and thermal probe. The laser fiber is housed in dual lumen catheter that flows saline 
around the fiber to prevent charring. The thermal probe consists of a single Luxtron fluoroptic probe housed in a 15Ga 
flexi-needle. 
 
3.2.2. Treatment Protocol & Follow-up 
To minimize pain and discomfort patients were sedated with ketorolac (30mg) and 
midazolam (4mg) and a periprostatic nerve block consisting of a 50-50 mixture of 
bupivacaine and 1% lidocaine was administered with the patient in the left lateral 
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decubitus position. Patients then transitioned to the lithotomy position for transperineal 
insertion of interstitial thermal probes, including the rectal monitor. Probe insertion was 
verified using a side firing transrectal ultrasound probe. The patient was subsequently 
returned to the lateral decubitus position and a 3D ultrasound scan was performed with 
an end-fire transrectal ultrasound probe and the fusion device. The treatment plan was 
then imported and fused with the real-time ultrasound image by the fusion device.  
The ultrasound probe was then aligned to the trajectory defined in the treatment 
plan to facilitate insertion of the laser fiber through the main channel of the needle 
guide. A 13Ga open ended catheter was inserted using a biopsy needle as a trocar. 
Advanced of the needle was monitored via ultrasound in an effort to ensure that it was 
positioned at the correct depth. The needle was then removed and the dual lumen 
catheter was advanced through the 13Ga catheter with laser fiber ultimately positioned 
5mm shallow of the catheter tip. Finally, the efficacy probe was advanced through the 
secondary channel in the needle guide and aligned with the tip of the laser fiber. Over 
time the procedure evolved with the introduction of an echogenic biopsy needle greatly 
enhancing visualization resulting in improved positioning of the dual lumen catheter. 
Each laser activation was performed at 13.7W for up to 3 minutes under active 
cooling from the peristaltic pump. Laser activation was terminated prematurely if the 
rectal monitor indicated rapid temperature rise or if it exceeded 42°C. This protocol was 
followed to prevent damage to the rectal wall which may lead to a rectal fistula which is 
defined as a serious adverse event.  
Following treatment, patients were transferred to an MRI suite and underwent 
multiparametric MRI. Dynamic contrast enhanced MRI was performed to facilitate 
identification of the ablation zone as a region of non-perfused tissue. Patients were then 
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discharged with follow-up PSA tests and questionnaires at 3 months. In addition, 
multiparametric MRI and biopsies were performed at 6 and 12 months to assess 
treatment efficacy. 
 
3.3. Results 
A total of 11 men were enrolled in the study, one of whom did not receive FLA due to 
difficulties encountered during flexi-needle insertion. The mechanical properties of the 
prostate were compromised by a prior transurethral resection resulting in the inability 
to correctly anchor flexi-needles at the correct location.  For the first 4 men, the dual 
lumen catheter was placed using a standard biopsy needle which proved to be difficult 
to monitor via the end-fire transrectal ultrasound probe. Consequently, it was replaced 
with a biopsy needle containing an echogenic tip which was easily tracked on ultrasound. 
Interestingly, this problem did not arise when visualizing the transperineal thermal 
probes (Figure 12) due to their angle of insertion relative to the imaging plane.  
 
Figure 12: A) Illustration depicting the insertion of transperineal thermal probes under US guidance. B) Probe 
positioning on transverse imaging plane. Note the rectal monitor highlighted in red. C) Rectal monitor location in sagittal 
imaging plane. 
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In the 10 treated patients the laser was activated a 13.75W for an average of 144 
seconds and mean total procedure time of 95 minutes (range 71-105). Figure 13 shows 
an example of the data from the thermal probes and the corresponding ablation zone. 
In this patient, the laser was activated twice with high temperatures recorded by the 
‘efficacy probe’ (probe 4) while the rectal monitor (probe 1) remains at approximately 
body temperature. As expected, the ablation zone identified on MRI extends as far as 
the efficacy probe while the rectal wall appears intact. Similar results were seen in all 10 
patients with the ablation zone consistently confined within the prostate capsule leaving 
the rectal wall intact (Figure 14). A total of 38 grade 1 and 6 grade 2 adverse events were 
recorded with short term hematuria the most frequently reported.  
 
Figure 13: A) Temperature recorded by interstitial thermal probes during two consecutive laser activations. Note the 
laser tip exceeds 60°C while the rectal experiences negligible heating B) Non-perfused zone observed on MRI 
immediately after FLA. Note the that probe 4 lies on the edge of the ablation zone and the rectal wall remains intact. 
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Figure 14: Contrast enhanced MRI acquired immediately after receiving FLA. In all 10 patients a distinct zone of non-
perfused tissue is observed within the prostate capsule. 
 
Median PSA decreased from 7.35 ng/ml at baseline to 2.55 ng/ml at 6 months 
follow-up (Wilcoxon signed rank test p = 0.28). The procedure was found to be tolerable 
with patients reporting a median maximum pain score of 5 (medium). Six-month biopsy 
results found clinically significant disease in the treatment zone and margin of the first 
4 patients. Microfocal Gleason 3+3 was observed in 3 patients with 3 more cancer free. 
Figure 15 shows the MRI and biopsy cores before and six months after treatment for one 
of the successful procedures. Before treatment, a tumor is visible on MRI and found to 
be Gleason 7 via MR-US fusion biopsy. Six months after treatment no cancer was detected 
by MRI or biopsy. 
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Figure 15: Imaging histologic findings in a patient successfully treated with MR-US fusion guided focal laser ablation. 
The top row shows the MR-visible tumor with positive biopsy cores (Gleason 7) within the ROI. Six months after 
receiving FLA, no tumor was visible on MRI and biopsy cores identifying coagulative necrosis within the ablation zone 
and no cancer outside the ablation zone. 
Table 4: Summary of clinical trial patient characteristics. No serious adverse events were reported. 
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MR-guided FLA is the current state of the art and is under investigation at multiple 
centers. We contend that FLA can be performed under MR-US guidance with substantially 
reduced resource requirements, similar clinical outcomes and improved patient 
experience. While it is too early to draw definitive conclusions, we can compare key 
metrics between the MR-guided and MR-US fusion guided FLA trials performed at UCLA 
(Table 5). The MR-US guided trial exhibited greater ablation volume with an overall 
treatment time approximately 70% shorter than the MR-guided trial. The overall results 
also indicate fewer adverse events and improved oncologic outcomes in the US-guided 
trial. IT should be noted that the PSA score was only comparable the MRI-guided trial 
after the introduction of amended treatment protocol for the last six patients. Finally, 
the US-guided trial proved to be inherently less resource intensive as it can be performed 
in a urology clinic rather than an MR suite and requires two fewer critical personnel. 
Table 5: Comparison of key metrics between UCLA’s MR-guided and US-MR fusion guided clinical trials 
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3.4. Discussion 
The goal of this study was to demonstrate that MR-US fusion guided FLA is both feasible 
and safe. FLA for the treatment of prostate cancer has previously been demonstrated by 
multiple groups using MRI for both targeting and monitoring [6], [9]–[11]. In contrast, in 
this study we successfully performed FLA using MR-US fusion guidance and interstitial 
thermal probes for guidance and monitoring respectively. Although the procedure was 
technically feasible, numerous difficulties were encountered due to the lack of 
specialized instrumentation. In particular, MR-US fusion guidance was sufficient for 
ensuring catheter trajectory adhered to the treatment plan; however, achieving the 
correct depth required visualization of the trocar on ultrasound. This proved to be 
difficult until the introduction of the echogenic biopsy needle used on the last six 
patients. Other issues encountered include: catheter deflection, catheter movement after 
placement and thermal probe movement relative to the catheter tip. It is anticipated that 
all of these issues can be resolved with the development of appropriate instrumentation. 
In general, the procedure was found to be safe with overall number of adverse 
events similar to that observed in the UCLA MR-guided trial (mean of 3.4 vs 3.6). 
Additionally, only 2.3 adverse events were seen in the group of patients treated after the 
introduction of the echogenic biopsy needle.  Similarly, at 9-month biopsy, the overall 
PSA response was somewhat disappointing compared to the MR-guided trial (-1.8 ng/ml 
vs -4.2 ng/ml) but improved substantially in the last 6 patients (-4.3 ng/ml). On the 9-
month biopsy the overall incidence of Gleason 3 and Gleason 4 were 70% and 40% which 
compares favorably to the MR-guided trial result of 88% and 63%. Moreover, in the last 
6 patients these figures drop to 50% and 0% as a result of improved catheter 
visualization. While the sample sizes are too small to draw statistically valid conclusions, 
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the evidence strongly suggests that MR-US fusion guided FLA is at least as safe and 
effective as direct MR-guided FLA. Given that it also inherently less resource intensive, 
it may help to accelerate widespread adoption of FLA for the treatment of prostate 
cancer. 
 
3.5. Retrospective Analysis of Thermal Probe Utility 
FLA achieves cancer control via thermally induced coagulative necrosis. This process is 
a function of both temperature and time. Many groups have attempted to estimate the 
extent of cell death based on the Arrhenius model introduced by Moritz and Henriques 
in 1947 [122]–[125]. Indeed, the Visualase system which is used in the majority of MR-
guided clinical trials, relies on this model to create damage maps based on MR 
thermometry data. The damage maps quantify the extent of the ablation in real-time and 
inform the decision to deactivate the laser. Damage is quantified using a single 
parameter (Ω) as shown below: 
ln (
𝐶(0)
𝐶(𝑡)
) =  𝐴 ∫ 𝑒
−
𝐸𝑎
𝑅𝑇(𝑡)
𝜏
0
 𝑑𝑡 = Ω(𝑡) 
where C(0) is the concentration of viable cells before the procedure, C(𝝉) is the 
concentration at time=𝝉, A is the pre-exponential/frequency factor [s-1], 𝐸𝑎 is the 
activation energy barrier (J mole-1), R is the universal gas constant (1.987 x 10-3 
Kcal/mole∙ 𝐾, and T is the temperature (K). 
The fraction of surviving cells is thus given by: 
𝐶(𝜏) = 100𝑒−Ω (%) 
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The model requires a priori knowledge of the tissue specific kinetic parameters 
𝐸𝑎 and A. Many authors have empirically determined these values for prostate as shown 
in Table 6. The values determined by Henriques et al were found based on analysis of 
skin burns; however, these are the values used by the commercially available Visualase 
system.  
Table 6: Kinetic parameters used in modelling thermally induced coagulative necrosis in the prostate 
 Bhowmick 
[130] 
Henriques 
[122] 
Jacques 
[194] 
Skinner 
[195] 
Ea (kJ/mol) 160.7 630 186.6 385 
A (s-1) 7.78x1022 3.1x1098 2.08x1027 3.8x1057 
 
To assess the utility of the Arrhenius damage model, we applied it to the thermal 
data acquired by the efficacy probe in the clinical trial and calculated the optimal 
exposure duration (the minimum exposure duration required to cause coagulative 
necrosis at the location of the probe i.e. 8mm from the laser fiber). Figure 16 shows the 
resulting estimated cell death as function of time for a single burn. Laser activation 
causes a steady increase in temperature with rapid cooling observed after laser 
deactivation. Consequently, the majority of cell death occurs during laser activation. It 
is generally assumed that 63% cell death is sufficient to render the tissue non-viable. 
Under this assumption, 7 laser activations from the clinical trial produced ablation zones 
that matched or exceeded the target radius of 8mm. This does not include laser 
activations that may overlap existing ablation zones. For these 7 laser activations, 93% 
(mean) of total cellular death occurred during laser activation with 7% during the cooling 
phase. The optimal exposure duration was therefore defined as the exposure duration 
necessary to achieve 59% cell death during laser activation. The optimal exposure 
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duration was found for a further 5 laser activations via extrapolation giving a total 
dataset of 12 laser activations (Figure 17). The average optimal exposure duration was 
determined for these laser activations using each of the kinetic parameters shown in 
Table 6 (Figure 18). Using a one-way ANOVA, a statistically significant difference was 
found between the estimates (p < 0.01). A post-hoc analysis (Tukeys HSD) shows that 
there is no statistically significant difference between the estimates provided by Skinner 
et al and Jacques et al. 
 
Figure 16: Estimated cell death during FLA of a patient based on the Arrhenius model and interstitial thermal probe 
data (Kinetic parameters: Jacques et al) 
 
 
Figure 17: Optimal exposure duration for select laser activations (Kinetic parameters: Jacques et al) Note: all patients 
received multiple ablations but the dataset was limited to those in previously untreated tissue. Mean =145.8 standard 
deviation = 37.2s. 
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Figure 18: Comparison of optimal exposure duration estimated suing the Arrhenius model with kinetic parameters from 
the literature. 
The Arrhenius model provides an elegant method of determining the extent of 
coagulative necrosis and thus informing the decision to cease laser activation. However, 
it may be inherently unreliable due to inaccurate a priori knowledge of the kinetic 
parameters 𝐸𝑎 and A. By applying the model to clinical data, we have shown that the 
published values for these parameters result in significantly different estimates of the 
exposure duration necessary to induce coagulative necrosis. Given the variation in 
published values for the kinetic parameters, it is possible that they vary between 
samples and thus cannot be determined for a given patient. We can therefore conclude 
that the utility of interstitial thermal probes for monitoring FLA is inherently limited 
due to the inability to accurately model thermally induced coagulative necrosis using 
the Arrhenius model. 
 
3.6. Conclusion 
MR-US fusion guided FLA for the treatment of prostate cancer is safe and potentially 
effective. In this preliminary study there was no long-term impact on sexual, urinary or 
general patient health. The initial protocol used to treat the first 4 patients was 
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ineffective due to difficulty visualizing catheter placement. With the introduction of 
improved instrumentation, the incidence of residual clinically significant disease 
dropped substantially. In addition, both the clinical outcomes and resource 
requirements compare favorably to our previous MR-guided trial. Further refinement of 
the procedure followed by a larger multicenter center trial is necessary to assess the 
oncologic effectiveness of the treatment. Improved real-time monitoring was identified 
as a key area in need of development as the utility of interstitial thermal probes is 
inherently limited due inaccurate thermal models.  
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Chapter 4 
Optical Monitoring as a Potential Alternative 
to Thermal Monitoring 
 
4. Optical Monitoring as a Potential Alternative to Thermal Monitoring 
4.1. Introduction 
In chapter 3 we demonstrated that FLA can be performed safely using MR-US fusion for 
guidance and interstitial thermal probes for feedback. We also analyzed the Arrhenius 
damage model that is frequently used to estimate the extent of coagulative necrosis 
based on thermal history. The model requires a priori knowledge of tissue specific 
kinetic parameters. Many groups have empirically derived these values; however, in 
chapter 3 we demonstrated that the variability between these values has a significant 
impact on the exposure duration determined by the damage model. To improve the 
method of monitoring MR-US fusion guided FLA, either accurate kinetic parameters for 
prostate must be determined or an alternative monitoring method must be developed. 
Given that the former has proved to be somewhat elusive we elected to focus on an 
alternative monitoring modality, specifically interstitial optical monitoring. 
Interstitial optical monitoring may offer numerous advantages over interstitial 
thermal monitoring. The primary advantage is that it does not rely on the Arrhenius 
damage model. The Arrhenius model itself was developed to analyze the relationship 
between temperature and the rate constant of a chemical reaction. Empirical studies 
later demonstrated that it could be used to model thermally induced coagulative 
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necrosis [123]. It is therefore not based on comprehensive understanding of an 
underlying physical principle. In contrast, optical monitoring is based on the 
fundamental principles of laser-tissue interaction. Consequently, it provides a more 
direct method of characterizing the coagulative state of tissue rather than relying on an 
empirical model.  
The second advantage of optical monitoring is that the intensity of light at a given 
position is a function of light-tissue interactions throughout a volume. Therefore, in 
contrast to a thermal probe, the signal recorded by an optical probe may be sufficient 
to infer the coagulative state of tissue at a distance from the probe. This is of particular 
interest in FLA due to tissue charring which can occur around the laser fiber as was 
observed in the clinical trial. Char acts as a light trap; therefore, an optical probe may 
be able to correlate signal loss to the onset of char. If treatment continues after the onset 
of char, the vast majority of photons will be absorbed near the fiber resulting in 
temperature sufficient to melt the dual lumen catheter. This could potentially result in 
detachment of the catheter tip which represents a serious adverse event and must be 
surgically removed.  
A further advantage of interstitial optical monitoring is that feedback occurs near 
instantaneously with software processing the likely limiting factor. When monitoring a 
critical structure such as the rectal wall, an optical probe can immediately identify if the 
laser fiber is too close and likely to induce thermal damage. In contrast, a thermal probe 
can only provide similar feedback after sufficient energy has been deposited in the tissue 
to cause a temperature elevation. If the laser fiber is sufficiently close and activated at 
high power, the critical structure may be damaged before a thermal sensor can provide 
feedback. 
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The final advantage of optical monitoring is the ability to assess tissue condition 
after cooling. Clinically, FLA generally requires multiple overlapping ablations; therefore, 
both the laser fiber and the dosimetry probe must be repositioned between ablations. 
Protein coagulation causes a persistent change in laser-tissue interaction. As result it is 
possible confirm that the laser fiber and probe have been inserted into native rather 
than coagulated tissue. In contrast, a thermal probe can only estimate cellular damage 
by recording the thermal response during ablation. It is therefore not possible to 
determine tissue condition after repositioning for a second ablation.  
In this chapter, we will outline the fundamental principles of laser-tissue in the 
context of FLA and then apply these principles to generate our hypothesis that an 
interstitial optical monitoring system can be used to monitor FLA. A short series of 
experiments are then presented as proof of concept. The chapter closes with a 
discussion of the steps necessary to robustly demonstrate the correlation between a 
measured optical signal and the growth of the coagulation zone during FLA. 
  
4.2. Fundamentals of Laser Tissue Interaction 
The propagation of light in tissue is governed by the absorption coefficient (𝜇𝑎) and the 
reduced scattering coefficient (𝜇𝑠
′ ) as depicted in Figure 19. In FLA, light is emitted from 
an interstitial optical fiber; therefore, reflection and remission can be ignored. In this 
research, we are concerned with FLA performed with a 980nm laser which has a 
relatively shallow penetration depth; thus, remission and transmission are also 
negligible.  
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Figure 19: Laser-tissue interactions [196] 
 
4.2.1. Absorption Coefficient 
Photons continue to propagate through tissue until they are absorbed by a chromophore. 
The probability of absorption per infinitesimal path length (Δ𝑥) is 𝜇𝑎Δ𝑥. Additionally, 
1/𝜇𝑎 is the mean free path length between absorption events. At 980nm, the wavelength 
of FLA in our clinical trial, the primary absorbers are water molecules, oxyhemoglobin 
and deoxyhemoglobin (Figure 19). 
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Figure 20: Absorption coefficient as a function of wavelength for typical chromophores in tissue[196] 
 
4.2.2. Scattering and Reduced Scattering Coefficients 
As photons propagate through tissue, interactions with scatterers (Figure 21), result in 
a change in propagation direction without energy deposition. This behavior is 
characterized by the scattering coefficient (𝜇𝑠). Scattering events are classified as either 
Mie scattering or Raleigh scattering with the former relevant for FLA. The probability of 
scattering per infinitesimal path length (Δ𝑥) is 𝜇𝑠Δ𝑥 while 1/𝜇𝑠 is the mean free path 
length between scattering events. Mie scattering is not isotropic and the scattering 
direction is quantified using the anisotropy factor (g) which ranges from 0 (isotropic) to 
1 for forward scattering 0 to -1 for backscattering. Light tends to scatter forwards in 
tissue with typical values for g in the range 0.8 to 0.99. Taking into account the direction 
of light propagation, scattering can be better defined using the reduced scattering 
coefficient: 𝜇𝑠
′ = 𝜇𝑠(1 − 𝑔). 
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Figure 21: Mie and Raleigh scattering 
 
4.2.3. Effective Penetration Depth 
The effective penetration depth is defined as the mean free path between attenuation 
events and is given by: 
𝛿𝑒𝑓𝑓 =
1
𝜇𝑒𝑓𝑓
 
with the effective attenuation coefficient defined by: 𝜇𝑒𝑓𝑓 =  √3𝜇𝑎(𝜇𝑎 + 𝜇𝑠). In tissues with 
long penetration depth, light is distributed over a large volume while the opposite occurs 
if the penetration depth is short. 
 
4.3. Laser-Tissue Interaction During FLA 
4.3.1. Dynamic Optical Properties 
FLA achieves cancer control through thermally induced coagulative necrosis. During this 
process, proteins coagulate resulting in an increase in 𝜇𝑠
′  while 𝜇𝑎 remains relatively 
constant. Consequently, FLA is characterized by a decrease in 𝛿𝑒𝑓𝑓. For near infrared 
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light, 𝛿𝑒𝑓𝑓 will decrease approximately 30% due to an increase in 𝜇𝑠
′  of approximately 
130% (Table 7). The influence of the optical properties on the coagulative response can 
be seen in a paper by Jiang et al [197]. In this work FLA was simulated in the liver with 
lasers of different wavelengths (850nm, 980nm, 1064nm). As expected 850nm and 
980nm lasers induce a similar coagulative response; however, the 1064nm laser 
coagulates a much smaller volume of tissue. This occurs because the penetration depth 
is too large and thus energy deposition in the tissue is not sufficiently concentrated to 
increase the temperature above the coagulation threshold. During FLA, the opposite 
phenomenon occurs after the onset of coagulation. The coagulation zone expands 
outward from the laser fiber creating a zone of tissue with a short 𝛿 which decreases the 
amount of light reaching areas distal to the fiber and limits the growth of the ablation 
zone. As light becomes trapped near the fiber, excessive temperatures can occur causing 
tissue char and potentially damaging the laser fiber and catheter. In an effort to reduce 
this risk, the catheter is cooled through continuous circulation of saline. 
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Table 7: Optical Properties of Prostatic Tissue in the Native and Coagulated State 
Tissue 
𝝀 
(nm) 
𝝁𝒂_𝒏𝒂𝒕𝒊𝒗𝒆 
 (cm-1) 
𝝁𝒂_𝒄𝒐𝒂𝒈𝒖𝒍𝒂𝒕𝒆𝒅 
(cm-1) 
𝝁𝒔
′
_𝒏𝒂𝒕𝒊𝒗𝒆 
(cm-1) 
𝝁𝒔
′
_𝒄𝒐𝒂𝒈𝒖𝒍𝒂𝒕𝒆𝒅 
(cm-1) 
𝚫𝝁𝒂 
(%) 
𝚫𝝁𝒔
′  
(%) 
𝚫𝜹𝒆𝒇𝒇 
(%) 
Human 
[198] 
850 0.6 0.7 6 13.8 +17 +130 -38 
Human 
[198] 
1064 0.3 0.4 4 9 +33 +125 -41 
Human 
[199] 
1064 0.78 0.75 6.3 10.8 -4 +71 -20 
Canine 
[198] 
850 0.6 0.7 5.2 13.5 +17 +160 -41 
Canine 
[198] 
1064 0.4 0.5 4.4 8.8 +25 +100 -36 
Canine 
[199] 
1064 0.27 0.19 17.6 24.4 -30 +39 +17 
Canine 
[199] 
1064 0.71 0.47 7.9 29.4 -34 +272 -34 
Average Change in Optical Properties +3 +128 -30 
 
 
4.3.2. Hypothesis Generation 
The dynamic optical properties observed during FLA could potentially serve as a 
contrast mechanism to indicate the onset and propagation of thermally induced tissue 
coagulation. This concept was explored by Whelan et al who used an isotropic point 
detecting optical fiber to monitor fluence during FLA [188]. This fiber was placed 5mm 
from the source fiber during FLA in porcine kidney in vivo. Tissue coagulation resulted 
in 49% decrease in optical intensity.  
Rather than monitoring the absolute change in optical intensity we hypothesize 
that the relative change will be of greater utility. To generate our hypothesis we 
performed the simplified thought experiment outlined in Figure 22 in which we consider 
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the effect of thermal coagulation on the optical signal recorded by an interstitial thermal 
probe.  
A. When the laser is initially activated, photons follow a relatively direct path 
towards the sensor. Consequently, many photons reach the sensor and the signal 
is high. Let’s assume that of all the photons that propagate towards the sensor, 
90% reach the sensor and 10% are absorbed.  
B. The absorbed photons cause tissue coagulation and thus increased scatter. As 
more photons are released, they scatter through the coagulated tissue and thus 
the path length to the sensor has been increased. The longer path length 
increases the number of interactions with chromophores leading to greater 
energy deposition in the tissue. Now, let’s assume that 40% of photons are 
absorbed and only 60% reach the sensor. 
C. The deposited photons increase the volume of coagulated tissue resulting in an 
increase in scatter. Again, the path length is increased and now fewer photons 
reach the sensor as much of the energy is deposited in the tissue. Let us assume 
that 30% of the photons reach the sensor. 
D. At this point, the coagulation boundary has propagated as far as the sensor. The 
newly deposited photons cause further growth of the coagulation zone but the 
path length remains unchanged and thus the optical signal has reached a plateau.  
E. If laser activation continues, the coagulation zone expands beyond the optical 
sensor; however, as the path length remains constant so too does the optical 
signal. 
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The results of this thought experiment allow us to formulate the hypothesis that: 
an interstitial optical probe can be used to ensure complete thermal necrosis in a 
predefined region of prostatic tissue. This can be achieved by placing the probe at the 
desired boundary and terminating laser ablation once the recorded optical signal 
reaches a plateau. 
The thought experiment greatly simplified the dynamic response of laser 
irradiated tissue. For example, light is highly scattered even when all of the tissue is in 
the native state. It is therefore, more scientifically rigorous to describe laser tissue 
interaction in terms of the dynamic optical properties shown in Table 7. Here we see 
that thermal coagulation causes a substantial increase in 𝜇𝑠
′  (~130%) and a corresponding 
decreasing in 𝛿 (~30%). Therefore, as the coagulation boundary propagates towards the 
optical sensor, the average 𝛿 (the penetration depth of all tissue between the laser source 
and sensor) decreases and reaches a steady state once all the tissue is coagulated. 
Further expansion of the coagulation boundary has no impact on the optical properties 
of the tissue between the laser source and the sensor; therefore, the optical signal 
remains constant.  
In this scenario a ballistic optical sensor is used i.e. a sensor in which only 
photons travelling directly from the source are detected. An alternative hypothesis can 
be formed by rotating the sensor away from the source as depicted in Figure 23. Here 
we assume that none of the photons are detected until the coagulation boundary passes 
the sensor and induces sufficient scatter to cause some photons to travel backwards 
after passing the sensor (Figure 23D). Once this occurs an increase in optical signal is 
observed; hence, an optical sensor that only detects backscatter could be used to identify 
the coagulation boundary based on a sudden increase in optical signal. Consequently, it 
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is clear that the design of the sensor is critical to ensure accurate identification of the 
ablation boundary. Indeed, it may be beneficial to detect both ballistic and backscattered 
photons so that the passing of the coagulation boundary is indicated by an optical 
intensity inflection point rather than a plateau. An obvious disadvantage of the 
backscatter sensor is that there is no feedback until the coagulation boundary passes 
the sensor; therefore, it is not possible to confirm the inset and propagation of the 
coagulation front. While this may true in our simplified analysis, in practice it is likely 
that there is always some backscatter even with all of the tissue in the native state; 
however, the resulting optical signal be of insufficient magnitude to register with the 
photodiode.  
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Figure 22: Thought experiment with ballistic optical sensor 
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Figure 23: Thought experiment with backscatter optical sensor 
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4.4. Proof of Concept 
A simple experiment was undertaken to illustrate proof of concept and identify the key 
challenges that must be overcome. The experimental setup is illustrated in Figure 24. Ex 
vivo bovine muscle was preheated to 37°C and placed in a 3D printed sample holder. A 
water-cooled catheter (Visualase, Medtronic) housing a laser fiber was inserted into the 
center with a thermal and optical probe positioned either side at a radial distance of 
8mm. The thermal and optical probes consist of 14Ga flexi-needles containing a 
fluoroptic thermal sensor (Lumasense, CA) and a 600µm optical fiber with a 5mm long 
cylindrical diffuser respectively. The optical probe is connected proximally to a 
photodiode (PDA36A, Thorlabs, NJ) which outputs an analog signal in the range 0-10V. 
A voltage divider was used to decrease the range to 0-5V to accommodate the 
microcontroller (Arduino Leonardo, Arduino LLC, Italy)  which converts the analog signal 
to a digital signal and outputs the data to a PC. Custom built software (Python) is then 
used to display the signal in real-time and save the results to disk as a .csv file. Similarly, 
the thermal sensor is connected to the FOT lab kit, voltage divider, microcontroller and 
finally to the PC. FLA was performed at 13.75W for 200s using a 980nm laser. After laser 
deactivation, the sample was removed from the holder and sliced along the trajectory of 
the catheters to facilitate visual inspection of the coagulation zone. 
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Figure 24: Experimental setup – 1) Ex vivo bovine muscle sample holder with laser fiber, thermal probe and optical 
probe, 2) Photodiode, 3) FOT lab kit, 4) Voltage divide, 5) Voltage divider, 6) Microcontroller, 7)  Dedicated PC and 8) 
Custom built software for data visualization and recording 
 
Temperature and normalized photovoltage are shown in Figure 25. Within 
seconds of laser activation, the temperature begins to rise while the normalized 
photovoltage falls. Normalized photovoltage falls because the tissue coagulates causing 
an increase in the reduced scattering coefficient and thus total attenuation. The results 
correlate with previously published data by Whelan et al who performed a similar study 
using in vivo porcine kidney [200]. Interestingly after approximately 60s the normalized 
photovoltage stops falling. This appears to indicate that the coagulation boundary is 
approaching the sensor. These events are not detected by the thermal sensor, which 
continues to show a steady rise in temperature. 
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Figure 25: Temperature and photovoltage during FLA 
 
Figure 6 compares damage estimates using the Arrhenius thermal damage model 
outlined in Chapter 3. Again, the normalized photovoltage drops throughout the 
procedure indicating the development of tissue coagulation while none of the damage 
estimates show significant coagulation until 100s.  This clearly demonstrates that unlike 
the thermal system, the optical monitoring system provides an instantaneous 
representation of opto-thermal events occurring throughout the volume. Additionally, 
the thermal damage estimates vary wildly as observed in Chapter 3. Finally, the slope of 
the normalized photovoltage could be used to modulate laser power. For example, a 
steep slope may indicate that char will occur before the desired volume is ablated. This 
data could be used to decrease laser power; thus, allowing for greater heat transfer via 
conduction before the tissue chars. In this way the size of the ablation zone can be 
maximized. 
The key limitation of this study is the inability to correlate the optical signal with 
the growth of the coagulation zone. It is also difficult to quantify the final coagulation 
zone as illustrated in Figure 27. While the coagulation zone is clearly visible, accurately 
delineating the coagulation boundary remains challenging. Consequently, in order to 
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empirically demonstrate the utility of the optical monitoring system, further studies 
must be undertaken in a material in which the growth of the coagulation zone can be 
quantified and compared to the optical signal. 
 
 
Figure 26: Temperature and predicted cell death during FLA 
 
 
Figure 27: Ex vivo bovine muscle after FLA treatment. Note the extensive char visible along the length of the laser fiber 
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4.5. Conclusion 
The signal recorded by an interstitial optical probe during FLA appears to correlate with 
the propagation of the coagulation boundary. In contrast, temperature rises at an 
approximately steady rate providing no information regarding the location of the 
coagulation boundary. The damage estimates provide by the Arrhenius damage model 
also appear to correlate with the growth of coagulation zone but conflicting estimates 
are provided due to inconsistent kinetic parameters.  
To fully illustrate the correlation between the growth of the coagulation zone and 
the optical signal, a material is required in which the propagation of the coagulation 
zone can be accurately quantified. In the next chapter, we outline our efforts to develop 
such material and demonstrate its similarity to in vivo human prostate. In subsequent 
chapters the utility of interstitial optical probes will be demonstrated using this material 
as a prostate model and finally the probes will be tested in ex vivo bovine muscle. 
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CHAPTER 5 
A Tissue-Mimicking Prostate Phantom for 
980nm Focal Laser Ablation 
 
5. A Tissue-Mimicking Prostate Phantom for 980nm Focal Laser Ablation 
5.1. Introduction 
Focal laser ablation has been demonstrated to be a promising method of focal therapy 
for prostate cancer [10], [11], [73], [192]. The procedure consists of inserting a laser fiber 
into a target tumor and raising the temperature above 60°C. A 980nm diode laser is 
frequently used. Given the fixed wavelength, the induced zone of coagulative necrosis is 
primarily dependent on laser power, exposure duration and device characteristics such 
as diffuser length. Understanding the effect of these parameters on the resulting damage 
zone is critical for clinical success. Prior work investigating thermal response has relied 
on animal models [201]–[203] and cadaveric prostate [204]. Such models are 
heterogeneous across specimens, resulting in the requirement for a large number of 
samples to accurately assess laser-tissue interaction. The optical properties of these 
models may not be sufficiently similar to human prostate and the experimental 
approach is complicated by their biohazardous nature. Additionally, the zone of thermal 
necrosis is difficult to quantify and requires histologic analysis. Therefore, there is a 
need to develop a tissue-mimicking phantom to provide a standardized, controllable 
model for investigations of both the optical and thermal response of prostatic tissue to 
980nm focal laser ablation. 
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Magnetic resonance thermometry is frequently used as a method of monitoring 
FLA; however, the resulting damage maps have been shown to overestimate the extent 
of thermal necrosis due to motion artifact and inaccurate thermal damage models [132]. 
Interstitial thermal probes have also been used as a method for monitoring ablation 
[193], [205]. In contrast to MRT, interstitial probes only provide thermal data for a single 
point. It is therefore necessary to utilize a priori assumptions to estimate the volume of 
coagulative necrosis. A tissue-mimicking phantom would provide a robust platform for 
further development of both MRT and interstitial thermal probes in this field. In this 
work we have developed the requisite phantom and demonstrated similarity to prostatic 
tissue using previously acquired clinical data. Furthermore, it is envisioned that the 
phantom will find utility in the development and characterization of FLA systems as well 
as for validation of computational models. 
The propagation of light in tissue is governed by the absorption coefficient (𝜇𝑎) 
and the reduced scattering coefficient (𝜇𝑠
′ ). The reduced scattering coefficient is given 
by 𝜇𝑠
′ = 𝜇𝑠(1 − 𝑔), where 𝜇𝑠 and 𝑔 are the scattering coefficient and anisotropy factor 
respectively. In order to achieve clinically relevant thermal damage volumes in a 
phantom, the material must possess both a similar 𝜇𝑎 and 𝜇𝑠
′  to tissue. Moreover, studies 
have shown that thermal tissue damage can cause up to a five-fold increase in total 
attenuation [195], [206], [207]. This is predominantly due to increased scatter as a result 
of thermally induced protein coagulation. The phantom material must therefore, also 
exhibit dynamic optical properties such that 𝜇𝑠
′  increases substantially when exposed to 
temperatures sufficient to induce rapid protein coagulation. This threshold is generally 
accepted to be 60°C [24]. Studies have highlighted the correlation between optical 
properties and the resulting coagulation zone during FLA. For example, using an in vivo 
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murine model, Nikfarjam et al. found that an Nd-Yag (1064nm) laser takes 50s to achieve 
the same coagulation zone diameter as observed after 20s with a diode laser (980nm) 
[208]. This occurs because the diode laser has a shorter penetration depth. Similar 
results were reported by Jiang et al. through simulation of FLA in the liver [197]. After 
600s the predicted volume of coagulated tissue was almost three times greater using a 
980nm (native: 𝜇𝑎=0.6cm
-1, 𝜇𝑠
′ = 9.7cm-1, coagulated: 𝜇𝑎=0.5cm
-1, 𝜇𝑠
′ = 14.7cm-1) laser 
compared to a 1064nm (native: 𝜇𝑎=0.3cm
-1, 𝜇𝑠
′ = 9.0cm-1, coagulated: 𝜇𝑎=0.2cm
-1, 𝜇𝑠
′ = 
13.9cm-1) laser.  
Both thermal conductivity and specific heat capacity also play an important role 
in determining the final ablation volume. It is difficult to manipulate these properties 
without altering the material’s optical properties; however, most phantoms are 
composed primarily of water which has similar thermal properties to tissue. Finally, the 
thermal damage volume must be observable post-ablation. This can be achieved by 
sectioning the phantom and quantifying the thermal damage under direct visualization. 
It is also advantageous to observe the damage volume without disturbing the material 
via ultrasound or MRI.   
Many tissue-mimicking phantoms have been proposed for the analysis of thermal 
therapy. Negussie et al. reported on a polyacrylamide gel doped with thermochromic ink 
[209] with color changes correlated with temperature increase. They also demonstrated 
that the phantom exhibited thermal properties similar to human soft tissue. Zhang et al. 
developed a similar phantom in which the damage zone was visualized through the 
coagulation of BSA [210]. BSA is optically transparent in its native state but opaque when 
coagulated. This phantom was based on prior work by McDonald et al. who 
demonstrated that the coagulation temperature of BSA can be altered by controlling pH 
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[211]. Without altering the pH, BSA coagulates in polyacrylamide phantoms at 70°C [212] 
which is considerably higher than observed during FLA.  
McDonald et al. also demonstrated that the coagulation zone can be quantified with T2-
weighted magnetic resonance imaging (MRI). This was possible in that phantom due to 
the thermal response of the protein in the BSA. Thermally-induced protein aggregation 
hinders the rotational averaging of protein dipolar interactions, thus; protein-proton 
transverse relaxation time is reduced resulting in contrast between native and 
coagulated states [213]. T1-weighted imaging may also be used; however, the T1 
relaxation times for proteins are very long and are not as heavily impacted by protein 
aggregation.  
While all of these phantoms are useful for analyzing thermal damage, none of 
them have been demonstrated to possess optical properties similar to human tissue and 
thus they are not suitable for the analysis of FLA. In contrast, Iizuka et al. demonstrated 
a method for quantifying phantom optical properties and designed an albumin and agar 
phantom with similar optical properties to human tissue at 805nm [214]. The albumin 
is a key ingredient as it ensures an increase in 𝜇𝑠
′  during FLA. In this chapter we use the 
same method as Iizuka et al. for quantifying phantom optical properties to develop a 
tissue-mimicking prostate phantom for FLA at 980nm. While the optical properties of 
prostatic tissue may vary between patients and even within the same patient, we sought 
to achieve an 𝜇𝑎 and 𝜇𝑠
′  of 0.66cm-1 and 8.1cm-1 respectively as these values have been 
reported for human prostate at 980nm [215]. To our knowledge these are the only 
published values for 𝜇𝑎 and 𝜇𝑠
′  at 980nm in human prostate; however, they are consistent 
with other studies in the near-infrared region [198], [207]. In addition, the coagulation-
induced increase in scatter in the human prostate has been reported to range from 71-
95 
 
130% in the near-infrared region [198], [207]. As a result, we elected to design the 
phantom with a 100% coagulation-induced increase in 𝜇𝑠
′  (Δ𝜇𝑠
′ ). 
In contrast to Iizuka et al., we utilized a polyacrylamide gel doped with BSA to 
ensure that the coagulation temperature can be adjusted using the pH method 
demonstrated by McDonald et al. We then demonstrate that the thermal response of the 
phantom can be measured via interstitial thermal probes and MRT. Quantification of the 
coagulation zone was demonstrated non-invasively using T2-weighted MRI and via direct 
visualization after sectioning. Finally, we compared our results with our previous clinical 
trial in which FLA was used for the treatment of prostate cancer [205]. 
 
5.2. Methods 
5.2.1. Phantom Construction 
Polyacrylamide gel was chosen as the base material for the phantom due to its high 
melting point, optical transparency, and appropriate thermal properties [209]. The gel 
was prepared by mixing Acrylamide/bis-acrylamide (19:1 40% w/v, Thermo Fisher 
Scientific Inc., CA, AM9024) with degassed deionized water. The solution was then doped 
with various ingredients to change the phantom optical properties. At 980nm, the 
primary absorbers in tissue are water molecules, oxyhemoglobin and deoxyhemoglobin. 
As polyacrylamide contains a large quantity of water the 𝜇𝑎  of the base material is close 
to that of prostatic tissue. To match  𝜇𝑎 to prostatic tissue, Naphthol Green B (Sigma-
Aldrich, MI, N7257-100G) was used as it is readily absorbed in water; thus, resulting in 
minimal scatter. In contrast Intralipid (20% v/v, Fresenius Kabi, Sweden) was used to 
increase 𝜇𝑠
′  as it is an effective scatterer and a weak absorber. Moreover, Intralipid 
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preferentially scatters light in the forward direction; therefore, phantoms doped with 
Intralipid will possess g values similar to soft tissue [216]. Intralipid is a solution of 
soybean oil (20%), egg yolk phospholipids (1.2%), glycerin (2.25%) and water (76.55%). 
Phospholipid micelles from the soybean oil scatter light; thus, 𝜇𝑠
′  can be altered by 
varying Intralipid concentration [217]. Finally, BSA (30.8% w/v, Boval Co., TX, CF-0020) 
was used to ensure an increase in 𝜇𝑠
′  post ablation while also providing contrast for MRI 
and direct visualization.  
To reduce the coagulation temperature of BSA to 60°C, a 0.2M citrate buffer was 
added to ensure a pH ~ 4.7. The buffer consists of citric acid anhydrous (Sigma-Aldrich, 
MI, C0759) and sodium citrate tribasic dehydrate (Sigma-Aldrich, MI, S4641). Further 
details on this method can be found in McDonald et al [211]. To prevent bubbles from 
appearing in the phantom, the BSA was thoroughly degassed and added after all other 
ingredients were dissolved in water. Since the polymerization reaction is exothermic, 
and could cause premature BSA coagulation, the solution was chilled (4-8°C) before 
adding the initiator. Due to the reduced pH, the widely used combination of TEMED and 
ammonium persulfate could not be used to initiate polymerization. Instead, 
polymerization was initiated via a combination of L-ascorbic acid (Sigma-Aldrich, MI, 
A5960), iron (II) sulfate heptahydrate (Sigma-Aldrich, MI, F7002) and hydrogen peroxide 
(30% w/v, Sigma-Aldrich, MI, H1009) as previously used by McDonald et al.[211]. . The 
solution was then immediately poured into 70mm x 70mm x 40mm thin walled (1mm) 
prefabricated molds, sealed and refrigerated. Table 8 shows the recipe for a 1L phantom 
without altering the optical properties by addition of Naphthol Green B, Intralipid or 
BSA. Throughout this paper, the increase in volume due to the addition of BSA and/or 
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Intralipid addition was offset by a corresponding reduction in water volume; hence, the 
total volume remained constant. 
Table 8: Phantom recipe prior to altering optical properties (1L) 
Ingredients      Dosage 
Acrylamide/bis-acrylamide (40% w/v) 250ml 
Deionized water 744.5ml 
Citric Acid Anhydrous 17.063g 
Sodium Citrate Tribasic Dehydrate 32.696g 
  
Initiator-Activator  
L-ascorbic acid 1g 
FeSO4 (1% w/v) 2.5ml 
Hydrogen Peroxide (3% v/v) 3ml 
 
 
 
5.2.2. Absorption Coefficient as Function of Naphthol Green B 
Concentration 
Naphthol Green B was identified as an appropriate dye to increase the absorption 
coefficient as it is a known absorber at 980nm. Solutions of Naphthol Green B (0.05%-
0.4% w/v) dissolved in water were tested to ensure that FLA would not bleach the dye or 
otherwise alter the 𝜇𝑎. 7ml of each solution was placed in a test-tube and a 600µm core 
laser fiber with a 15mm long diffuser (Medtronic, Dublin, Ireland)) was inserted into the 
center of the tube. Each sample was then exposed to 980nm light at 13.75W for 3 
minutes. These parameters were chosen to match those used in a previously conducted 
clinical trial of prostate cancer FLA to enable comparison with in vivo patient data [205]. 
A spectrophotometer (Agilent 8453 UV-visible Spectroscopy System) was used to 
measure the absorbance (A) of each solution before and after exposure to the laser light. 
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By assuming negligible scatter, 𝜇𝑎 was calculated using the following formula which can 
be derived from Beer’s Law [218]: 
 
𝜇𝑎 = 𝑙𝑛 (
100
%𝑇
)𝑑 
(Eqn. 1) 
where %T is the percentage of light transmitted (𝐴 = 2 − log10 %𝑇) and d is the thickness 
of the cuvette (1cm).  
Phantoms doped with increasing concentrations of Naphthol Green B (0%, 0.05%, 
0.15%, 0.25% and 0.35% w/v) were manufactured to determine its relationship with 𝜇𝑎 
using the above method. Five samples of each concentration were prepared by adding 
Naphthol Green B to the recipe outlined in Table 8. It was anticipated that the initiator, 
hydrogen peroxide, would bleach the dye; therefore, measurements were made in the 
polyacrylamide phantom rather than in a dye and water solution. The phantoms were 
prepared from 20ml solutions, 3ml of which was placed in a cuvette immediately after 
the addition of the initiator. The cuvettes were then covered and refrigerated. To assess 
the bleaching effect, the 𝜇𝑎 was determined for each sample at 24 hrs., 48 hrs. and 72 
hrs. 
 
5.2.3. Method of Measuring the Reduced Scattering Coefficient 
The apparatus shown in Figure 28 was used to measure the 𝜇𝑠
′  as previously 
demonstrated by Iizuka et al [214]. In contrast to Iizuka et al, measurements were taken 
after polymerization. It consists of a 3D printed testing chamber, a point source probe 
(Pioneer Optics, Bloomfield, CT) connected to a 980nm diode laser (Photex Inc, Houston, 
TX), a micrometer-controlled translation stage (Thorlabs, Newton, NJ) and a dosimetry 
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probe (Pioneer Optics, Bloomfield, CT) connected to an amplified photodetector 
(PDA36A, Thorlabs, Newton, NJ). 
 
Figure 28: Apparatus used to quantify 𝜇𝑠
′ . Phantoms were cast in 70mm x 70mm x 40mm thin walled (1mm) containers 
with holes for the source and dosimetry probes. During testing the container holding the phantom is placed in the 
measurement chamber before inserting the probes 
 
Each of the probes consists of a 400µm optical fiber with a polycarbonate case 
attached to the distal 20mm (Figure 29). The fiber terminates inside the polycarbonate 
immediately proximal to titanium dioxide power. The powder scatters light in all 
directions; therefore, ensuring that the probe can act as either an isotropic point source 
or an isotropic point detector. The polycarbonate case is press-fit into a stainless tube 
and the fiber is secured proximally with a Tuohy Borst adapter and Luer lock. 
 
Figure 29: Design of the isotropic point source/detector probes. 
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As depicted in Figure 30, the light detected by the dosimetry probe is transmitted 
to an amplified photodetector which outputs a voltage in the  range 0-10V. A voltage 
divider is used to reduce the range to 0-5V so that an Arduino Leonardo (Arduino LLC, 
Italy) can be used for analog to digital conversion. The digital signal is then transmitted 
to a PC over USB where custom-built software (Python) facilitates real-time data 
visualization and recording. 
 
Figure 30: 1-Fluence box apparatus, 2 – Amplified photodetector, 3 – voltage divider, 4 – Arduino Leonardo, 5 – PC 
and 6 – Custom-built software 
 
Using custom-built software and a microcontroller (Arduino Leonardo, Arduino 
LLC, Italy), the photovoltage (V) was recorded every 500µm as the dosimetry probe was 
advanced towards the source probe. These data were then used to calculate the effective 
attenuation (𝜇𝑒𝑓𝑓) coefficient as the fluence rate (𝜙) for an isotropic point source radiator 
is given by [218]:  
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𝜙(𝑟) ∝  
𝑒𝑥𝑝 (−𝜇𝑒𝑓𝑓𝑟)
𝑟
 
(Eqn. 2) 
where 𝑟 is the distance between the source and detector. Given that V ∝ 𝜙, the magnitude 
of the slope of ln(𝑉 ∙ 𝑟) vs 𝑟 is the 𝜇𝑒𝑓𝑓. As 𝜇𝑎 is known, the 𝜇𝑠
′  can then be determined 
using the following definition of 𝜇𝑒𝑓𝑓 [218]: 
 𝜇𝑒𝑓𝑓 = √3𝜇𝑎 ∙ (𝜇𝑎 + 𝜇𝑠
′ ) (Eqn. 3) 
 
The apparatus was calibrated against a spectrophotometer using a non-scattering 
medium as there was no material with a known 𝜇𝑠
′  available. Briefly, 300ml phantoms 
doped with Naphthol Green B (0-0.35%) were manufactured and poured into custom 
designed 3D printed boxes prior to polymerization. 3ml of each solution was also placed 
in cuvettes for spectrophotometric analysis. 𝜇𝑒𝑓𝑓 was determined from absorbance using 
Eqn. 1, Eqn. 2 and assuming that 𝜇𝑎 ≫ 𝜇𝑠
′ . A standard 2-point calibration was then 
performed using the phantoms with 0% and 0.35% Naphthol Green B. 
 
5.2.4. Reduced Scattering Coefficient as a Function of BSA & 
Intralipid Concentration 
Phantoms doped with 0.144% (w/v) Naphthol Green B (derived optimal concentration) 
and 12.5%, 25% and 37.5% (v/v) BSA were manufactured in triplicate. The phantoms were 
cast in thin walled containers with openings to facilitate two measurements in the 
fluence box apparatus (Figure 28). The two measurement sites are separated by 23mm 
which is sufficient to ensure that an existing needle track will not affect the second 
measurement. Due to the bleaching effect previously observed, testing was performed 
~48hrs after initiation of polymerization. The 𝜇𝑠
′  was determined for each phantom at 
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room temperature. The phantoms were then placed in plastic bags to prevent water 
absorption and submerged in a water bath for 2hrs at 70°C. This was found to be 
sufficient to raise the temperature of the entire phantom above 65°C; thus, ensuring 
coagulation throughout the volume. The  𝜇𝑠
′  was then quantified again using a different 
section of the phantom. The optimal concentration of BSA was defined as the 
concentration that results in 𝛥𝜇𝑠
′  of 8.1cm-1 (a 100% increase 𝜇𝑠
′ ).   
BSA causes minimal scatter in its native state, thus the addition of Intralipid was 
required to achieve the desired 𝜇𝑠
′  of 8.1 cm-1 in the native state. A second set of 
phantoms was manufactured in triplicate containing 0.144% Naphthol Green B (derived 
optimal concentration), 31.4% BSA (derived optimal concentration) and increasing 
concentrations of Intralipid (0%, 5%, 10%). The 𝜇𝑠
′  was determined in the native and 
coagulated states following the same protocol outlined for the BSA only phantoms.   
 
5.2.5. Testing Optimized Phantom 
The derived phantom recipe was used to create eight optimized phantoms. Five of these 
phantoms were used to determine 𝜇𝑠
′  in the native and coagulated states following the 
same protocol as used previously. The remaining three phantoms were tested to assess 
the thermal response under the same conditions previously used in a clinical trial [205]. 
The trial utilized components from an existing magnetic resonance-guided laser ablation 
system (Medtronic, Dublin, Ireland) along with magnetic resonance - ultrasound fusion 
guidance via the Artemis® device (Eigen, Grass Valley, California). The key components 
were a 15W 980nm laser (BioTex, Houston, Texas), a 600 µm core laser fiber (Medtronic, 
Dublin, Ireland), K-pump surgical infusion pump (K.M.I., Corona, California), Uro-kit 600 
dual lumen catheter (Medtronic, Dublin, Ireland), Fluoroptic® thermal probes 
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(Lumasense, Santa Clara, California) and a custom-fabricated needle guide. Figure 31A 
depicts the clinical setup in which the laser fiber housed in a saline cooled dual lumen 
catheter was inserted into the target. The procedure was monitored via a thermal probe 
placed level with the catheter tip and at a radial distance of 8mm. Figure 31B elucidates 
the phantom experimental setup designed to match the clinical procedure. The 
experiment utilizes the same laser fiber, dual lumen catheter, infusion pump and 
thermal probe. Component placement was achieved using a custom-fabricated insulated 
box with needle tracks placed 8mm apart. Prior to being placed in the box, phantom 
temperature was raised to 37± 1 °C using a water bath. FLA was performed for 3 min. at 
13.75 W, matching parameters of the clinical trial. In contrast to the clinical trial, the 
experiment was simultaneously monitored via gradient echo magnetic resonance 
thermometry to demonstrate the utility of the phantom for the development of MRT 
sequences.    
Measurement of the coagulation zone was then demonstrated using MRI and 
direct visualization. Immediately after laser deactivation, a high resolution T2-weighted 
turbo spin echo image was acquired (echo time = 52ms, repetition time = 2000ms, 
resolution = 0.5*0.5*1mm3) using a 3T scanner (Prisma, Siemens). Alignment of the 
imaging plane with the fiber trajectory was achieved using a fiducial marker within the 
insulated box. The fiducial marker consisted of a 2x2mm2 water-filled channel 
circumscribing the phantom. Following laser application, the phantom was sliced in half 
along the fiber trajectory and photographed.  
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Figure 31: A) Clinical setup during MR-US fusion guided FLA for the treatment of prostate cancer. FLA was performed 
in the region of interest (ROI) for 3 min. at 13.75W with a 980nm laser. A thermal probe was used to record temperature. 
B) Experimental setup mimicking clinical conditions. The phantom was heated to 37°C in a water bath prior to being 
placed in the insulated box. FLA was performed using the same equipment and configuration used clinically 
 
5.3. Results 
5.3.1. Absorption Coefficient  
The effect of photobleaching was examined by comparing µa before and after FLA in 
Naphthol Green B and water solutions (Figure 32). The difference in µa was found to be 
negligible at all concentrations (mean absolute error = 0.035 cm-1); therefore, it can be 
assumed that Naphthol Green B will not photobleach during FLA. In polyacrylamide 
phantoms, a non-linear relationship was observed between Naphthol Green B 
concentration and µa (Figure 33). This was previously observed by Iizuka et al [214], who 
attributed this effect to bleaching induced by the initiator, ammonium persulfate (APS). 
They found that bleaching only occurs during the first 2 hours after the addition of APS. 
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In contrast, hydrogen peroxide was used as the initiator in our phantoms and appears 
to cause bleaching beyond 24hrs. No further bleaching was observed after 48 hours. The 
requisite concentration of Naphthol Green B to achieve the desired µa of 0.66 cm
-1 was 
determined by interpolating the data from the 48hr and 72hr measurements. It was 
found that 0.144% Naphthol Green B results in an µa of 0.66 ± 0.06 cm
-1.  
 
Figure 32: The effect of photobleaching in Naphthol 
Green B/water solutions at 980nm. No change was 
observed as a result of laser exposure 
 
Figure 33: µa as function of Naphthol Green B 
concentration at 980nm in polyacrylamide gel. µa was 
determined by a spectrophotometer at 24, 48 and 72 
hours. No further bleaching was observed after 48 hours. 
By interpolation (dashed black line), a 0.144% 
concentration of Naphthol Green B was found to provide 
the desired µa of 0.66cm-1. 
 
5.3.2. Reduced Scattering Coefficient  
Prior to determining the reduced scattering coefficient, the fluence box was calibrated 
against a spectrophotometer. 𝜇𝑒𝑓𝑓 measured by the fluence box was linear (r
2 = 0.998) 
throughout the measurement range. After standard 2-point calibration was applied, 𝜇𝑒𝑓𝑓 
measured by the fluence box and spectrophotometer was equivalent (mean absolute 
error = 0.033 cm-1).  
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Figure 34A shows the data measured by the fluence box in order to calculate 𝜇𝑠
′  
for a set of phantoms doped with various concentrations of BSA before and after 
coagulation. The slope of the curves gives 𝜇𝑒𝑓𝑓 which was used to generate Figure 34B 
as previously described (Eqn. 2). Figure 35 shows the corresponding curves for phantoms 
doped with the optimal concentration of BSA and increasing concentrations of Intralipid. 
All measurements were taken at least 48 hours after adding the initiator to ensure that 
the bleaching effect had subsided. As expected, the presence of BSA ensures a 
coagulation-induced increase in 𝜇𝑠
′  with 31.4% BSA providing the desired Δ𝜇𝑠
′  of 8.1 cm-
1. In the native state the target 𝜇𝑠
′  is also 8.1 cm-1 which is achieved by adding 8.06% 
Intralipid. Interestingly, Intralipid also appears to have some effect on the coagulation-
induced increase in 𝜇𝑠
′ . 
 
Figure 34: A) Normalized 𝑙𝑛(𝑉 ∙ 𝑟) vs r for a single set of phantoms doped with 12.5%, 25% and 37.5%  BSA and 
0.144% Naphthol Green B. B) The effect of BSA concentration on 𝑢𝑠
′  before and after coagulation measured in 3 sets 
of phantoms. Given the desired coagulation-induced change in 𝜇𝑠
′  of 8.1cm-1, the requisite concentration of BSA was 
found to be 31.4%. Error bars represent one standard deviation and are not visible at all points 
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Figure 35: A) Normalized 𝑙𝑛(𝑉 ∙ 𝑟) vs r for a single set of phantoms doped with 0%, 5% and 10%  Intralipid (IL), 0.144% 
Naphthol Green B and 31.4% BSA. B) The effect of Intralipid and BSA concentration on 𝑢𝑠
′  before and after coagulation 
measured in 3 sets of phantoms. By interpolation, the requisite concetraion of Intralipid was found to be 8.06%. Error 
bars represent one standard deviation and are not visible at all points 
 
Incorporating optimized concentrations for BSA and Intralipid yielded a final 
phantom recipe (Table 9) which was subsequently characterized in the same manner as 
before (Figure 36). The optical properties are summarized in Table 10. The mean Δ𝜇𝑠
′  
across the five tested samples was 113±11%.  
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Table 9: Tissue-mimicking phantom recipe (1L) 
Ingredients      Dosage 
Acrylamide/bis-acrylamide (40% w/v) 250ml 
Deionized water 349.9ml 
Naphthol Green B 1.44g 
Intralipid (20%) 80.6ml 
BSA (30.6%) 314ml 
Citric Acid Anhydrous 17.063g 
Sodium Citrate Tribasic Dehydrate 32.696g 
  
Initiator-Activator  
L-ascorbic acid 1g 
FeSO4 (1% w/v) 2.5ml 
Hydrogen Peroxide (3% v/v) 3ml 
 
 
 
Figure 36: Normalized ln(V.r) vs r for a single optimized phantom before and after coagulation. A total of five phantoms 
were tested and one standard deviation was used to quantify the uncertainty in the measured optical properties shown 
in Table 10. 
Table 10: Optical properties of tissue-mimicking phantom 
 𝝁𝒂 (cm
-1) 𝝁𝒔
′  (cm-1) 
Native 0.66 ± 0.06 8.27 ± 0.50 
Coagulated 0.66 ± 0.06 17.63 ± 1.41 
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5.3.3. Thermal Response 
Figure 37 compares the thermal response of the phantom to a patient under the same 
conditions. The temperature was recorded at radial distance of 8mm from the laser fiber 
in both cases. After 180s, the laser was deactivated and the maximum temperature was 
found to be 64.1±0.9°C and 66.9°C in the phantom and patient respectively. The 
temperature dropped rapidly following laser deactivation, reaching 60°C in 10s and 
44±5s for the patient and phantom respectively. 
 
 
Figure 37: Temperature at a radial distance of 8mm from the laser as measured in a patient and three phantoms. 
 
Figure 38(A-C) demonstrates the utility of the phantom as a robust platform for 
the development of MRT sequences for monitoring FLA. Thermal maps were calculated 
from phase maps acquired during the procedure. The zone of elevated temperature was 
localized around the laser fiber as expected. The growth of this zone was evident as the 
procedure progressed. Additionally, the maximum temperature recorded in each of the 
three phantoms was 98.8°C, 99.2°C and 99.7°C. 
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Figure 38: Absolute temperature (°C) during FLA of the optimized phantom as determined by MRT at 0 (A), 90 (B) and 
180 (C) seconds after laser activation. The location of the laser fiber (dashed red line) and thermal probe (dashed black 
line) are marked 
 
5.3.4. FLA Induced Coagulation 
Figure 39 compares the induced coagulation zone in (A) a patient, (B) a phantom under 
T2-weighted MRI, and (C) a phantom under direct visualization. The experiment was 
performed on three phantoms and in all cases the coagulation zone approximates an 
ellipse. The major and minor axes for the phantom were 2.65±0.03cm and 1.6±0.05cm 
on MRI and 2.58±0.03cm and 1.52±0.01cm under direct visualization. A similar 
coagulation zone was observed clinically with major and minor axes of 2.44cm and 
1.51cm respectively. 
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Figure 39: A) Zone of coagulative necrosis in a patient as indicated by non-perfused tissue. The scan was acquired 
immediately after the patient received FLA for 3 min. at 13.75W. Further information can be found in Natarajan et al 
(2017)1. B) Phantom coagulation zone under T2-weighted MRI showing major and minor axes (white arrows). Note 
that the catheters in the center and on the right contain the laser fiber and thermal probe respectively. C) Phantom 
coagulation zone under direct visualization showing major and minor axes (white arrows). Note the needle tracks in the 
center and to the right. 
 
5.4. Discussion 
We have developed a novel tissue-mimicking phantom with similar optical and thermal 
properties to human prostatic tissue. The relationship between phantom ingredients and 
optical properties was determined empirically using fluence measurements and light 
diffusion theory. In the native state 𝜇𝑎 and 𝜇𝑠
′  have  been reported as 0.66cm-1 and 8.1cm-
1 in human prostate at 980nm [215]. In addition, FLA causes coagulative necrosis leading 
to an increase in 𝜇𝑠
′  which is expected to lie in the range of 71-130%  [198], [207]. To 
mimic these properties the requisite concentrations of Naphthol Green B, Intralipid and 
BSA were quantified and found to be 0.144%, 31.4% and 8.06% respectively which 
resulted in 𝜇𝑎 and 𝜇𝑠
′  of 0.66±0.06cm-1 and 8.27±0.5cm-1 in the native state. After 
coagulation 𝜇𝑠
′ , increased to 17.63±1.41 which corresponds to an increase of 113%. The 
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phantom optical properties therefore correspond to the expected values of prostatic 
tissue at 980nm. In addition, the phantom coagulation threshold was matched to tissue 
(~60°C) by reducing pH to 4.7 as outlined in a previous study [211] 
The measured change in 𝜇𝑠
′  after coagulation is higher than predicted as we 
assumed that the coagulation-induced increase in 𝜇𝑠
′  was solely due to BSA protein 
coagulation and independent of Intralipid. This assumption was found to be incorrect 
as the presence of Intralipid led to a relatively small increase in the coagulation induced 
change in 𝜇𝑠
′ . This was not anticipated but may be due to   interaction between the two 
substances. Indeed, earlier studies have shown that fatty acid alters the BSA 
denaturation process [219], [220]. Moreover, in our calculations we have assumed that 
𝜇𝑎 remains constant during laser exposure. While we demonstrated that this is true for 
the absorbing agent Naphthol Green B, when dissolved in water, it is possible that 
interactions with other ingredients results in an alteration of 𝜇𝑎. This is unlikely as it 
has previously been demonstrated that the effect of dyes dissolved in water on 𝜇𝑎 is 
independent of scattering introduced by Intralipid [221]–[223]. While the assumption is 
frequently made when designing tissue mimicking phantoms, it could be verified using 
alternative techniques such as the inverse adding doubling method [224]. Nevertheless, 
the measured increase in 𝜇𝑠
′  is similar to previously reported values for prostatic tissue 
in the near-infrared region [198], [207]. In the limited number of human prostate 
samples studied, the maximum coagulation-induced increase in 𝜇𝑠
′  was 130%, while 272% 
was reported for canine studies with a much larger sample size. 
It should also be noted that in contrast to a previous study by Iizuka et al. [214], 
we were able to measure the optical properties after polymerization; thus, chemical 
reactions with the initiator have been accounted for. This greatly reduces measurement 
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uncertainty as the initiator contains hydrogen peroxide which bleaches Naphthol Green 
B resulting in a decrease in 𝜇𝑎 after polymerization. For some studies it may be desirable 
to increase the BSA content in an effort to achieve a greater post-coagulation increase in 
𝜇𝑠
′ . While this is possible, we limited BSA concentration to 37.5%, as higher 
concentrations resulted in the formation of large bubbles.  
The thermal response of the phantom was compared to previously acquired 
clinical data. The maximum temperature observed clinically was 66.9°C while the 
phantom peaked at 64.2±0.9°C at the same location. Interestingly, after laser 
deactivation, the temperature drops to 60°C, the theorized damage threshold, 44s earlier 
in the patient. Given this relatively short timeframe it is likely that there is only a minor 
increase in coagulation volume as minimal damage occurs during the cooling phase 
[225]. This variation in the rate of cooling is likely due to the absence of perfusion in the 
phantom as well as possible disparity in active cooling. Perfusion has been shown to 
affect both the volume of thermal damage and the temperature distribution during FLA 
[226]. In addition, further active cooling is provided by continuous circulation of water 
through the dual lumen catheter; however, the flow rate and temperature were not 
precisely controlled. Positioning of the thermal probe was also a challenge in the clinical 
setting. A needle guide was used to aid in placement; however, the needle was 
susceptible to deflection when passing through the prostatic tissue. Additionally, in the 
clinical study, the distal section of the thermal probe was covered with a thin copper 
film to prevent laser light from interfering with the thermal measurement. This occurs 
as the thermal probe relies on fluoroptic technology in which the temperature is 
determined based on the decay rate of a phosphor element at the tip of the probe. The 
decay rate is assessed using a photodiode sensitive to 980nm light. In our MRI 
114 
 
experiments the copper film was removed and an in-line filter was used to remove the 
offending light. This approach was taken as the copper film would likely cause an 
artifact on MRI. The absence of the copper film may also explain the initial rapid heating 
observed in the phantom as light can be absorbed directly by the Tefzel jacket covering 
the thermal probe. Likewise, the rate of cooling in the clinical setting may have been 
faster as the copper film rapidly conducts heat away from the sensor tip after laser 
deactivation. 
We also demonstrated that the thermal response during FLA can be monitored 
via MRT as shown in previous clinical trials [11], [192]. The data from the MRT images 
facilitates analysis of the thermal response throughout a single plane. At the end of FLA, 
data from the MRT images shows that the temperature near the fiber is approximately 
100°C with a maximum temperature of 99.7°C. This was expected and correlates with 
clinical experience in which char is frequently observed on the dual lumen catheter after 
removal. Despite the high temperatures, the phantom does not appear to melt. While we 
did not measure the melting point, a previous study found the melting point of similar 
polyacrylamide phantoms to be 113°C [227]. 
Finally, the FLA-induced coagulation zone was compared to that found clinically. 
In the phantom, the induced coagulation zone was readily apparent under T2-weighted 
MRI and direct visualization after sectioning along the laser fiber trajectory. It was found 
to be quantitively and qualitatively similar to the non-perfused region observed on a 
contrast-enhanced MRI acquired immediately after a patient received FLA for the 
treatment of prostate cancer. Moreover, the MRT derived temperature map acquired 
during FLA of the phantom (Figure 38) appears to correlate with the coagulation zone 
identified in both the patient and phantom (Fig. 10). This suggests that the phantom 
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provides a useful platform for studying the effect of procedure parameters on the 
resulting coagulation zone and also for development of feedback techniques including 
MRT. 
The advantages of this phantom over ex vivo tissue are numerous. It is 
homogenous, reproducible, and easy to work with as it is not a biohazard, unlike 
cadaveric tissue. It should be noted that acrylamide monomers are toxic; therefore, 
safety procedures must be adhered to during fabrication. After polymerization the risk 
is substantially reduced; however, nitrile gloves should still be worn due to the 
possibility of residual monomers. A key advantage of this phantom is the ability to 
accurately quantify the coagulation zone. This can be achieved via either direct 
visualization or T2-weighted MRI. Given this characteristic, the phantom should find 
utility in both the development and characterization of focal laser ablation systems. 
Finally, the thermal and optical properties of the phantom are similar to human prostate; 
thus, the phantom provides a useful platform for the development of monitoring 
modalities such as magnetic resonance thermometry and interstitial thermal probes. 
Like many other phantoms a lack of perfusion is the primary limitation of this 
model; therefore, this phantom is likely to find utility as a substitute for ex vivo rather 
than in vivo studies. In addition, the phantom does not account for in vivo factors such 
as the urethra, prostate capsule, prostate stones or capsular cooling. Consequently, the 
phantom should not be used for direct pre-treatment planning. It should also be noted, 
that while every effort was made to match the phantom’s optical properties to human 
prostate, batch to batch variation in the optical properties of Naphthol Green B, 
Intralipid and BSA was not considered in our analysis. This potential variation is likely 
to be minor and have a limited impact on the phantom’s thermal response. Finally, 
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knowledge of g and 𝜇𝑠 are important for Monte Carlo modelling but could not be 
determined due to the employed method of measuring the optical properties. This 
limitation can be overcome by assuming g=0.74 as previously reported for Intralipid 
[216]. This assumption must be utilized with some caution as the effect of BSA 
coagulation on g is unknown. 
To our knowledge this is the first phantom with all of the following 
characteristics: (1) optical properties matched to bulk prostatic tissue at 980nm, (2) 
thermal response similar to clinical data, and (3) visualization of the induced damage 
zone via MRI and direct visualization. These characteristics make this phantom ideal for 
the development and characterization of tools for focal laser ablation at 980nm. 
In chapter 4, we performed FLA experiments using ex vivo bovine muscle as a 
prostate model. In general, ex vivo tissue is difficult to work with because it is excessively 
pliable. As a result, it is challenging to insert the catheters and probes without 
compressing the tissue. It is also difficult to slice the tissue along the trajectory of the 
laser fiber. Even, if correctly sliced, the tissue is likely to expand after it is sliced; 
therefore, the size of ablation zone cannot be accurately measured. In addition, it is 
difficult to delineate the ablation boundary via direct visualization while there is no 
obvious contrast mechanism for MRI. Finally, the optical properties are unknown and 
inconsistent due to both inter and intra-sample variation which naturally results in 
variation in the size of the ablation for a given set of laser exposure parameters. Due to 
this variation in optical properties and the inability to non-invasively monitor the 
ablation zone with MRI, it is impossible to demonstrate the utility of optical monitoring 
as the optical signal cannot be correlated with the growth of the ablation zone. As 
outlined in Table 11, all of these limitations have been successfully addressed through 
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the development of the tissue mimicking phantom. Consequently, it is now possible to 
proceed with development and validation of an interstitial optical monitoring system. 
Table 11: Tissue mimicking prostate phantom vs ex vivo tissue 
 
 
 
5.5. Conclusion 
A tissue mimicking phantom was developed to facilitate the study of FLA at 980nm in 
prostatic tissue. The thermal and optical properties of the phantom were designed to 
match human prostatic tissue. As a result, the thermal response of the phantom was 
consistent with that observed clinically. The induced coagulation zone can be observed 
directly or via T2-weighted MRI. Furthermore, FLA-induced coagulation is both 
qualitatively and quantitatively similar to that observed in in vivo human prostate. This 
phantom provides a useful platform for the development and optimization of FLA 
techniques including monitoring modalities such as interstitial probes and MRT. Indeed, 
this phantom provides the necessary platform for testing our hypothesis that interstitial 
optical probes can be used to monitor FLA. In the next chapter, we will outline the 
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development of an optical monitoring system and perform initial validation using the 
tissue mimicking phantom. 
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CHAPTER 6 
Development of an Interstitial Optical 
Monitoring System 
 
6. Development of an Interstitial Optical Monitoring System 
6.1. Introduction 
Foal laser ablation offers a minimally invasive approach for the treatment of cancer and 
has been used in many organs including prostate [11], [29], [73], breast [74], liver [75], 
lung [76] and brain [77]. During FLA, a laser fiber is inserted into the target tumor and 
oncologic control is achieved via thermally induced coagulative necrosis. Successful 
treatment is contingent upon inducing coagulative necrosis throughout the target 
volume; therefore, treatment monitoring is critical. Magnetic resonance imaging is 
frequently employed for this purpose as it can be used to guide the laser fiber to the 
target and monitor thermal changes via magnetic resonance thermometry. For example, 
in a recent study, FLA was performed on 120 patients with prostate cancer and 
monitored with MRT [6]. At one year follow up there was an 83% freedom of retreatment 
rate and the median procedure time was 122 minutes (range, 60-250 minutes). While the 
clinical results are promising the high cost associated with extended use of MRT is a 
major barrier to the widespread adoption of FLA in oncology. As a result, there are 
ongoing efforts to develop interstitial probes capable of monitoring FLA in real time. 
These efforts have largely focused on the use of interstitial thermal probes consisting 
of either thermocouples [98], [99] or fluoroptic probes [29], [73], [205].  
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Given that FLA achieves cancer control through hyperthermia, it seems logical to 
monitor temperature; however, raw thermal data is of limited utility for predicting 
cellular death. Instead thermal data is generally used in conjunction with the Arrhenius 
thermal damage model [11], [228], [229]. The model predicts cell death based on thermal 
history i.e. taking into account both the magnitude and duration of hyperthermia. Tissue 
specific kinetic parameters are also required inputs for the model and have proven to 
be difficult to quantify. Indeed, due to the variation in estimated kinetic parameters the 
Arrhenius model may be inherently inaccurate when monitoring FLA. Moreover, a recent 
study found that the Arrhenius model overestimates the extent of thermal necrosis 
when compared to histopathology and T1-wieghted contrast enhanced MRI [132]. 
Consequently, there is a need to develop alternative interstitial probes that do not rely 
on thermal data and inaccurate damage models. 
In this chapter we outline the development of an interstitial optical monitoring 
system that monitors laser-tissue interaction during FLA. Previous work by Whelan et al 
demonstrated that in contrast to interstitial thermal probes an interstitial optical probe 
can detect the onset and propagation of thermal coagulation during FLA [188]. Further 
publications by the same group utilized monte carlo modelling to characterize laser 
tissue interaction during FLA to demonstrate the potential of optical monitoring [189], 
[230]. As outlined in chapter 4, coagulation is characterized by an increase in the reduced 
scattering coefficient and therefore a decrease in the optical penetration depth which 
results in a corresponding decrease in optical intensity recorded by an interstitial optical 
probe. To our knowledge no study has empirically demonstrated the utility of optical 
monitoring due to an inability to visualize the propagation of the coagulation zone and 
quantify the coagulation radius as function of time. The tissue mimicking phantom 
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presented in chapter 5 was specifically designed to overcome this limitation and thus 
facilitate temporal registration of the optical response and the coagulation radius. 
We begin with a detailed description of the prototype optical monitoring system. 
The performance of four optical probe designs are then assessed using the tissue 
mimicking phantom which simulates the optical properties of prostatic tissue during 
FLA. In contrast to previous work, growth of the coagulation is monitored in near real-
time via T2-weighted MRI. This enables correlation of optical probe data with the 
coagulation radius. Finally, we demonstrate the utility of the system in an ex vivo bovine 
muscle model under the same conditions used in a previous clinical trial [205]. 
 
6.2. System Design 
6.2.1. System Requirements 
The optical monitoring must be capable of minimally invasively monitoring light 
intensity at a predefined location deep within the target tissue. The measured signal 
must be recorded, displayed and analyzed in real-time. To this end the key components 
that must be developed are: 1) an interstitial optical probe, 2) hardware for optical to 
digital signal conversion, and 3) software for real-time analysis. 
 a software package capable of analyzing the resulting signal. 
The following design requirements were identified for the interstitial optical probes: 
1. Light Collection & Delivery: 
The probe must be able to collect light at a known location near the probe tip. In 
the clinical setting, the interstitial optical probes and laser fiber are inserted 
parallel to each other using a needle guide; therefore, it is necessary to be able to 
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collect light travelling perpendicular to the long axis of the probe. This precludes 
the use of a simple bare cut fiber in which light primarily enters the fiber parallel 
to the long axis. Collected must then be transferred from the probe tip to a 
photodiode with minimal loss. 
2. MR safe: 
While clinically the system is expected to be used in an office setting, testing and 
validation will be performed under MRI surveillance; thus, the probes must be MR 
safe. Consequently, to prevent torqueing and susceptibility artifacts, the probes 
cannot contain ferromagnetic components. Additionally, the photodiode must be 
placed sufficiently far from the scanner to minimize both the interreference and 
attractive force of the magnetic field. Five meters from isocenter was deemed 
sufficient. 
3. Probe diameter: 
In our clinical trial (Chapter 3), the largest needle used was a 13Ga flexi-needle. 
This corresponds to an outer diameter of 2.413mm; therefore, this value was 
chosen as the maximum probe diameter. 
4. Mechanical Properties: 
Although not explicitly measured, the probe must be rigid to facilitate insertion 
without flexion. These probes were designed primarily for use with a soft 
hydrogel tissue mimicking phantom; therefore, while sharp tips are required, they 
do not need to meet the requirements of a typical needle. 
5. Thermal Properties: 
During testing of the tissue mimicking phantom under magnetic resonance 
thermometry (Chapter 5) the maximum temperature recorded was 99.7°C but this 
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occurs close to the fiber. The interstitial probes will be tested at radii of 4mm, 
5mm, 6mm and 7mm where maximum temperatures were observed to be 86°C, 
77°C, 60°C and 65°C respectively. The probe must remain thermally stable at these 
temperatures; therefore, the melting point of the probe materials must be greater 
than 86°C. 
The following hardware requirements were identified: 
1. Optical to analog conversion 
Optical to analog conversion can be achieved with an amplified photodiode. To 
maintain MR safety, the photodiode must be located at least 5m from isocenter. 
It is anticipated that the optical signal will be relatively weak; therefore, up to 
70dB gain may be necessary. 
2. Analog to digital conversion 
Rapid analog to digital conversion is necessary to facilitate real-time signal 
analysis. It Is preferable to perform this step in the MR environment with resulting 
digital signal transmitted to the control room. 
3. Signal Analysis & Display 
A dedicated PC is required in the control room to run custom built software for 
signal display, analysis and feedback 
 
Finally, the software requirements are: 
1. Data Collection & Display 
The raw data received must be collected and displayed in a real-time so that user 
can see the optical signal as a function of time. A rate of 1Hz should sufficient 
for the proposed application. The software should be capable of simultaneously 
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managing two optical and four thermal signals. In addition, during subsequent 
analysis it will be necessary to temporally register the MRI data with the optical 
data. As data is collected on different computing platforms, the individual 
timestamps will not be sufficient. 
2. Data analysis & Feedback 
Rapid data processing must be undertaken to facilitate application of a feedback 
algorithm in real-time. Consequently, the software requires dedicated thread for 
data collection and analysis. The output from the feedback algorithm must be 
displayed on screen with an alert to notify the user to deactivate the laser when 
the complete coagulation has occurred within the target volume 
3. Data storage 
The optical signal, feedback algorithm and respective timestamps must be saved 
to disk upon completion of each experiment. 
 
6.2.2. System Architecture & Optical Probe Design 
As depicted in Figure 40A, the key components of the optical monitoring system are: 1) 
custom designed interstitial optical probe, 2) photodiode, 3) voltage divider, 4) 
microcontroller, 5) Computer and 6) custom built software. Light collected by the 
interstitial probe is transmitted along a 5m optical fiber to the photodiode, Si switchable 
gain detector (Thorlabs, NJ), using an SMA905 connector. The photodiode outputs an 
analog signal in the range 0-10V. Analog to digital conversion is performed by a 
microcontroller, Arduino Leonardo (Arduino LLC, Italy), at 1Hz. The microcontroller 
operates with a maximum voltage of 5V; therefore, a voltage divider is used to reduce 
the analog output range from the photodiode to 0-5V. Data from the microcontroller is 
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transferred in real-time via USB to computer in the control room. The computer runs the 
in house developed ‘FLA Monitor’ software (Python) which enables real-time data 
collection, visualization and analysis. This software package is discussed in more detail 
in the next section. 
A total of four interstitial optical probes were designed, manufactured and 
evaluated. The primary difference between probes lies in the range of angles over which 
they collect light.  
 
Design 1: Ballistic 
This probe is designed to predominantly detect ballistic and snake photons, that is 
photons that undergo no scattering or minimal scattering while travelling from the laser 
towards the probe. To achieve this the probe collects light from a single point at the 
distal end with a limited cone of acceptance as depicted in Figure 1B. During use, the 
probe is rotated such that the cone of acceptance points directly towards the laser fiber. 
The probe consists of a 5m long, 200µm core optical fiber with the tip encased in a 
20mm section of polycarbonate tubing (Pioneer Optics, CT). The tip of the polycarbonate 
is sharp to facilitate insertion and coated with black epoxy (3M, DP-420, McMaster-Carr 
#7467A51) to block incoming light. The polycarbonate is press-fit into a carbon fiber 
tube and the fiber is secured proximally with a Tuohy Borst adapter. The tip of the 
optical fiber is polished to 43° to facilitate collection of light through the side of the 
polycarbonate casing as illustrated by the ‘cone of acceptance’ in Figure 1B. 
Hypothesis: The probe is expected to primarily detect ballisitc and snake photons; 
therefore, photovoltage will drop as the coagulation boundary grows and reach steady 
state once the coagulation boundary reaches the probe. 
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Design 2: Backscatter  
This probe is identical to the previous probe; however, during testing the probe is 
rotated such that the cone of acceptance points directly away from the laser source. 
Consequently, the probe should primarily detect photons travelling back towards the 
laser source after undergoing multiple scattering events. 
Hypothesis: The probe is expected to primarily detect photons that travel past 
the probe undergo multiple scattering events and are ultimately backscattered towards 
the probe; therefore, the photovoltage should decrease as the coagulation boundary 
grows and then increase once the coagulation boundary passes the probe. 
 
Design 3: Spherical 
Figure 44C illustrates an alternative design, designated ‘Spherical’, which facilitates light 
collection from all angles. This is achieved by scattering the light off titanium dioxide 
powder embedded in the polycarbonate tubing directly in front of the optical fiber. In 
contrast to the previous designs the optical fiber has a core diameter of 400 µm. The 
fiber and polycarbonate casing are embedded in a carbon fiber tube as outlined in Design 
1. 
Hypothesis: This probe detects photons travelling in all directions; therefore, 
photovoltage will decrease as the coagulation zone increases. 
Design 4: Radial 
The final probe shown in Figure 40D is designated ‘Radial’ as it accepts light from all 
directions in a single plane. The fiber has a core diameter of 400 µm and the tip is 
tapered to a point which facilities photon acceptance from all radial angles. 
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Hypothesis: This probe detects ballistic/snake photons and backscattered 
photons; therefore, the optical signal will decrease as the coagulation zone increases 
and increase once the coagulation zone passes the probe. 
 
The following summarizes how each of the design requirements were satisfied: 
1. Light Collection – Collect light at tip of probe and transmit to photodiode 
• Achieved using angled fiber tip (Ballistic, Backscatter and Radial) or 
titanium dioxide powder (Spherical) and 5m long optical fiber 
2. MR Safe – no ferromagnetic material within 5m of iso-center 
• Probe shaft made from carbon fiber (non-ferromagnetic) 
• Probe tip made from polycarbonate (non-ferromagnetic) 
• Optical fiber made from silica (non-ferromagnetic) 
• 5m long optical fiber ensures photodiodes can be placed sufficiently far 
from iso-center 
3. Probe diameter - <2.413mm 
• The carbon fiber tube has a diameter of 3.2mm but the distal section is 
turned down to 2.4mm to ensure that the section within the tissue 
mimicking phantom is less than 2.413mm. 
4. Mechanical Properties – Rigid  
• Probe shaft made from carbon fiber which has comparable mechanical 
properties to metal (aluminum 6061) 
5. Thermal properties – melting point > 86°C 
• Carbon fiber mechanical properties rated at 82°C by the manufacturer but 
no adverse effects were observed when placed in boiling water 
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• Polycarbonate melting point = 147°C 
• Silica (optical fiber) melting point >400°C. 
• Titanium dioxide melting point = 1855°C 
 
 
Figure 40: A - Components of the optical monitoring system: 1) Interstitial optical probe, 2) Photodiode, 3) Voltage 
divider, 4) Microcontroller, 5) Computer and 6) Custom built software. B – Detailed view of interstitial optical probe with 
a defined cone of acceptance. C – Detailed view of tip of interstitial probe with spherical acceptance. D - Detailed view 
of tip of interstitial probe with radial acceptance. 
. 
 
129 
 
6.2.3. FLA Monitoring Software 
The FLA monitoring software consists of the graphical user interface (GUI) shown in 
Figure 41. It was designed to simultaneously record, display and analyze data from up 
to four Fluoroptic® thermal probes (Lumasense, Santa Clara, California) and two custom 
designed optical probes. The graphs ‘A’ and ‘B’ display real-time data for the thermal 
and optical probes respectively (In this chapter, the thermal probes will not be used). 
The buttons highlighted by the blue circle allow the user to start/stop data collection 
and save results as a .csv file. Buttons in the red circle allow the user to record the timing 
of events including pump on/off, laser on/off and MRI on/off. The latter of which is 
crucial to enable temporal registration between the optical data and the imaging data 
from the MRI scanner. Finally, in the yellow circle, the output from the feedback 
algorithm is displayed in real-time. 
 
Figure 41: Custom built FLA monitoring software 
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The feedback algorithm is based on the hypothesis that the fluence at a fixed 
point within the ablation zone will drop during coagulation and either reach a steady 
state or an inflection point once the coagulation boundary has propagated up to that 
point. The photovoltage is proportional to fluence; therefore, we hypothesize that steady 
state indicates that all material has coagulated between the probe and the laser fiber. 
The feedback algorithm is designed to notify the user when the photovoltage has 
reached a steady state. As shown Figure 42, the algorithm analyzes data in a 10 second 
window. A 2nd order polynomial is fit to this data and the instantaneous rate of change 
at the last datapoint is quantified and displayed in the GUI (yellow circle). This feedback 
begins 15 seconds after the ‘Laser On’ button is activated to account for the initial steady 
state photovoltage which can be seen in Figure 42. This occurs because it takes time for 
the tissue temperature to reach a sufficient magnitude to induce coagulative necrosis. 
Once steady state has been achieved (slope = 0), the color of the text changes from black 
to red to notify the user that the ablation has been successful. Clinically, the laser should 
be deactivated once the steady state notification has been displayed.  
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Figure 42: Feedback algorithm – A 2nd order polynomial is fit to the most recent 10s of data and the instantaneous rate 
of change (m) at the most recent data point is quantified. We hypothesize that a steady state (m=0) indicates complete 
coagulation of all tissue between the probe and the laser fiber. 
 
6.3. System evaluation: Tissue Mimicking Phantom 
6.3.1. Methods 
Each of the four interstitial optical probes was tested in a tissue mimicking phantom 
under the same conditions as in a previous clinical trial (Figure 43).  Chapter 3 provides 
further detail on the clinical trial. Briefly, in the clinical setting a needle guide was used 
to insert the dual lumen catheter and a thermal probe in parallel into the prostate. We 
have simulated this setup using the tissue mimicking phantom developed in chapter 5. 
The phantom is preheated in a water bath to 37°C and then placed into a 3D printed 
testing rig consisting of an insulated box with channels for laser fiber and probe 
insertion. These channels are used to secure the probes at known distances from the 
laser fiber. The setup is similar to that described in detail in chapter 5 with the exception 
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that the insulated box contains multiple probe channels and is designed to 
accommodate two tests per phantom.  
 
 
Figure 43: A) Clinical setup during FLA. B) Experimental setup designed to match clinical conditions with an optical 
probe used instead a thermal probe 
 
For each test, FLA was performed at 13.75W for 3 min as in the clinical trial.  The 
interstitial optical probes were tested at radial distances (r) of 4mm, 5mm, 6mm and 
7mm and simultaneously monitored with 3T MRI (Prisma, Siemens). The imaging plane 
was aligned along the trajectory of the laser fiber and the optical probe with both objects 
in the field of view. This was achieved using water fiducials that are visible in images 
acquired by the MRI localizer. The fiducials were created by designing the testing rig to 
contain 1mmx1mm channels as shown in Figure 44. The channels circumscribe the 
testing rig and are filled by injecting water through the screw holes used to seal the lid. 
The cross-section of the fiducials can be seen on the transverse image acquired by the 
MRI localizer. The coronal plane is then positioned such that it intersects both fiducials, 
the laser fiber and the optical probe. A T2-weighted turbo spin echo sequence was then 
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acquired to confirm correct alignment (PRE). Once confirmed, an altered version of this 
sequence (CINE) was used to monitor the growth of the coagulation zone in near real-
time. To ensure rapid image acquisition a trade-off was made between the signal to noise 
ratio (SNR) and the scan time. After laser deactivation another high-quality scan is 
acquired (POST) using the same imaging parameters as the PRE scan. The POST scan was 
later used to calibrate the automatic edge detection algorithm as described in the results 
section. Table 12 outlines the key parameters of each sequence. The scan duration of 
the CINE sequence is considerably shorter than the POST sequence due to a shorter echo 
time (TE), a shorter repetition time (TR) and a larger pixel size. In an effort to increase 
the SNR, the slice thickness was also increased relative to the PRE sequence. Figure 44 
also shows the thumb screws that are used to seal the lid and secure the probes after 
insertion. This method cannot be used for the laser fiber as it is inserted through a dual 
lumen catheter which flows water around the fiber during laser activation. Using locking 
screws would impede water flow; therefore, the laser fiber is simply fixed in place by 
taping it to the already secured optical probe. 
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Figure 44: Detailed view of the testing rig with one wall rendered transparent to highlight the location of the water 
fiducials. Note that there are 2 fiducials as each phantom is used for two tests; one in the top section and one in the 
bottom section. An O-ring and thumb screws are used to seal the lid in place to minimize heat loss to the surroundings. 
Thumb screws are also used to secure the optical probes in place.  
 
Table 12: MRI Sequence Parameters 
Scan TE 
(ms) 
TR 
(ms) 
Echo Train 
Length 
Scan  
Duration (s) 
Pixel 
(mm) 
Slice Thickness 
(mm) 
CINE 16 390 13 2 0.75*0.75 2 
PRE/POST 52 2000 13 47 0.5*0.5 1 
 
The final setup is shown in Figure 45 which depicts the setup in the MRI suite. 
The testing rig was placed on the scanner bed and advanced to isocenter after inserting 
the optical probes, dual lumen catheter and laser fiber. The optical fibers are 5m long 
and connect directly to photodiodes which are located as far from the scanner as 
possible but still within the magnet room. Data from the photodiodes is recorded by the 
microcontroller and transmitted via USB through a waveguide to the dedicated PC 
located in the control room. The laser and pump are also located in the control room 
and waveguides are used to connect the respective optical fiber and cooling line to the 
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dual lumen catheter. Finally, in order to temporally register the optical probe data and 
the imaging data, key events (MRI on/off, Pump on/off and laser on/off) were time 
stamped using the FLA monitoring software interface while the corresponding time 
reported by the MRI scanner was manually recorded. 
 
 
Figure 45: A) Block diagram of experimental setup using MRI to monitor laser ablation in the tissue mimicking phantom. 
B) Photograph of testing rig (inset) on the scanner table prior to placement at isocenter. 
 
6.3.2. Results 
Accurate imaging plane alignment is crucial for determining the coagulation radius and 
was achieved using water fiducials as illustrated in Figure 46. Figure 46A shows an 
example of the transverse image acquired by the MRI localizer. The cross-section of the 
fiducials is clearly visible; therefore, the coronal plane can be correctly aligned as 
indicated by the dashed red line. Alignment is confirmed using the PRE scan as shown 
in Figure 46B. The fiducials, dual lumen catheter and optical probe are clearly visible; 
thus, confirming correct alignment. To reduce the number of scans required, two optical 
probes were inserted for each test. While both probes are parallel to the dual lumen 
catheter, one probe is placed out of plane. This is necessary as the probe in-plane 
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interferes with the calculation of the ablation radius. Consequently, the ablation radius 
is determined from the opposite side only and the ablation zone is assumed to be 
cylindrically symmetrical.  
 
 
Figure 46: A) Transverse image acquired by the MRI localizer. The cross-sections of the fiducials are clearly visible 
(red arrows). Note that there are two sets of fiducials as each phantom is used for two tests. In this case the test is 
being performed in the top section of the phantom where the dual lumen catheter (black arrow) and optical probes are 
visible. B) PRE scan used to confirm alignment. The fiducials (red arrows), dual lumen catheter (black arrow) and one 
optical probe can be seen. The second optical probe is not in the imaging plane. 
  
An example of the normalized photovoltage (each datapoint divided by initial 
photovoltage) recorded by the optical monitoring system is shown in Figure 47 along 
with corresponding MR images.  The selected images illustrate the growth of the ablation 
zone over time and indicate that there is a correlation between the photovoltage and the 
coagulation radius. The first image was taken at the instant of laser activation. Both the 
dual lumen catheter and optical probe are visible and the ablation zone has yet to form. 
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In the second image the ablation zone has formed and is expanding towards the optical 
probe while the temporally registered photovoltage has begun to decrease. The edge of 
the ablation has been outlined using the edge detection algorithm which will be 
discussed in the next section. The next image shows that the ablation zone has reached 
the optical probe while the photovoltage has reached a steady state. In the final image, 
the ablation boundary extends beyond the optical probe and was taken just before laser 
deactivation.  
 
 
Figure 47: Photovoltage recorded using ‘Ballistic’ optical probe placed at 5mm for the laser fiber and corresponding 
MR images. The orange line in the MR images is the coagulation boundary derived using the edge detection algorithm. 
The green line denotes the location of the laser fiber. 
To further illustrate the correlation between the photovoltage and the coagulation 
radius, it is necessary to quantify the coagulation radius as a function of time and 
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temporally register the datasets. To do so, an edge detection algorithm was developed 
using MATLAB and Python to derive an equation describing coagulation radius as a 
function of time. The algorithm follows this protocol: 
Step 1: Create image dataset containing images acquired during laser activation only 
• Import all images from an experiment into MATLAB 
• The laser activation time reported by the scanner was manually recorded during 
the test 
• Each laser activation lasted for 180s 
• Given this information and the timestamps stored in the DICOM metadata, it is 
trivial to reduce the dataset to include only images acquired during laser 
activation 
Step 2: Identify laser fiber and optical probe co-ordinates 
• Using a custom GUI, the user manually selects the co-ordinates of the tip and base 
of both the laser fiber and optical probe from the first image in the dataset. Note, 
the laser fiber is housed inside the dual lumen catheter and is always located in 
the center of the phantom. 
• Analysis of these co-ordinates indicates the location of the optical probe (left or 
right) and subsequent analysis is undertaken on the opposite side only. This is 
necessary as both the probe and the coagulation zone appear as areas of low 
signal; therefore, it is difficult to differentiate between them. 
Step 3: Define coagulation-native threshold 
• Coagulated pixels appear dark (low signal) and native pixels appear bright (high 
signal) 
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• A sample of definitely coagulated pixels is taken from the final image in the 
dataset (Figure 48). 
• A series of thresholds are defined: 
threshold = mean of coagulation sample + (X*standard deviation of coagulation 
sample)  
where X is 0.5-3 in steps of 0.25 
• All pixels with a value less than the threshold are defined as coagulated 
Step 4: Delineate the coagulation boundary 
• A circular pattern of vectors is defined around the center of the ablation. 
• For each vector on the side without the probe, the boundary is determined using 
each threshold defined in step 3 
• This process is repeated for every image in the dataset 
• Let’s define the resulting datapoints as ‘boundaryData’. 
Step 5: Coagulation Radii 
• The coagulation radius is defined as the maximum value in ‘boundaryData’  
• At this stage, each image has multiple estimates of the radius as the radius is 
determined for every threshold value defined in Step 3 
• For convenience, lets define this data as ‘radiiData’ 
Step 6: Subsample ‘radiiData’ at 1Hz 
• Photovoltage was recorded at 1Hz while the MRI scanner acquired images at 
approximately 0.5Hz. To temporally register the two datasets the relationship 
between the coagulation radius and time must be determined  
• The dataset ‘radiiData’ was imported into Python 
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• A 3-sample moving average filter was applied to ‘radiiData’ to reduce the effect 
of noise introduced due to the poor image quality of the CINE sequence 
• Coagulation radius as a function of time was then derived using a logarithmic fit 
as shown in Figure 48. Note that the derived equation ignores radii less than 1mm 
to account for pixels occupied by the dual lumen catheter.  
• Using the derived equation, it is trivial to subsample ‘radiiData’ at 1Hz 
• For convenience, lets define the resulting dataset as ‘radiiData1Hz’. Note that 
‘radiiData1Hz’ contains estimates of the radius at each second during laser 
activation. There are multiple estimates at each second as the radius was 
estimated for each threshold defined in Step 3. 
Step 7: Identify optimum coagulation threshold 
• In this final step, the data (radius vs time at 1Hz) in ‘radiiData1Hz’ is filtered 
using the final radius (designated ‘r’ in Figure 48) determined from the higher 
resolution POST scan using Radiant DICOM Viewer 
• The optimum coagulation threshold is then defined as the threshold that 
minimizes the error between the final radius and the radius at the last time point 
(180s) in ‘radiiData1Hz’ 
• The final dataset, designated ‘radiusVsTime’, is then simply the data from 
‘radiiData1Hz’ that was found using the optimum coagulation threshold. This 
data is temporally registered with the photovoltage dataset by filtering the latter 
for photovoltage > 0 i.e. laser active.  
 
The edge detection algorithm was applied to data gathered in each experiment 
and in all experiments a logarithmic fit proved sufficient to describe coagulation radius 
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as a function of time (r2>0.92). In addition, the coagulation boundary shown in Figure 47 
was found using the ‘boundaryData’ dataset where the threshold is equal to the optimum 
coagulation threshold found in Step 7. To create the plot the data is mirrored across the 
laser vector defined in Step 2. 
 
 
Figure 48: Coagulation radius as a function of time as determined by the edge detection algorithm using both the CINE 
and POST scan data. 
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For each experiment the edge detection algorithm was used to temporally register 
the photovoltage (from the FLA monitoring software) and the coagulation radius (from 
the MRI). To illustrate the relationship between photovoltage and the coagulation radius, 
the normalized photovoltage was plotted against the coagulation radius as shown in 
Figure 49 (left column). In addition, data from the feedback algorithm is shown Figure 
49 (right column). 
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Figure 49:  Normalized photovoltage and instantaneous rate of change (slope) as a function of coagulation radius for 
each interstitial optical probe. Arrows identify the signal plateau/inflection point for each probe 
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In this set of experiments, the feedback algorithm was ignored and laser 
activation continued for three minutes in all tests. Retrospective analysis was performed 
to determine the coagulation radius that would have been achieved if the algorithm was 
used to determine the laser deactivation time. To assess the accuracy of each probe, the 
feedback algorithm derived coagulation radius was compared to the true radius as 
defined by the MRI data (Figure 50).  Finally, to quantify the accuracy of each probe the 
absolute error (mean ± one standard deviation) was calculated as shown in Table 13. 
 
 
Figure 50: Comparison of the feedback algorithm coagulation radius 
and the true coagulation radius derived from the MRI data. 
 
Table 13: Absolute error (mean ± one 
standard deviation) for each optical probe 
 
 
 
 
 
6.3.3. Discussion 
The primary components of the optical monitoring system are the optical probe, 
photodiode, microcontroller and FLA monitoring software. Throughout testing, the 
system performed as designed and no unexpected problems were encountered. There 
was some concern that the photodiode and microcontroller would suffer from 
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interference or magnetic attraction as they were located in the magnet room. These 
concerns proved to be unwarranted as no issues were encountered. Additionally, the 
FLA monitoring software successfully displayed photovoltage in real-time and recorded 
the timing of key events (MRI on/off, pump on/off and laser on/off). All data were saved 
as .csv files with no data loss observed during subsequent data analysis. 
MRI scanning was also successful with the fiducials in the testing rig proving 
sufficient to correctly align the imaging plane with the laser fiber and optical probe 
under evaluation. In addition, the thumb screws secured the optical probes and 
prevented unwanted movement during advancement of the scanning table into the bore. 
Likewise, no movement of the dual lumen catheter was observed as the proximal end 
was taped to the adjacent optical probe. 
The PRE, CINE and POST MR scans were all able to identify the coagulation zone. 
As expected, the image quality of the CINE scan suffers because the sequence was 
designed to minimize scan duration which results in reduced SNR. Nevertheless, the 
growth of the coagulation zone over time was successfully quantified through the use 
of the edge detection algorithm. The relationship between coagulation radius and time 
was described using a logarithmic fit with r2 > 0.92 in all cases. 
Four optical probe designs were tested in a tissue mimicking phantom using a 
custom designed testing rig to match conditions to those in a previous clinical trial. The 
key design requirements were identified as 1) interstitial light collection and delivery to 
photodiodes, 2) MR safe, 3) diameter <2.413mm, 4) sufficiently rigid to prevent flexion 
during insertion, and 5) thermally stable during FLA. All probes successfully met these 
conditions. Throughout laser activation a voltage was recorded by the photodiodes; thus, 
confirming that the optical probes are capable of interstitial light collection and delivery 
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to the photodiodes. Moreover, the recorded signal is relatively noise free suggesting that 
the MR scanner magnetic field does not cause interference. The probes themselves 
contain no ferromagnetic material and thus no movement or imaging artifact was 
observed during testing. The absence of large imaging artifacts is critical to facilitate 
quantification of the coagulation radius using the edge detection algorithm. Finally, the 
diameter of the carbon fiber probe shaft was designed and manufactured at 2.4mm and 
no flexion or melting was observed during or after testing. 
 
Each optical probe possesses unique light collection capabilities: 
 
Design 1: Ballistic 
Hypothesis: The probe is expected to primarily detect ballisitc and snake photons; 
therefore, photovoltage will drop as the coagulation boundary grows and reach steady 
state once the coagulation boundary reaches the probe. 
The results in Figure 49 support this hypothesis with photovoltage observed to 
decrease as the coaguation radius expands towards the probe. During the initial growth 
of the coagulation radius (<3mm), a minimal change in photophotovoltage is observed. 
This is followed by a sharp decrease in photovoltage when the coagulation radius lies in 
the range 3-4mm. This characteristic was observed for all probe positions and 
demonstrates that the optical signal is dependent on optical interactions througout a 
volume of material. In contrast an interstitial thermal probe only records the temperture 
of tissue under direct contact.  A similar observation was made by Whlean et al who 
recorded the repsonse of an interstitial thermal probe and an interstitial optical probe 
duirng FLA of porcine kidney in vivo [200]. In that experiment the thermal output 
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remains approximately constant while the photovoltage decreases. In contrast to our 
work, they were unable to derive the relationship between the coagulation radius and 
time. Consequently, the correlation between photovoltage and coagulation radius could 
not be assessed.  
From Figure 49, it is also evident that the photovoltage reaches a steady state 
once the coagulaiton boundary propogates up to the optical probe. This characterisitc 
represents a promising method of monitoring FLA. A pre-dfined coagulation zone may 
be achieved by placing the laser fiber in the center and the optical probe at the desired 
margin with laser activation continuing until steady state photovoltage is observed. 
 
Design 2: Backscatter  
Hypothesis: The probe is expected to primarily detect photons that travel past the probe 
undergo multiple scattering events and are ultimately backscattered towards the probe; 
therefore, the photovoltage should  decrease as the coagulation boundary grows and 
then increase once the coagulation boundary passes the probe. 
In contrast to the ‘Ballisitc’ probe, the optical repsonce with the ‘Backscatter’ 
probe appears to depend on its position. When placed 4mm from the laser fiber, no drop 
in photovoltage is observed. Instead, the photovoltage remains constant until the 
coagulation radius exceeds 3mm. The photovoltage then rises rapidly and eventually 
saturates the photodiode at approximately 5mm. This behaviour is indicative of the 
‘light trapping’ effect that occurs due to a coagulation induced increase in the reduced 
scattering coefficient and a correspnding decrease in the optical penetration depth. 
Interestingly, this effect is reduced substantially when the probe is placed at 5mm and 
is completely absent when the probe is positioned at 6mm and 7mm. The data therefore 
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does not support our hypothesis at radii greater than 5mm. Moreover, in tissue with 
different optical properties, the ‘light trapping’ effect may extend beyond 5mm or 
possibly not even reach 4mm. For this reason it is difiicult to design an algorithm to 
automatically detect the ablation boundary based on data from the ‘Backscatter’ probe. 
  
Design 3: Spherical 
Hypothesis: This probe detects photons travelling in all directions; therefore, 
photovoltage will decrease as the coagulation zone increases and subsequently increase 
once the coagulation radius passes the optical probe. 
Again, no drop in photovoltage is observed for a coagulation radius less than 
3mm. For all probe positions a sharp drop in photovoltage is then observed followed by 
an inflection point once the coagulation boundary propagates as far the optical probe. 
This data supports the hypothesis and like the ‘Ballistic’ probe it provides a useful 
method of identifying the instant the coagulation radius reaches the optical probe. 
 
Design 4: Radial 
Hypothesis: This probe detects ballistic/snake photons and backscattered photons; 
therefore, the optical signal will decrease as the coagulation zone increases and increase 
once the coagulation zone passes the probe. The response of the ‘Radial’ probe 
approximates that of the ‘Spherical’ probe and therefore supports our hypothesis.  
 
In summary, all of the optical probes except for the ‘Backscatter’ probe behave as 
expected and can potentially be used to monitor FLA with a high level of accuracy as 
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indicated in Figure 50. For these three probes the mean absolute error ranged from 
0.25mm to 0.39mm which suggests that no design is inherently superior.  
The ideal optical probe should be able to detect light at multiple locations 
simultaneously. For example, when treating prostate cancer, it is critical that the rectal 
wall remains free from thermal damage. With a multielement optical probe, a single 
probe could be used to monitor both the rectal wall and the intended coagulation 
boundary. It may also be advantageous to combine thermal and optical probes into a 
single probe. In both cases, only the ‘Ballistic’ probe can be easily integrated as it only 
requires line of sight at a single point. In contrast, the addition of extra elements would 
block some of the light that would otherwise be collected by ‘Spherical’ and ‘Radial’ 
probes. Moreover, the ‘Ballistic’ probe can be fixed to the outside of a rigid opaque needle 
which greatly eases manufacturing.  
For these reasons the ‘Ballistic’ probe was chosen for the optical monitoring 
system. Further testing in the tissue mimicking phantom will not provide useful data as 
the tissue mimicking phantom was designed with known optical properties and 
therefore the optical response should be consistent across experiments. Instead, in the 
next section, the optical monitoring system with the ‘Ballistic’ probe will be tested in ex 
vivo bovine muscle. The optical properties of ex vivo bovine muscle should be similar to 
in vivo soft tissue; however, in contrast to the phantom there is likely to be variability 
between samples. This ensures that the optical monitoring system can be tested in a less 
controlled environment than the phantom.  
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6.4. System Evaluation: Ex Vivo Bovine Muscle 
6.4.1. Methods 
A total of 20 ex vivo bovine muscle samples were prepared and placed in 3D printed 
sample holders as shown in Figure 51. The sample holders consist of two sections which 
split along the trajectory of the laser fiber. After the tissue sample is inserted into the 
bottom section a compression plate is placed on top of the sample and the top section 
of the sample holder is secured in place with four screws. A further pair of screws is 
then used to force the compression plate downwards and compress the sample within 
the holder. This is necessary to secure the sample in place and facilitate dual lumen 
catheter and probe insertion. Without the compressive force, the sample is excessively 
pliable making it difficult to accurately insert and remove the dual lumen catheter and 
optical probe. 
 
 
Figure 51: Ex vivo bovine tissue sample holder. The image on the right is orientated in the direction of the black arrow 
and the top section of the sample holder is rendered transparent 
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The fully assembled sample holder is shown in Figure 52A. The sample holders 
are then placed in sealed bags and submerged in a water bath to raise the temperature 
to 37°C. Each sample is then tested in an insulated testing rig similar to the MRI testing 
rig (Figure 52B). FLA is performed with the ‘Ballistic’ optical probe and is monitored via 
the FLA monitoring software. The feedback algorithm outlined in Figure 42 is used to 
notify the operator when the coagulation boundary has successfully propagated as far 
as the optical probe. The test was performed five times with the optical probe placed at 
4mm, 5mm, 6mm and 7mm from the laser fiber. After each test, the sample was removed 
from the testing rig, placed in a sealed bag and stored in a freezer for at least 12 hours. 
The frozen samples were then removed from the freezer and the top section of the 
sample holder was detached. Figure 52C shows the sample in the bottom half of the 
holder with the compression plate still on top of the sample. The frozen sample is then 
sectioned along the surface of the sample holder using a deli slicer. This process ensures 
that the sample is sectioned accurately along the laser fiber trajectory. It is difficult to 
identify the ablation zone when the sample is frozen; therefore, the sample is allowed 
to thaw for approximately 45 minutes. The final sample is then ready to be 
photographed from directly above as indicated in Figure 52D. 
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Figure 52: A) Cold tissue sample in tissue holder. B) Sample holder in testing rig after being preheated to 37°C. C) 
Sample holder with top section 
 
To ensure consistent lighting across samples photographs were taken in a 
lightbox with a Canon EOS Rebel camera as shown in Figure 53.  
 
 
Figure 53: A: Setup for acquiring photograph of sample ablation zone. To ensure consistent lighting a professional 
lightbox was used. B) Sample image showing ruler which will be used to scale the acquired photograph. Photographs 
used for analysis were taken with greater magnification 
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6.4.2. Results 
Each photograph was analyzed using a custom python script with the following steps: 
Step 1: Prepare images for analysis 
• Each image is imported into python and a custom GUI is used to select the co-
ordinates of the laser fiber and the edges of the sample holder.  
• Using these co-ordinates, each photograph is then rotated and cropped as shown 
in Figure 54 (middle row) 
Step 2: Define coagulation thresholds 
• Coagulated pixels appear bright (high signal) and native pixels appear dark (low 
signal) 
• A sample of definitely coagulated pixels is taken from within the ablation zone. 
• A series of thresholds is defined: 
threshold = mean of coagulation sample - (X*standard deviation of 
coagulation sample)  
where X is 1-3 in steps of 0.25 
Step 2: Define profile line 
• Using a second GUI, the user specifies the co-ordinates of a profile line (see Figure 
54).  
• The profile is placed immediately above the optical probe and the user must select 
a location that is not obscured by fat. Both fat and coagulated tissue appear white; 
therefore, it is difficult to differentiate them. 
• The profile line is eleven pixels thick. The average pixel intensity along the profile 
line is shown in the bottom row of Figure 54. This step is necessary to reduce the 
effect of artifact from glare and fat which both appear bright 
154 
 
Step 3: Analyze profile line to determine coagulation radius 
• By observation, the user specifies the window of pixels in which each edge lies.  
• Linear regression is used to fit a line to the data within each window 
• Using the equation of this line, the coagulation boundary is quantified for each 
threshold defined in Step 2 
• This process is performed on both edges of the ablation zone and the radius is 
simply half the distance between the points 
• If fat obscures one edge, the radius is calculated from the center of the laser fiber 
as shown in Figure 54 at ‘r=5mm’. If fat obscures both edges, the image is 
removed from the dataset and the experiment is repeated. 
Step 4: Optimum threshold and estimated radius 
• Multiple estimates of the coagulation radius exist at this point as the coagulation 
radius was quantified using the series of thresholds defined in Step 2. 
• A leave-one-out approach is used to define the optimum threshold for each 
image: 
o A subset of data is created containing every image except the image under 
analysis 
o The optimum threshold is then chosen to minimize the error between the 
estimated radius and the expected radius (probe location) 
o This threshold is then used to define the estimated coagulation radius in 
the image under analysis 
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Figure 54: Photovoltage recorded during FLA experiments in ex vivo bovine muscle (Top row), photographs of the 
ablation zone after FLA (middle row) and profile lines used to determine the coagulation radius (bottom row). Note that 
‘r’ indicates the distance between the probe and the laser fiber.  For r=5, fat obscures the left edge and is seen as 
signal spike on the profile line (yellow star). In this case the radius is measured from the center of the dual lumen 
catheter. 
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Figure 54 shows examples of the photovoltage, coagulation zone and profile line 
recorded for each probe position. Each of these experiments was repeated five times for 
a total of twenty experiments. The utility of the feedback algorithm is demonstrated in 
Figure 55 which compares the measured damage radius (calculated as in Figure 54) 
against the target damage radius. The target damage radius is the position of the probe 
relative to the laser fiber as the proposed protocol for achieving a predefined radius is 
to place the optical probe at the desired margin. As expected, there is a strong linear 
relationship between the measured damage radius and the target damage radius (r2 
=0.91) and the absolute error (mean ± SD) is 0.3±0.1mm. 
 
Figure 55: Comparison of the measured damage radius (from analysis of the ablation zone) against the target damage 
radius (position of the probe relative to the laser fiber). Error bars signify one standard deviation.  Mean absolute error 
= 0.3±0.1 
 
Finally, we compare the laser exposure duration for  each coagulation radius in 
ex vivo bovine muscle, the tissue mimicking phantom and in vivo human prostate. For 
bovine muscle, it was necessary to assume that the measured damage radius was equal 
to the target damage radius. The phantom calculation was based on the’radiusVsTime’ 
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dataset outlined in the edge detection alrogithm section and Figure 48. The laser 
exposure duration is interpolated from three minute laser activations. Consequently, it 
does not account for growth of the coagulation zone after the laser is deactivated; 
however, this error is expected to be minimal due to rapid cooling. The prostate data is 
taken from the clincal trial (see chapter 3) in which ten men received FLA followed by an 
MRI to assess the extent of coagulation based non-perfused tissue. While ten patients 
were treated, nine of them received overlapping ablation zones, rendering it impossible 
to correlate the coagulation zones with the laser exposure duration. For coagulation radii 
less than 6mm, the laser expoure duration is similar for bovine muscle and tissue 
mimikcing phantom; however, there is a statistically significant difference (p<0.01) 
between the two at radii of 6mm and 7mm. In contrast, the laser expousre duration 
necessary to achieve a coagulation radius of 7.5mm is similar for the tissue mimicking 
phantom and in vivo human prostate. 
 
Figure 56: Laser (980nm) exposure duration at 13.75W required to achieve predefined coagulation radii in ex vivo 
bovine muscle, tissue mimicking phantom and in vivo human prostate. *P<0.01 (Wilcoxon rank-sum) 
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6.4.3. Discussion 
FLA achieves oncologic control by inducing hyperthermia throughout the target volume. 
Consequently, many groups have attempted to use thermal monitoring methods as a 
feedback modality.  MRT [6] and interstitial thermal probes [29], [73], [98], [99], [205] 
have been widely investigated for this purpose.  To estimate the induced cell death, the 
thermal data is generally used in combination with an Arrhenius thermal damage model 
[11], [228], [229]. In addition to thermal data, these models require tissue specific kinetic 
parameters. In chapter 3 we demonstrated that published values for these parameters 
result in significantly different estimates of the optimal exposure during FLA. In this 
chapter we have explored the effect of thermal coagulation on laser-tissue interactions 
in an effort to develop an alternative method of monitoring FLA that does not rely on 
thermal damage models.  
In the previous sections we described an optical monitoring system and tested 
various interstitial optical probes in a tissue mimicking phantom. Ultimately, an 
interstitial radiance probe designed to preferentially collect ballistic and snake photons 
was identified as the optimal interstitial optical probe for the proposed application. In 
this section we sought to characterize the performance of the optical monitoring system 
in a less controlled environment than that provided by the tissue mimicking phantom. 
Ex vivo bovine muscle was chosen as a testing model as it is readily available and unlike 
the tissue mimicking phantom the optical properties are unknown and likely to vary 
between samples. Ex vivo bovine muscle has been used in similar studies analyzing the 
effect of thermally induced coagulation on tissue properties [188], [206], [231].  
In contrast to the tissue mimicking phantom, the growth of the coagulation zone 
cannot be tracked in ex vivo bovine muscle via MRI. Instead we have performed FLA 
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using the FLA monitoring software to identify the correct time to deactivate the laser. 
Tests were performed with the interstitial optical probes placed at 4mm, 5mm, 6mm 
and 7mm from the laser fiber. The feedback algorithm in the FLA monitoring software 
indicates when the coagulation boundary has propagated up to the probe. Accurate 
assessment of the coagulation radius was successfully achieved using a 3D printed 
sample holder (Figure 52) and a deli slicer to section the sample along the laser fiber 
trajectory (Figure 54). The sample was then photographed and the coagulation radius 
was found using a custom-built image analysis algorithm developed in python.   
The accuracy of the interstitial optical monitoring system was assessed by 
comparing the measured coagulation radius against the target coagulation radius. The 
absolute error (mean ± SD) was found to be 0.3±0.1mm.  While this result provides strong 
evidence in support of the optical monitoring system, a key limitation of the 
experimental approach must be considered. Specifically, the image analysis algorithm 
used to determine the coagulation radius defines the coagulation threshold such that it 
minimizes the overall error. This threshold is determined from a dataset that does not 
include the image under analysis; however, it is still likely that the true absolute error is 
greater than reported here. For example, if the optical monitoring tends to 
underestimate the extent of ablation, the resulting bias is removed by the image analysis 
algorithm. However, the advantage of the algorithm over direct measurement is that 
measurement errors tend be systematic i.e. if the algorithm underestimates the ablation 
radius in one image by 1mm, then it underestimates the radius in all images by 
approximately 1mm. For this reason, we have also shown that there is strong linear 
relationship between the measured damage radius and the target damage radius (r2 
=0.91). The coefficient of determination is largely independent of the bias removed by 
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the image analysis algorithm. Again, if the algorithm underestimates the coagulation 
radius, all measurements are equally effected; therefore, the relationship between the 
measured and true coagulation radius will change but the coefficient of determination 
will not. 
The goal of testing in ex vivo bovine muscle as well as the tissue mimicking 
phantom was to demonstrate that the utility of interstitial optical monitoring in media 
with various optical and thermal properties. The tissue mimicking phantom was 
designed to possess dynamic optical properties similar to human prostate. As a result, 
the laser exposure time required to achieve a coagulation radius of 7.5mm was found to 
be similar in the phantom and in vivo human prostate (Figure 56). In contrast ex vivo 
bovine muscle only exhibits a similar laser exposure time at radii of 4mm and 5mm with 
a significant difference (p<0.01) observed for radii of 6mm and 7mm. These results 
suggest that the optical and/or thermal properties of ex vivo bovine muscle are not 
closely matched to the tissue mimicking phantom and are therefore also not similar to 
in vivo human prostate. In spite of this, the optical monitoring system performed 
adequately in both models as both exhibit the characteristic coagulation induced 
increase in scatter. This increase in scatter is present for all soft tissues therefore, the 
optical monitoring system is likely to find utility in various soft tissues such as brain, 
liver and kidney. 
 
6.5. Conclusion 
An interstitial optical monitoring system was successfully designed, constructed and 
evaluated. While, three optical probe designs (‘Ballistic’, ‘Spherical’ and ‘Radial’) were 
found to be suitable for monitoring focal laser ablation, the ‘Ballistic’ probe was 
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identified as the optimal design as it can easily be expanded to a multi-element probe. 
A feedback algorithm, based on the instantaneous rate of change of measured 
photovoltage as a function of time, is capable of identifying the coagulation boundary. 
The utility of the optical monitoring system was successfully demonstrated in ex vivo 
bovine muscle with a mean absolute error of 0.3±0.1mm observed in coagulation 
volumes in the range 4-7mm. It is anticipated that the optical monitoring system will 
provide accurate feedback in a variety of soft tissue such as brain, liver and kidney. 
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CHAPTER 7 
Conclusions and Future Directions 
 
7. Conclusions and Future Directions 
7.1. Summary 
Radical prostatectomy and radiation therapy represent the current state of the art in 
interventional treatment for prostate cancer. Both modalities are associated with 
numerous side-effects including erectile dysfunction and urinary incontinence. The 
advent of improved diagnostic techniques has facilitated localization of the tumor 
within the gland. This has led to a growing interest in developing minimally invasive 
technologies that treat the target tumor while sparing surrounding healthy tissue and 
thus limiting undesirable side-effects. FLA represents a promising modality; however, it 
is currently preformed using MRI to both guide the laser to the target tumor and monitor 
treatment progress. The resource intensive nature of this approach presents a barrier to 
widespread adoption. Consequently, our research efforts have focused on developing 
technology to translate FLA from the MRI suite to the urology clinic.  
To perform FLA in the absence of MRI, alternative methods must be developed 
for both guiding the laser fiber to the target and monitoring treatment progress in real-
time. At our institution, there is considerable experience with MR-US fusion guided 
biopsies. In this procedure, ROIs are generated from existing MRI data and co-registered 
with real-time ultrasound imaging. This facilitates targeted biopsies in which tissue 
samples are drawn from suspicious areas identified via MRI. These procedures are 
routinely performed in under 30 minutes. Given that a biopsy needle can be guided to a 
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predefined location with MR-US fusion guidance, there should be minimal difficulty 
swapping the biopsy needle for a laser fiber. The greater challenge lies in replicating 
MRI’s ability to monitor treatment progress in real-time.  
In this thesis, I sought to demonstrate that FLA can be performed safely and 
effectively in a urology clinic using MR-US fusion guidance and interstitial probes for 
targeting and monitoring respectively. As FLA aims to achieve oncologic control via 
hyperthermia, the utility of interstitial thermal probes was initially investigated. A 
clinical trial was performed in which FLA was safely performed in 10 patients using MR-
US guidance and interstitial thermal probes for targeting and monitoring respectively. 
However, retrospective analysis of thermal data highlighted limitations inherent to 
thermal monitoring. As a result, alternative monitoring modalities were sought, with 
interstitial optical probes presenting a particularly promising solution.  
To demonstrate a correlation between laser-tissue interaction and propagation of 
the coagulation boundary it is necessary to be able to visualize the latter as the treatment 
progresses. This cannot be achieved in ex vivo tissue samples as no imaging modality is 
capable of accurately differentiating coagulated and native tissue in non-perfused 
samples. This considerable hurdle was navigated by developing a tissue mimicking 
phantom that simulates the optical and thermal properties of prostatic tissue while also 
facilitating visualization of the coagulation zone via MRI. An optical monitoring system 
was then designed, constructed and validated using the tissue mimicking phantom. The 
acquired data enabled development of an algorithm capable of identifying the 
coagulation boundary in real-time. The algorithm was subsequently evaluated in ex vivo 
bovine muscle and found to provide an accurate method of monitoring FLA. 
 
164 
 
7.2. Conclusions 
 
7.2.1. Monitoring Focal Laser Ablation with Interstitial Thermal 
Probes 
Focal laser ablation achieves coagulative necrosis by inducing hyperthermia through the 
absorption of optical energy. Monitoring the thermal response presents a potential 
method of ensuring the safety of critical structures and the complete coagulation of the 
target tumor. In our proposed approach laser targeting will be achieved with MR-US 
fusion; therefore, the laser fiber and thermal probe must be integrated into the existing 
clinical setup used for targeted biopsies. With these requirements, we designed a dual 
channel needle guide that attaches to an ultrasound probe in a similar manner to the 
guide routinely used for MR-US fusion biopsy. The two channels are parallel and 
separated by 8mm. One channel houses the laser fiber, while an interstitial thermal 
probe is inserted through the other. The thermal probe consists of a fluoroptic probe 
inside a flexi-needle. The goal is to maintain laser activation until lethal temperatures 
are recorded by the thermal probe; thus, ensuring coagulative necrosis in all of the tissue 
between the laser fiber and the probe. As light is emitted from a cylindrical diffuser, it 
is expected that the coagulation zone will approximate a cylinder of 8mm radius. A 
clinical trial was undertaken to demonstrate the feasibility of performing FLA with MR-
US fusion guidance and interstitial thermal probe monitoring. 
Focal laser ablation was performed in 10 men using MR-US fusion guidance for 
targeting and interstitial thermal probes for monitoring. The goal of the trial was to 
demonstrate that the procedure was safe and feasible. We can conclude that these 
endpoints were successfully achieved as no serious adverse events reported. Although 
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the trial did not focus on efficacy, promising results were observed with Gleason 4 CaP 
found in only 40% of patients at 9-month follow-up. While these results are encouraging, 
considerable improvement is necessary before FLA can be widely adopted for the 
treatment of low and intermediate risk CaP. Greater oncologic control requires the 
development of improved instrumentation. The custom designed needle guide and 
echogenic trocar utilized in the trial were sufficient to enable MR-US fusion targeting as 
routinely performed during biopsy. In contrast, improved real-time monitoring was 
identified as a key area in need of development because the utility of interstitial thermal 
probes appears to be inherently limited due to inaccurate thermal models. This 
conclusion stems from retrospective analysis of the thermal data acquired during the 
clinical trial.  
The Arrhenius damage model is the standard approach to estimating thermally 
induced cellular death. The key inputs to the model are thermal history and tissue 
specific kinetic parameters. These parameters have been determined by multiple groups 
and when combined with the thermal data from the trial we found that the Arrhenius 
model outputs significantly different estimates of cellular death depending on the 
choice of kinetic parameters (p < 0.01). Considerable efforts have already been made by 
other groups to both improve the Arrhenius model and better characterize the kinetic 
parameters of prostate tissue. Consequently, we concluded that we should focus on the 
development of an alternative monitoring modality which led to interest in interstitial 
optical monitoring. 
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7.2.2. Monitoring Focal Laser Ablation with Interstitial Optical 
Probes 
In FLA, laser-tissue interaction is characterized by two coefficients: 1) the absorption 
coefficient, and 2) the reduced scattering coefficient. The optical penetration depth is a 
function of these coefficients with an increase in either coefficient resulting in decreased 
optical penetration. Previous studies have demonstrated that ablation causes an increase 
in the reduced scattering coefficient while the absorption coefficient remains relatively 
unchanged. Increased scatter results in reduced optical penetration; therefore, once the 
tissue has coagulated, photons tend to be absorbed closer to the laser fiber. This ‘light 
trap’ represents a limitation of FLA as it prevents the creation of large ablation zones. 
However, we sought to utilize this limitation as a mechanism for identifying the 
coagulation boundary by interrogating the optical response during FLA.  
We hypothesized that the signal recorded by an interstitial optical probe would 
decrease with the growth of the ablation zone during FLA and reach a plateau/inflection 
point once the coagulation boundary has propagated up to the sensor. Therefore, the 
desired ablation radius could potentially be achieved by placing an interstitial optical 
probe at the requisite distance from the laser fiber and terminating laser activation once 
a signal plateau is observed. The optical probe may be used instead of or in conjunction 
with the interstitial thermal probe deployed in our clinical trial. 
A series of preliminary experiments were undertaken to ascertain whether or not 
this approach warranted further investigation. FLA was performed in ex vivo bovine 
muscle with both interstitial thermal probes and interstitial optical probes employed as 
monitoring modalities. The predicted signal plateau was observed while there was no 
obvious correlation between thermal data and the propagation of the coagulation 
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boundary. It was therefore concluded that optical monitoring may present a viable 
alternative to interstitial thermal probs with further investigations necessary to 
demonstrate utility. In addition, these experiments identified the lack of an appropriate 
model as a key barrier to the development of novel FLA monitoring modalities such as 
optical monitoring. Ex vivo tissue is not a suitable model as it is not possible to non-
invasively quantify the growth of the ablation zone; therefore, the ablation zone cannot 
be correlated with the signal recorded by an interstitial optical probe. An appropriate 
model must have the following characteristics: 1) optical and thermal properties 
matched to prostatic tissue, 2) sufficiently solid to support needle insertion, and 3) 
enable non-invasive quantification of the growth of the ablation zone.  
We created the requisite model though the development of a tissue mimicking 
prostate phantom consisting of a polyacrylamide hydrogel with optical properties 
matched to prostate. The gel was doped with Naphthol Green B to match the absorption 
coefficient of prostatic tissue while Intralipid and BSA were used to match the reduced 
scattering coefficient. The necessary concentration of each ingredient was determined 
via fluence measurements and light diffusion theory. The phantom was then validated 
by comparing the thermal response during FLA with that observed in the clinical trial. 
Both the thermal response and the shape of the induced coagulation zone were found 
to be similar to that observed clinically. In addition, coagulation of the BSA facilitates 
non-invasive quantification of the coagulation zone via T2-weighted MRI. This an 
important characteristic for the development of the proposed optical monitoring system 
as it facilitates correlation of the optical signal with the growth of the coagulation zone.  
Finally, an interstitial optical monitoring system was designed, constructed and 
evaluated using the tissue mimicking phantom. The primary components of this system 
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are an interstitial optical probe, an amplified photodetector, a microcontroller and a 
dedicated PC running custom built software. A cine MRI sequence was also developed to 
rapidly acquire images during FLA and thus enable tracking of the expanding ablation 
zone. This sequence along with the phantom should find further utility in the 
development of FLA instrumentation. 
A total of four interstitial optical probe designs were evaluated. The 
distinguishing feature between each is the range of angles over which light is collected. 
The utility of each probe was assessed by performing FLA in the tissue mimicking 
phantom with simultaneous MRI and optical monitoring. Three of the probes (‘Ballistic’, 
‘Spherical’ and ‘Radial’) were found to be suitable for monitoring focal laser ablation. 
Ultimately, the ‘Ballistic’ probe was identified as the best design as it can easily be 
expanded to a multi-element probe. A feedback algorithm was developed based on the 
acquired data. The algorithm monitors the instantaneous rate of change of the optical 
signal and notifies the user when an inflection point has been reached. The inflection 
point was shown to correlate with the instant the coagulation boundary reaches the 
sensor. The feedback algorithm was subsequently validated in ex vivo bovine muscle. 
Predefined coagulation radii were successfully achieved with a mean absolute error of 
0.3±0.1mm. 
In conclusion, an interstitial optical monitoring system was developed and 
demonstrated to be capable of identifying the ablation boundary during FLA. The system 
can be deployed in a similar fashion to the thermal probes used in the clinical trial in 
chapter 3. Further work is necessary to create multi-element optical probes capable of 
distributed sensing. In addition, the system must be validated against histologically 
quantified ablation zones in human prostate. 
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7.2.3. Impact on Prostate Cancer Management 
It is widely recognized that there is a need to develop a treatment for prostate cancer 
with fewer associated complications than radical prostatectomy and radiation therapy. 
FLA has shown considerable promise; however, current investigations utilize MRI to both 
guide the laser to the desired ROI and monitor the growth of the ablation zone. 
Widespread adoption of FLA is likely to be hindered due to the cost and limited 
availability of MRI. The work presented in this thesis shows that FLA can be safely 
performed in a urology clinic without direct MRI. This represents a substantial 
development as it ensures that a large number of patients can be treated. However, in 
order for FLA to be considered a viable treatment, efficacy must be comparable to 
current gold standard treatments. In an effort to ensure efficacy, we developed an optical 
monitoring system which must be validated in further pre-clinical and clinical studies. 
If successful, FLA may provide a solution for CaP with minimal side-effects. This is 
particularly beneficial for patients diagnosed with low-to-intermediate risk CaP. This 
cohort is currently faced with the dilemma of living with CaP or undergoing treatment 
resulting in a reduction in quality of life due to treatment complications. Many of these 
patients elect for radical intervention due to the fear of living with a potentially life-
threatening disease. FLA may provide a solution for this group and the work presented 
in this thesis lays the foundation for the clinical deployment of this revolutionary 
technology. 
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7.3. Future work  
7.3.1. Validation Against Histology 
In chapter 6 we derived a feedback algorithm for the optical monitoring system by 
testing the optical probe in the tissue mimicking phantom. The algorithm was 
subsequently validated in ex vivo bovine muscle. A key limitation of this work lies in the 
method of quantifying the ablation zone. This was achieved by photographing the 
ablation zone and employing an image analysis algorithm to identify the ablation 
boundary. While this method is a substantial improvement over direct measurement 
with calipers, it is unclear whether or not pixel intensity changes coincide with 
coagulative necrosis. To alleviate this limitation, future work should be undertaken to 
validate the optical monitoring system in ex vivo human prostate with histologic analysis 
utilized to quantify the ablation zone.  
The proposed experiments should be performed under MRT surveillance. Testing 
rigs similar to those used in chapter 6 will be required to facilitate co-registration of the 
MRT and histology data along the trajectory of the laser fiber. We hypothesize that the 
damage zone estimated by the optical monitoring sensor will correlate with the 
histologically confirmed zone at least as well as that provided by the MR data. Should 
this prove to be correct, the study will provide robust evidence supporting the 
translation of FLA from the MR suite to the clinic. The associated reduction in cost and 
complexity may lead to widespread adoption of FLA for the treatment of prostate cancer. 
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7.3.2. Multi-element Thermal and Optical Probe 
The outer diameter of the largest flexi-needle used in the clinical trial (chapter 3) was 
2.4mm. As the diameter of the fiber optic cables can be less than 200µm, it should be 
feasible to develop an optical probe containing multiple optical sensors arrayed along 
the length of the probe. Given the size of the optical cables and the likely layout, it 
should also be possible to included multiple micro-thermocouples as depicted in Figure 
57. The advantage of a linear sensor array is that some of the sensors can be used to 
monitor the growth of the ablation zone while others ensure the safety of surrounding 
structures. In particular, it is of critical importance that the rectal wall remains intact. 
This could be achieved by positioning the proximal sensor between the rectal wall and 
the distal edge of the laser fiber. In chapter 3, this task was accomplished using 
transperineal thermal probes; however, this approach greatly increases the complexity 
of the procedure. 
The combined use of thermal and optical probes may lead to an improved 
monitoring algorithm once a feedback loop is implemented between the sensor and the 
laser. For example, if the tissue exhibits an unusually short penetration depth, the tissue 
near the fiber will coagulate rapidly. The optical sensor will show a decrease in signal 
while the thermal probe remains unusually low. By analyzing this data in real-time it 
may be possible to salvage the ablation by reducing the power output to increase the 
impact of the thermal conduction. Moreover, in the absence of feedback, this particular 
scenario would result in the formation of char around the laser fiber and which could 
lead to melting of the dual lumen catheter. In the worst-case scenario, the distal portion 
of the dual lumen catheter may detach and have to be surgically removed. 
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Figure 57: Proposed multi-element dual thermal and optical interstitial probe 
 
7.3.3. Clinical Implementation  
Our clinical study (chapter 3) demonstrated that it is both safe and feasible to perform 
FLA using interstitial thermal probes as a monitoring modality. A further ‘intent-to-treat’ 
trial must be undertaken to assess the efficacy of this procedure. With the development 
of a dual thermal and optical probe it will be possible to gather optical data while actively 
using feedback from the thermal probes as in the previous trial. The utility of optical 
monitoring can then be assessed via a retrospective study comparing both the optical 
and thermal data to the non-perfused zone observed on post-treatment MRI. This study 
should lead to the development of a robust feedback algorithm incorporating both 
optical and thermal data. Moreover, if the trial establishes that the procedure is 
efficacious, we can proceed to disseminate the technology to other institutions with the 
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ultimate goal of providing a minimally invasive treatment for the 175,000 men 
diagnosed with CaP every year. 
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